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Chapter ι 
G E N E R A L I N T R O D U C T I O N 
L I Epidemiology, genetics and aetiology 
Psoriasis is a common chronic disease In Europe, North America, East Afri­
ca and South Asia the prevalence ranges between ι and 2% Psoriasis is virtu-
12 ally absent in Eskimo and Native American populations 1 Males and females 
are equally affected,2 s however, in females psoriasis tends to develop earlier 
than in males 1 3 6 7 In the majority of patients the first manifestations appear 
during the second decade of life It has been shown that non pustular psoria­
sis shows two distinct forms, one of which is hereditary, with early onset, and 
the other is sporadic and occurs in older age 8 
Hereditary factors play an important role in the aetiology of psoriasis 
Several studies indicate a strong familial aggregation and diverse patterns of 
inheritance in families Statistical analyses have shown that siblings of 
psoriatic patients were more frequently affected if also one parent had psoria­
sis s y '" Comparing monozygotic and dizygotic twin pairs a far higher con­
cordance rate has been observed in the former 2 1 1 Data obtained from 
Danish studies indicate that individuals who have twin partners with psoria­
sis run a risk of at least 70% when they belong to monozygotic pairs 1 2 1 4 The 
results of a genetic analysis of psoriasis suggest that psoriasis is inherited as a 
polygenic multifactorial t rai t 1 5 A study on pedigrees in 2035 families with 
psoriasis again strongly supports the concept that psoriasis is a polygenic 
and multifactorial disease u ' Several psoriasis-associated alleles at the HLA 
and complement loci have been defined The HLA alleles B13, B17, B37, Cw6, 
Cw7, DR7 and Dwn at three different loci (1 e В, С and D) are found more 
frequently in psoriatic than in non-psonatic control populations ' 1 7 2 0 From 
a statistical study of manv psoriasis-associated HLA alleles one may conclude 
that only the association of Cw6 is primary, other alleles being in linkage dis-
equehbrium with Cw6 2 1 An individual with HLA-Cw6 has a relative risk 
between 14 and 24 of developing psoriasis compared to an individual with 
other alleles 2 2 2Э Sakkas et al concluded from their investigation that a pro­
nounced HLA DR.7 association exists in patients with psoriasis 2 4 Recently a 
gene involved in psoriasis susceptibility was localized to the distal region of 
human chromosome i7q This studv demonstrates that in some families, 
psoriasis susceptibility is due to variation at a single major genetic locus other 
than the human lymfocyte antigen locus 2 5 
The onset and course of the disease is often unpredictable In predisposed 
persons exogenous and endogenous factors, like climate, streptococcal 
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infection, hormones, hypocalcemia, drugs (lithium, ß-blocking agents, 
indomethacin and anti-malarials) and psychological stress can trigger the 
onset or exacerbation of psoriasis.26"33 
Exogenous triggering factors may induce new psoriatic lesions. The 
response to these factors is the so-called Koebner phenomenon: the ap-
pearance of a psoriatic lesion following an injury of the skin or as a result of 13 
another skin disorder. This can occur for example at the site of trauma, vacci-
nation, contact dermatitis, excorations and sunburn.34 
1.2 Clinical appearance, course and differential diagnosis 
In general the clinical appearance of psoriasis permits a diagnosis "à vue". 
The erythematosquamous lesions are sharply demarcated (figure 1.1). The 
size may vary between pinpoint lesions and large plaques. The latter have 
developed from several smaller lesions which coalesce and can adopt polycy-
clic, annular or gyratory configurations. Occasionally erythroderma may 
occur. The morphological elements of the psoriatic lesion are scaling, thicke-
ning and erythema. The amount of scaling is variable. The early drop-like 
(guttata) lesions may be erythematous without any scaling, whereas an exces-
sive overproduction of scales occur in rupoid and elephantine psoriasis. 
A psoriatic lesion often is surmounted by silvery white scaling. After scrat-
ching the superficial scales one can observe the 'signe de la tache de bougie', 
as if one scratches on a wax candle. After removing the last membrane a wet 
surface can be seen with characteristic pinpoint bleedings. The latter pheno-
menon is caused by the upward migration of dermal papillae with vasodilata-
tion and is called 'signe d'Auspitz'. The psoriatic lesions are easily palpable 
for reason of epidermal thickening. The erythema consists of a full, rich sal-
mon pink like colour. Occasionally a clear peripheral zone, the halo of Woro-
noff, can be observed.35"17 
The morphology of the eruptions shows considerable variation. The 
lesions may be localized or generalized like in erythrodermic psoriasis. Gut-
täte psoriasis is characterized by erythematosquamous droplike papules dis-
seminated over the body, while the chronic plaque psoriasis shows sharply 
demarcated erythematosquamous plaques, varying from coin-sized (num-
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Figure 1.1 Sharply demarcated erythematosquamous lesion, typical for psoriasis. 
mular psoriasis) to palm-sized or larger. The plaques are usually distributed 
symmetrically on predilection sites like the scalp, the elbow, the sacral 
region, and the lower extremities. Topographical variations of psoriasis vul-
garis are psoriasis capitis (scalp), flexural or intertriginous psoriasis (axillae, 
submammary areas, groins and other body folds), palmoplantar psoriasis 
(palms and soles) and psoriasis unguium (nails). The pustular manifestation 
of psoriasis is less common. The pattern can be localized like in persistent 
pustulosis of hands and feet or generalized (generalized pustular psoriasis; 
figure I.2).35'36 
The clinical appearance in certain sites is modified. On the scalp one can 
observe very thick plaques. Intertriginous psoriasis is characterized by sharp-
ly defined erythematous plaques without the typical scaling. In the sacral 
region the chronic indurated plaques may show fissures and lichenification 
without the characteristic scaling. On hands and feet the plaques can be less 
well-demarcated. In 25-50% of all patients with psoriasis nail changes can be 
observed. Besides pitting, the most frequent nail changes are discoloration 
(oil drop phenomenon of the nail plate), subungual hyperkeratosis and ony-
cholysis.35-^38-39 
Psoriasis can be associated with arthritis. Hellgren found an occurence of 
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Figure 1.2 Sharply demarcated erythematosquamous lesion with pustules, typical 
for pustular psoriasis. 
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arthritis in six to ten percent in psoriatic patients.40 Most often the peripheral 
joints or the spine are affected.35,û 
The course and prognosis of psoriasis is unpredictable. Psoriasis is cha-
racterized by exacerbations and remissions. The lesions grow and regress. 
However, psoriasis can also remain stable for several years. Complete remis-
16 sions over 1-54 years are reported in 39% of a group of 5.355 patients.26 The 
genetic predisposition as well as triggering factors are important in the cour-
se of psoriasis. It has been reported that 85.3% of patients with early onset 
are HLA-Cw6 positive. In this group of patients, psoriasis followed an irregu-
lar course and showed a strong tendency to become generalized.0 External 
and internal triggering factors, like for instance skin traumata, stress, and 
infections are of great importance with respect to the course of the disease. 
The clinical characteristics as defined above are often sufficient to make 
the diagnosis. Seborrhoeic dermatitis, however, can be quite similar to pso-
riasis. In this disorder a more yellowish and greasy scaling is observed and 
the lesions cannot be palpated as "elevated" papules or plaques as in psoria-
sis. Hyperkeratotic eczema of the palms and palmoplantar psoriasis often 
lack the typical hall-marks of psoriasis and are best differentiated by histolo-
gy. In general the clinical aspect of the nail changes is diagnostic. However, 
thickened nail plates with yellow-brown discoloration may also represent 
onychomycosis. In case of doubt a direct investigation or cultures are indica-
ted. Lichen planus shows papules with a glistening surface and violaceous 
colour and oral changes are frequently present. The clinical picture is usually 
decisive, however in the verrucous variants histological investigation is requi-
red for a certain diagnosis. Infections like syphilis, candidiasis and tricho-
phyton rubrum can cause confusion. Histology, serology or mycological 
investigation might be helpful in case of atypical psoriasis. The premycotic 
phase of mycosis fungoides and Bowen's disease may be difficult to differen-
tiate on clinical grounds from psoriasis. A biopsy should be taken in case of 
selective resistance to effective antipsoriatic therapies in order to be informed 
about the histological appearance. In widespread psoriasis the differentia-
tion with pityriasis rubra pilaris might be difficult. However the latter is cha-
racterized by follicular arrangement of the lesions, islands of unaffected skin 
surrounded by involved skin and yellowish hyperkeratosis of palms and 
soles.^5'40·38 Complicated psoriasis may cause confusion. Co-occurrance of 
psoriasis and lichen simplex chronicus represents "itchy psoriasis" which 
can be extremely resistant to antipsoriatic treatments. 
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1.3 Histological aspects 
І .3Л ERYTHEMATOSQUAMOUS M A N I F E S T A T I O N S 
The histological aspects of psoriasis vulgaris may vary considerably, depen- 17 
ding on the stage of the lesion.41"43 The histological appearance of the early 
scaling papules and margin of advancing plaques is diagnostic for psoriasis. 
The histology of the central area of chronic plaque psoriasis is usually not 
specific. The earliest pinhead-sized macules or smooth-surfaced papules 
show capillary dilatation and edema in the papillary dermis, with mononu­
clear infiltrate surrounding the capillaries. This preceeds the migration of 
mononuclear cells into the lower part of the epidermis. Besides lymfocytes, 
also many neutrophils are present in the upper portion of the papillae.44 After 
the development of slight spongiosis, focal changes may occur in the upper 
part of the epidermis, where granular cells become vacuolated and disappear. 
Parakeratosis appears and the phenomenon of the "squirting papillae" is 
observed focally, neutrophils being discharged intermittently from the papil­
lary capillaries. Accumulation of PMN in the epidermis is surrounded by 
parakeratotic zones. 4 1 · 4 4 The epidermal cells may be intermingled with neu­
trophils, showing the histological picture of a small spongiform pustule of 
Kogoj. In this pustule, the spongiform aspect, with eosinophilic strands of 
keratinocytes is diagnostic.4 1 , 4 5 The parakeratotic mounds with neutrophils 
have been designated as Munro microabscesses.41 
Orthokeratosis is focally present with underlying granular cells. Orthoke­
ratosis usually is intermingled with parakeratosis in one single biopsy. A 
mild inflammatory infiltrate is present in the upper dermis consisting mainly 
of mononuclear cells.44 The upward movement of infiltrate cells into the epi­
dermis in active psoriasis is reflected in the topography of the dermo-epider-
mal interphase: the dermal papillae reach to just underneath the stratum cor-
neum whereas the epidermal papillae have a massive acanthotic appearance. 
The spongiform pustule of Kogoj and Munro microabscesses, co-occurance 
of parakeratotic and orthokeratotic foci and suprapapillary thinning and 
hyperplasia of the rete ridges are diagnostic for psoriasis.41 Whereas the his­
tological diagnosis is easy in the margin zone, the picture usually is less 
specific in the central areas (figure 1.3). 
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Figure 7.3 Histology: the dermal and epidermal changes in psoriasis vulgaris. 
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1.3.2 PUSTULAR MANIFESTATIONS 
The histopathology of pustular psoriasis is characterized by macropustules, 
which are formed through the migration of neutrophils from the papillary 
capillaries through the epidermis. The epidermal cells in the center of the 
pustule undergo complete cytolysis, forming a large single cavity. Typical are 19 
the small, spongiform pustules in the epidermal wall of the pustule.46 The 
neutrophils of the spongiform pustule move up into the stratum corneum, 
where they become pyknotic and assume the appearance of a Munro abscess 
(figure 1.4). In the upper dermis an infiltrate of lymfocytes and neutrophils, 
migrating into the epidermis, can be seen.41 The other epidermal changes in 
pustular psoriasis are like those seen in psoriasis vulgaris.41'47"48 
Figure 1.4 Histology: a typical Munro microabsces, the subcorneal accumulation of 
polymorphonuclear leucocytes. 
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ΐ·4 Pathogenesis 
I .4.I CELLULAR ASPECTS 
20 Psoriasis is characterized by epidermal hyperproliferation, abnormal kerati-
nization and inflammation. It is believed that changes both in dermis and 
epidermis are required before a lesion can develop.49"50 
1.4.1.1 Cellular infiltrate 
The cellular infiltrate in the dermal papillae and upper dermis, as can be seen 
in psoriasis, consists of Τ lymphocytes, monocytes, polymorphonuclear 
leukocytes and occasional eosinophils and plasma cells.45 
In prepinpoint papules the dermal infiltrate is mainly composed of granulo­
cytes, whereas in the pinpoint papule a mixture of monocytes and lymphocy­
tes with a preponderance of monocytes can be observed.51"52 In a later phase 
when the lesions progress a preponderance of Τ lymphocytes does exist."'5 6 
Τ Lymphocytes — In both the epidermis and dermis of active psoriatic lesions 
activated IL-2 receptor HLA DR+ Τ lymphocytes are found.5 7 '5 4 The IL-2 
receptor, also designated as the receptor for T-cell growth factor is a marker 
of early T-cell activation and is associated with T-cell proliferation.0()'&1'57 
It has been demonstrated that active psoriasis is associated with an increase 
of HLA DR+, CD4+ Τ lymphocytes in the epidermis, while the resolution of a 
psoriatic plaque is associated with HLA DR+ CD8+ Τ cells.59·02 It has also 
been shown that the majority of the dermal mononuclear cell infiltrate in 
psoriatic plaques is composed of HLA DR+ Τ cells/'3 Several antigens seem to 
be involved in cutaneous immune reaction, including the streptococcal anti­
gens. f '4 '6 7 Group A streptococcal antigen-specific Τ lymphocytes have been 
isolated from guttäte psoriatic lesions.68 
The activated Τ cells may release lymphokines and directly modulate kera-
tinocyte differentiation and growth. 6 9 7 1 
Also an antigen-independent T-cell activation pathway has been descri­
bed. Expression of UM4D4 (CDw6o), a surface molecule important in this 
novel pathway, was found to be increased in lesionai psoriatic T-cells compa­
red to normal skin.72 It was reported that the activation of lesionai T-cells 
through the UM4D4 surface molecule, results in T-cell proliferation and in 
the release of lymphokines that directly induce keratinocytes to express a 
phenotype which is displayed in psoriatic skin lesions.7Э 
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Polymorphonuclear leukocytes — The infiltrate in the papillary layer of prepin-
point lesions contains a considerable number of polymorphonuclears 
(PMN). Especially in the subepidermal zone numerous polymorphonuclear 
leukocytes can been seen, penetrating into the epidermis.51 The invading 
PMN form micropustules of Kogoj, which are located in the stratum Malpig-
hi.74 In a later stage they represent a characteristic histopathological feature 21 
of psoriatic skin: the subcorneal accumulation of polymorphonuclear leuko-
cytes, resulting in Munro's micro-abscesses. In unstable psoriasis and pustu-
lar psoriasis this may lead to clinically apparent sterile pustulation.75 In active 
psoriasis microabscesses were seen in 75% and exocytosis of PMN in 95% of 
the lesions, whereas in chronic stable plaque psoriasis intraepidermal penet-
ration of PMN was shown ¡n 41% of the lesions and micropustules of 
Kogoj were seen in 10% of the lesions. Munro microabscesses seem to occur 
exclusively within parakeratotic areas and were observed in 34% of the 
cases.46>7b 
A link between recruitment of cycling epidermal cells and invasion of PMN 
into the epidermis has been suggested. This recruitment process became evi-
dent at the moment the PMN had reached the stratum corneum.77 
Macrophages — In active psoriatic lesions macrophages are present in 
approximately equal numbers as Τ lymphocytes, whereas in chronic lesions 
Τ cells are the predominant mononuclear cells.54 Potentially mobile CD45+, 
CD68+ macrophages are restricted to the dermal compartment of psoriatic 
lesions, with only a few cells penetrating through the basement membrane. 
Thus, the macrophages are almost exclusively restricted to the dermal com­
partment. Immunohistological analysis demonstrated that these dermal 
macrophages are mainly present in the papillary dermis and arranged along 
the rete ridges in close proximity to proliferating cells.78 A monocyte chemo-
attractant, the monocyte chemotactic protein-i (MCP-i), has been isolated.74" 
8 0
 It was shown that MCP-i mRNA is highly expressed in lesionai psoriatic 
skin, but not in uninvolved psoriatic or normal skin. The MCP-i expression 
was particularly high in the basal layer of the rete ridges. The topographic 
relation between MCP-i mRNA expression in basal cells and the subepider­
mal accumulation of CD68+ macrophages suggests selective chemotactic 
properties of the MCP-i on macrophages. Thus, MCP-i may be important in 
regulating the interaction between proliferating keratinocytes and dermal 
macrophages in the pathogenesis of the psoriasis.78 
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Lamjerhans cells — I he Langerhans cells are known to belong to the macro 
phage-monocyte system and are derived from the bone marrow. They consti 
tute an intraepidermal network, but are not confined to this location. Like 
macrophages and other dendritic cells they are antigen-presenting cells к 
Τ lymphocytes during the induction of the immune respons. The Langerhan; 
22 cells have a membrane-expression of HLA DR. They also bear surface recep-
tors for C3 components and Fc portions of immunoglobulins. The regula; 
network of Langerhans cells and their clustering around T-cells, are disorga 
nized in psoriatic skin. It is suggested that this abnormality permits ar 
ongoing immune response in psoriatic lesions.81 HLA-DR+ keratinocytei 
and Langerhans cells may present an unknown autologous or exogenous 
antigen to Τ lymphocytes, which may result in T-cell activation with release o: 
mediators of inflammation and epidermal growth factors. This may provide 
an explanation for the chronicity of psoriasis.57 
In literature the question has not been settled whether the number of Lan­
gerhans cells is decreased or increased. 8 2 8 ' 
1.4.j.2 Kerarinocytes 
In normal human skin a dynamic balance between the epidermal prolifera­
tion rate and keratinization process exists. In a steady state condition the 
shedding of the stratum corneum cells is proportional to the epidermal rene­
wal, ensured by the continuous division of germinative cells.84 During 
differentiation into horny cells the keratinocytes are arranged in four com­
partments: the basal layer, the squamous cell layer (stratum spinosum), the 
granular layer and the horny layer. The mitoses take place in the basal and the 
adjacent suprabasal cell layers of the normal human epidermis. The basa 
layer consists of one single cell layer. The cells of the stratum spinosum are 
polygonal. In normal human skin the number of cell layers in the stratum spi­
nosum may vary between five to ten, depending on the localization.85 In the 
spinous cells a set of keratin filaments and cornified envelope precursors are 
synthesized.86"87 The cells of the granular layer are diamond shaped or flatte­
ned. Their cytoplasm is filled with keratohyaline granules. In the normal epi­
dermis the thickness of the granular layer is proportional to the thickness ol 
the horny layer. The keratohyaline granules form the interfibrillary matrb 
which are responsible for the cement for the keratin fibrils. The cells in the 
horny layer in normal epidermis are anuclear. 
Dendritic cells in the epidermis are the melanocytes, the Langerhans cells 
and indeterminate cells. The latter are only identifiable by electron microsco-
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py. About io°/o of the cells in the basal layer are melanocytes. The melanocytes 
supply the keratinocytes with melanine. The Langerhans cells can be seen in 
the suprabasal epidermis As the indeterminate cells react with the mono­
clonal antibody OK Γ6, they probably are related to Langerhans cells.85 
Hyperprohferation is one of the hall-marks of psoriatic skin It is now well 
established that the increased epidermal cell proliferation is due to recruit- 23 
ment of cycling epidermal cells from the resting Go population 8 X The mitotic 
activity within different psoriatic lesions may vary considerably, and is belie­
ved to be correlated with the degree of parakeratosis.42 
Abnormal keratimzation is another characteristic feature in psoriatic skin 
The psoriatic keratinocytes in the stratum mapighn show various abnormali­
ties lhe tonofilaments are lacking their regular aggregation, while their 
number and diameter are decreased The keratohyahne granules are greatly 
reduced in number and size, and may be absent.1*4 4 0 lhe corneocytes often 
still contain organelles and nuclei, being parakeratotic 4 1 
A pathological set of cytokeratins appear in the suprabasal compartment 
of the psoriatic lesion, keratin 6 and 16 appear whereas keratin 1 and 10 are 
focally less expressed °2 4 7 Filaggnn, a protein involved in the aggregation of 
keratins, is reduced in the lesionai skin of psoriatic patients 4 S Involucnn, the 
core protein for the cornified envelope formation, is increased in the supra-
basal compartment of the lesion " l h e enzyme transglutaminase has been 
reported to be increased in lesionai psoriatic skin 10° 1 0 1 The formation of 
cornified envelopes is also increased in psoriatic epidermis 1 0 2 So far, the 
interrelation between epidermal proliferation and various aspects of keratim­
zation during induction and regression of the lesions is not clear and remains 
to be established 
1.4.1.3 Fibroblasts 
The majority of the cells in the dermis consists of fibroblasts. Analysis of 
fibroblast lines cultured from lesionai and non-lesional skin of psoriatic 
patients demonstrated an increase in proliferation rate, collagen and general 
protein synthesis. Further, an increase of glycosaminoglycans was observed 
in involved and clinically uninvolved sk in . 1 0 4 1 0 4 Combined graft studies in 
nude mice demonstrated that only in the coexistence of psoriatic epidermis 
and psoriatic dermis the characteristics of psoriasis persist 4 0 1 0 5 1(17 Sund-
berg et al also demonstrated that the psoriasiform phenotype of the flaky skin 
mouse can persist indepently of the host thymic-denved immune system 1 U 7 
Fibroblasts from uninvolved as well as from involved psoriatic skin have the 
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capacity to induce hyperproiiferation in normal explanted epidermis, where­
as normal human skin-derived fibroblasts were unable to suppress the hyper­
proliferative activity of explanted involved psoriatic skin.1 0 6 However, there is 
still no clear consensus of opinion with respect to the relationship between 
keratinocytes and fibroblasts in psoriasis.108 
24 The regulation of epidermal proliferation, keratinization, abnormalities of 
the stroma and inflammation depends on the balance between interacting 
signalling networks. 
I.4.2 SIGNALLING 
1.4.2.1 Phospholipase C/Protein kinase С signal transduction system 
The phospholipase C/protein kinase С signal transduction system appears to 
be activated in psoriasis.100 Extracellular signals bind to specific cell surface 
receptors. The binding of ligand to its receptor activates phospholipase С 
(PLC), which hydrolyzes the membrane phospholipid phosphatidylinositol-
4,5-bisphosphate (PIP2). The products of this reaction are sn-i,2-diacylglyce-
rol (DAG) and inositol-i,4,5-trisphosphate (ІРз). These molecules act as in­
tracellular second messengers. DAG activates protein kinase С (PKC) and ІРэ 
does increase the intracellular concentration of free calcium.1 1 0"1 1 1 PKC 
phosphorylates proteins specifically at serine and threonine residues. Calci­
um binds to calmodulin and other calcium-sensitive proteins. Activated PKC 
and increased intracellular calcium together orchestrate a cascade of nuclear 
and non-nuclear biochemical reactions, which leads to cellular responses.1 0 9 
The induction of the keratinocyte transglutaminase gene expression by calci­
um is dependent on PKC, thus PKC plays a central role in regulating the late 
stages of epidermal differentiation.112 There are three major routes for atte­
nuation of the PLC/PKC signal transduction system: 
1. Feedback inhibition of receptor-coupled phospholipase С activity by pro­
tein kinase C; 
2. Conversion of the second messengers 1,2-diacylglycerol and inositol 1,4,5-
trisphosphate to inactive metabolites; 
3. Down-regulation of protein kinase C. 1 0 9 
This second messenger system integrates biological processes which are 
relevant with respect to psoriasis such as immune response, inflammation, 
differentiation and proliferation.109 
C H A P T E R I 
1.4-2.2 Receptor-linked tyrosine kinases 
The epidermal growth factor (EGF) receptor belongs to the family of cell sur­
face phosphoglycoproteins that binds polypeptide growth factors with high 
affinity at the extracellular surface and contains a cytoplasmic tyrosine kinase 
domain. Growth factor binding results in cell proliferation via the action of 
receptor coupled tyrosine kinase.1 0 9 The EGF receptor is overexpressed in the 25 
suprabasal layers of the hyperproliferative epidermis of the psoriatic pla­
que. 1 1 3 Transforming growth factor α (TGF-α) is structurally related to 
EGF. 1 1 4 Both molecules bind to the EGF receptor with high affinity.115 TGF-
α is detectable at low levels in normal epidermis and is markedly overexpres­
sed in psoriatic epidermis.1 1 6 In vitro TGF-α is more potent than EGF in pro­
moting epidermal proliferation.117 Therefore TGF-α may function as an 
autocrine or paracrine ligand that promotes epidermal proliferation in vivo 
via the EGF receptor.1"4 
1.4.2.3 Adenylate cyclase and cAMP-dependent protein kinase 
Enzymes and other proteins can be phosphorylated by ATP. Such is catalyzed 
by protein kinases. cAMP-Dependent protein kinase is active only in the pre­
sence of cAMP. Different enzymes can be phosphorylated by cAMP depen­
dent protein kinase. 
Low levels of cAMP favour the accumulation of precursors required for cell 
replication and are thereby associated with tissue proliferation.118 In the 
psoriatic plaque increased epidermal proliferation is a well established hall­
mark. It has been hypothesized that a defect in the cAMP cascade is responsi­
ble for this aspect.1 1 9 
1.4.2.4 Steroid receptor superfamily 
The steroid receptor superfamily comprises nuclear receptors with monospe­
cific binding for vitamin D3, retinoic acid, corticosteroids, thyroid hormone 
and estrogens.1 2 0"1 2 5 
It is of interest that vitamin Di, retinoic acid and corticosteroids are stan­
dard treatments for psoriasis. In the psoriatic skin no defect of compounds of 
the steroid superfamily has been reported so far. 
1.4.2.5 Eicosanoids and the cytokine пегшогк 
The eicosanoids and cytokines represent a family of inflammatory and mito-
genic mediators which are of relevance in dermo-epidermal interaction. 
Psoriasis is characterized by a disturbance of the eicosanoid metabolism with 
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a marked increase in free arachidonic acid, the precursor of the cicosanoids 
As a result, the level of the prostaglandins (PGE2 and PGF2), 12-hydroxy-eico-
satetraenoic acid (12-HETE), leukotnene Ik (LITE·.*) is elevated in psoriatic 
involved skin 1 2 f t n i EGF and TGF-a have been shown to stimulate arachido­
nic acid release and eicosanoid formation in EGF receptor-bearing cell types 
26 including epidermal cells " 2 m 
The increase of PGE2 and PGF2 mav be related to vasodilatation and kerati-
nocyte hyperprohferation in the psoriatic plaque 1 3 4 Arachidonic acid, LTB4 
and 12-HE ΓΕ have a potent chemotactic effect on polymorphonuclear leuko­
cytes and monocytes 1 3 S 1 3 f t 
It has been demonstrated that in lesionai psoriatic skin the amount of IL-
ια is decreased while the amount of IL-iß is increased as compared to the 
uninvolved skin of psoriatic patients and the normal human skin 1 , ? In-
creased levels of IL-6 are observed in active psoriatic lesions Immunohisto-
chemical staining was confined to keratmocytes and inflammatory dermal 
cells 1 , s п ч Whereas immunoreactive IL-8 is not found in normal skin, it has 
been located in suprabasal keratmocytes in psoriatic lesions 1 4 0 Also biologi­
cally active IL-8 and the level of IL-8 mRNA are elevated in psoriatic lesions, 
the latter especially in active plaques 1 4 1 1 4 2 
It is known that IL-8 attracts neutrophils and 1 lvmphocvtes It is therefore 
considered to be a key cytokine in the maintenance of psoriasis 
TNF-a is identified in macrophages in the upper dermis in lesionai skin, 
while there is no detectable TNF-a in normal skin 14() However, another 
group did detect TNF-a distributed throughout the epidermis, and 
specifically localized near dermal blood vessels in psoriatic skin and in lesser 
extent in uninvolved skin, while in normal skin TNF-a was predominantly 
localized in the basal cell layers of the epidermis and in association with 
eccnne ducts and sebaceous glands 1 4 3 
The expression of IFN-ycorrelates with the disease activity In highly active 
psoriatic lesions IFN-γ is confined to basal keratmocytes, corneocytes and 
dermal mononuclear cells In uninvolved psoriatic skin and normal healthy 
skin no expression of interferon was observed.144 
I 4 .3 LLSIONAL VERSUS CL1NICALLY U N I N V O L V E D SKIN 
The psoriatic plaque is characterized by chaos of abnormalities at the cellular 
and biochemical level Inflammation induces changes in the epidermal and 
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dermal compartment and vice versa. Studies on the clinically uninvolved skin 
might lead to the more primary aspects in the pathogenesis of psoriasis. 
Table i.i summarizes cellular and biochemical abnormalities in the symp­
tomless skin. 
Table i.i Changes in the distant clinically uninvolved skin compared to the skin of 
healthy controls. 
Compartment 
Epidermis 
Stroma 
Marker 
Phosphohpase A2 activity 
Calmodulin content 
Protein kinase С activity 
Release of arachidonic acid metabolites 
Polyamine synthesis 
DNA synthesis 
Proliferation and release of 
glycosaminoglycans by fibroblasts 
ICAM positive endothelial cells 
LTB4 induced PMN accumulation 
Activity 
Î 
N-Î 
1 
Τ 
τ 
î 
τ 
i 
i 
References 
145-146 
147 
148 
130,134 
149 
150 
103-104 
151 
152-153 
Our knowledge on the interphase between clinically uninvolved and lesionai 
skin is limited so far.1 5 4"1 5 7 
It has been shown that dermal changes (tenascin expression) and the 
inflammatory infiltrate appear peripherally to the epidermal changes (acan­
thosis, keratin 16 expression and recruitment of cycling epidermal cells).154 
However, there is also evidence that morphological changes in the epidermis 
preceed the dermal changes.1 5 8 Thus, it remains controversial whether the 
dermis or the epidermis shows the earliest changes. 
Contradictory information is present about the dynamics of epidermal 
changes during induction of the psoriatic lesion. Does epidermal prolifera­
tion anticipate or follow the abnormal keratinization? 
27 
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ΐ·5 Therapy 
Every patient with psoriasis has his own psoriasis The treatment of choice 
depends upon age, sex, personality, occupation, general health, intelligence, 
28 and the type, extent, duration, and natural history of the disease. Ihe treat­
ment must always be appropriate with respect to the severity of the disease 
and never be more demanding than the disease itself Attention must be given 
to the patient's general, physical and psychological health Reassurance and 
emotional support, stressing the non-contagious and benign nature of the 
disease is of great importance Ί he possibility of spontaneous remission and 
the availability of a wide range of therapeutic agents has to be discussed with 
the patient " 
Although a large repertoire of treatments is available for the clinical 
management of psoriasis, the mode of action of treatments is not known 
Several studies on in vitro systems indicate that all classical antipsonatic 
treatments interfere with various aspects of epidermal proliferation and kera-
tinization Studies on the in vivo effects of these treatments are spare In par­
ticular the question whether antipsonatic treatments interfere directly with 
aspects of keratimzation and recruitment of cycling epidermal cells in vivo is 
unsettled To what extent are modulations of epidermal behaviour in vitro of 
relevance for the antipsonatic effect in vivo7 
In the next sections several important therapies for psoriasis will be men­
tioned 
1 5 1 TOPICAL THFRAI'Y 
1 5 1 1 Tur therapy 
Perhaps the oldest antipsonatic treatment is coal tar 
Coaltar is a mixture of aromatic hydrocarbons manufactured by primary con­
densation during the carbonization of coal 1 S 4 A great variation in biological 
activity of various samples of tar has been demonstrated lbû Therefore a 
comparison of therapeutic results between different centres, is virtually im-
possible 
Гаг has been used as a topical agent for more than hundred years The use 
of tar in psoriasis was popularized bv Goeckerman His regime of daily appli­
cation of 2% to 5% crude coal tar, combined with a tar bath and UVR, was a 
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mainstay of in-patient treatment for more than fifty years.161 Many 
modifications of this regime have been advocated. Pretreatment with tar may 
allow for a lower daily and total dose of UVR radiation. 
Liquor picis carbonis, also designated as liquor carbonis detergens, in 
concentrations up to 6 or 10% can be incorporated in various vehicles. 
Tar therapy is safe. Tar treatment in patients with unstable psoriasis and 29 
application on the face, genitalia and in the flexures can cause primary irrita-
tion. Folliculitis is the commonest side effect. Except for one single epide-
miological study, suggesting an increased skin cancer incidence in psoriatics 
treated with tar and UVR, there are many other series showing no higher 
risk.162"104 Studies on the carcinogenicity of antipsoriatic treatment are ham-
pered by the fact that patients with longstanding psoriasis may have been 
treated in the past with X-rays or arsenic. Contra-indications to tar therapy 
are erythrodermic or generalized pustular psoriasis, pre-existing folliculitis, 
severe acne and the concurrent administration of photosensitizing drugs.35 
1.5.1.2 Dithranol 
The therapeutic value of chrysarobin (3-methyI dithranol), a bark extract 
from the aroba tree, was accidently found in 1876 by Dr. B. Squire.''5 In 1916 a 
synthetic derivative, dithranol, cignolin or anthralin (i,8-dihydroxy-g-an-
throne), was introduced by Unna. The activity is dependent on the associa-
tion of the hydroxyl, the carbonyl groups and the 10-methylene residue. The 
more lipophilic the vehicle the greater the penetration into the skin.165 The 
mode of action depends upon the induction of free radicals. A hydrogen atom 
from the 10-methylene group is released, thereby initiating biologically active 
free radicals. These radicals are responsible for the antipsoriatic activity but 
also for the skin irritancy, which is a limitation of this treatment. Oxidation 
products of dithranol cause for the staining of skin and environment.166 The 
mode of action of dithranol is probably not a single selective mechanism. 
Interference with epidermal growth and inflammation has been reported. It 
is has been suggested that dithranol acts by depriving the cells of the oxygen 
needed for their proliferating activity.167 
The Ingram regime, as described in 1953, was the golden standard in the 
treatment of psoriasis. In a hospital or a day-treatment setting a tar bath is 
followed by sub-erythematogenic dosages of UVB. Afterwards dithranol 
paste (0.05-3.0%) is applied on the lesions. Depending on the clinical impro-
vement and irritation the initial concentration is increased.35·167 
In the short-contact therapy with dithranol the application times are res-
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tricted between io and бо minutes. The strength of dithranol in the short-
contact regimes is increased from 0.5, to 1,2,3 and 5%. Changes in strength 
or time usually are made after a three days interval. Dithranol can be regarded 
as the most safe treatment for psoriasis; except for skin irritation and stai­
ning, no side effects have been observed after more than 75 years clinical 
30 application. In acute or unstable psoriasis dithranol can cause severe intole­
rance with the development of generalized exfoliation and pustulation. 
Because steroid-treated psoriasis is relatively intolerant to dithranol, a wash 
out period of two weeks before starting dithranol therapy will be safer. In this 
period bland preparations or a weak tar ointment can be used.1 0 7 
1.5.1.3 Corticosteroids 
Topical corticosteroids have been prescribed frequently in patients with pso­
riasis. The corticosteroids have the advantage of ease of application, lack of 
irritancy and the absence of staining of skin or clothing. However, overtreat-
ment with topical corticosteroids can lead to topical and systemic side-effects 
and may induce unstable psoriasis. 
The steroid structure consists of 17 carbon atoms arranged in four rings, 
three six-membered and one five-membered. Substitutions or alterations of 
the steric configuration of the substituents on the molecule can lead to chan­
ges in the biological activity. 
The mode of action may involve direct effects on epidermal proliferation, 
suppression of the synthesis of inflammatory mediators and modulation of 
the immunocompetent cell population, by regulating many aspects of the 
immunological process. 
Potent topical corticosteroids may achieve clearance of the lesion within 
2-3 weeks, when applied twice daily. To maintain remission, weaker prepara­
tions can be used. 
Local side effects are atrophic changes, striae, teleangiectases, purpura, 
localized fine hair growth, perioral dermatitis, and allergic contact dermati­
tis. A relapse of psoriasis and the conversion of chronic plaque psoriasis into 
generalized pustular psoriasis may be induced after the withdrawal of potent 
topical corticosteroids. The most potent preparations can cause suppression 
of plasma Cortisol levels, ifapplied on extended skin surfaces. Because of the 
risk of this adverse effect not more than than 45-90 g per week of the very 
potent steroids should be applied.Ift8 
Recently a new approach became available: the application of hydrocolloid 
dressings in combination with once weekly applications of a medium-potent 
topical corticosteroid. 
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1.5.1.4 Vitamin D3 
Since the observation by Kato and Kumahara of a patient with senile osteopo-
rosis and psoriasis vulgaris, in whom psoriastic lesions improved by oral 
administration of irx-hydroxyvitamin D3, many case reports and clinical stu-
dies on the beneficial effect of vitamin D3 dérivâtes have appeared in literatu-
re.104 '174 At the moment calcipotriol is the vitamin D3 derivate which is avai- 31 
lable for general use. Calcipotriol has an antipsoriatic potential, without 
significant interference with the calcium metabolism at therapeutic dosages. 
It has been shown that calcipotriol (50 μg|g ointment) applied twice daily on 
psoriatic plaques results in a reduction of polymorphonuclear leukocytes 
(PMN) after one week of treatment, a decrease of the epidermal proliferation 
after two weeks, and a significant reduction of T-lymphocytes and expression 
of keratin 16 after four weeks of treatment.17^ No systemic side effects have 
been reported. Up to dosages of 100 g/week serum levels of calcium and 
phosphate remain normal. Dwyeretal, however, reported hypercalciaemie in 
a patient with psoriasis who used more than twice the maximum dose. After 
discontinuing the therapy the calcium level normalized.1™ There is also a 
report on hypercalciaemie after calcipotriol treatment under occlusion.177 
Local irritation of the skin was observed in 4-20% of the patients. In most 
patients this side effect disappeared after continuing the therapy.1 7 5-1 7 8 
Calcipotriol treatment is applied twice daily. The total weekly dose has a 
maximum of 100 g. Maximal clinical improvement can be expected within 4-8 
weeks. 
1.5.1.5 Phototherapy 
Ultraviolet radiation (UVR), if given in mildly erythematogenic dosages, has a 
high clearing capacity in psoriasis.1 7 9 '1 8 2 UVR is part of the wide electromag­
netic spectrum. UVB (290-320 nm) has a substantial photodynamic effect as 
monotherapy, resulting in erythema and pigmentation, whereas UVA (320-
400 nm) has an important photodynamic effect in the presence of photosen-
sitisisers, as for instance after ingestion or application of 8-methoxypsoraIen 
in PUVA treatment. During UVR, the energy of a photon is transferred to a 
molecule by changing the rotation or vibration of the electrons from the 
ground state into a short-lived excited (singlet) state. The energy of the sing­
let state initiates chemical reactions by bringing oxygen into an excited state, 
which results in oxydation of a second molecule and in a subsequent cascade 
of biochemical reactions.1X3 The arachidonic acid pathway is activated follo­
wing UVR irradiation, which might explain the inflammation (post-radiation 
C H A P T E R I 
erythema and oedema). The proliferation associated enzyme ornithine decar­
boxylase is also stimulated after UVR.184 In proliferating keratinocytes cell 
death due to UVR is increased.185 On the other hand a single erythematogenic 
exposure to UVB results in an increase in unscheduled DNA syntheses.186 
The Langerhans cells are even more sensitive to UVR. After UVR the Langer-
32 hans cells are damaged and show functional impairment. Also the number of 
Langerhans cells is found to be decreased after UVR.183 
Although several investigations stress the potential carcinogenicity of 
UVR, only in one clinical study actually a significant increase in malignancies 
in patients after UVR was found. l f t 2 
The contraindications for treatment with UVR are chronic light-sensitive 
disease, the intake of phototoxic or photosensitizing drugs, a history of skin 
cancer or actinic keratoses, previous treatment with X-rays or arsenic, and a 
family history of melanoma. 
I .5.2 SYSTEMIC THERAPY 
1.5.2.1 Photochemotherapy 
The interaction of a photoactive drug with UVR results into an antipsonatic 
effect. The efficacy of the combination of oral and topical 8-MOP (8-me-
thoxypsoralen) and UVA has been well established.35 
In vitro studies have demonstrated the inhibition of the chemotactic activi­
ty of C5a and a psoriasis leucotactic factor.187 1 8 8 A decrease in the percenta­
ge of circulating Γ lymphocytes during PUVA therapy has been reported, 
while PUVA seems to inhibit the migration of PMN into psoriatic lesions, 
thus resulting in a reduced inflammatory reaction.189 
Adverse effects of PUVA are erythema, sunburn, nausea, pruntis, pigmen­
tation, PUVA-lentigines, bullae, hypertrichosis and cutaneous pain. Excessi­
ve cumulative dosages may result in cutaneous malignancy Relatively seldom 
cataract and hepatotoxicity have been reported.1 8 9 
Contraindications are renal, hepatic or severe cardio-vascular disease, 
cataract formation, systemic lupus erythematodes, porphyria, previous arse­
nic treatment or radiotherapy, a history of cutaneous malignancy , and preg­
nancy. 
PUVA treatment is indicated in severe psoriasis vulgaris, generalized 
pustular psoriasis and palmoplantar pustular psoriasis.189 
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1.5-2.2 Corticosteroids 
Systemic therapy with corticosteroids is of limited value in psoriasis. Their 
role is restricted to the management of persistent, otherwise uncontrol-
lable, erythroderma which causes metabolic complications and in fulmina-
ting generalized pustular psoriasis if other drugs are contraindicated or 
ineffective.35 33 
Systemic corticosteroids reduce the cellular infiltrate in psoriatic lesions 
and prevent the entry of PMN into affected areas by reducing their adherence 
to endothelial cells and reducing the quantity of chemotactic signals by inhi-
biting leukotriene production. Corticosteroids not only inhibit epidermal 
proliferation but suppress almost every phase of the immunological 
process.16* 
Besides the adverse effects as can be seen during topical treatment with 
corticosteroids, systemic treatment may of course induce the well known sys-
temic side-effects like suppression of the adrenal axis and a Cushing syndro-
me, osteoporosis, diabetes mellitus, peptic ulcera etc.35 
1.5.2.3 Methotrexate 
The use of folic acid antagonists in the treatment of psoriasis was described 
in 1951 for the first time.140 
During methotrexate (MTX) treatment the psoriatic lesions show early 
changes in proliferation followed by restoration of normal keratinization. 
MTX interferes with DNA, RNA and protein synthesis. The cell cycle remains 
in the Gi phase and the cells in the S phase are killed, resulting in a reduction 
of the total number of cycling cells.191 
MTX also inhibits PMN Chemotaxis at dosages which are effective in 
psoriasis.142 
Because of the potentially severe side-effects, MTX is never the first choice 
of treatment. The well known side effects of MTX are transient anorexia, nau-
sea, dyspeptic pain, burning sensations in the psoriatic lesions, hair loss, leu-
kopenia, thrombocytopenia, and megaloblastic anaemia. Long-term metho-
trexate treatment may cause liver fibrosis or cirrhosis. Because a mutagenic 
risk cannot be entirely ruled out, males and females who want to have child-
ren at short term should be excluded from MTX treatment. If other therapies 
have not been succesful it is justified to carry out a premethotrexate scree-
ning. Contraindications are significant renal and liver abnormalities, preg-
nancy, infectious disease, interfering medication, bone marrow hypoplasia, 
peptic ulcer, ulcerative colitis, psychosis or excessive alcohol intake.35192 
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Laboratory investigations are required at 4-6 weeks intervals and after 1.5 g 
MTX (cumulative dose) a liver biopsy should be performed. The initial dosa­
ges should always be at the lower end of the therapeutic range. The maximal 
response can be seen after 4-8 weeks.3S The maximum dosage of MTX is 
15 mg per week. 
34 
1.5.2.4 Retinoids 
The aromatic retinoids etretinate and acitretin are widely used in the systemic 
treatment of severe psoriasis. These retinoids should be considered as first 
line treatment for patients with pustular or erythrodermic psoriasis. In these 
patients retinoids have a therapeutic advantage compared to other treat­
ments. In plaque type psoriasis combination of retinoids and other treat­
ments should be considered.19Э 
Retinoid treatment in psoriatic patients exerts an antiproliferative 
effect.1 0 4'1 4 6 Inhibition of PMN migration into psoriatic epidermis and early 
reduction in the antibody-dependent cell-mediated cytotoxicity of PMN in 
psoriatic patients have been described.197"19'' Reduction of the expression of 
keratin 16 in psoriatic epidermis occurs during etretinate therapy.200 
Side-effects reported are peeling of the palms and soles, dryness of the lips 
and mucous membranes, epistaxis conjunctivitis, cheilitis, urethritis, bala­
nitis, gingivitis, pruritus, skin atrophy, hair loss, increased bruising, wide­
spread erythema, retinoid dermatitis, paronychia, impaired night vision and 
colour vision, joint stiffness and synovitis. Transient increases of aspartate 
transaminase (AST, SGOT), alanine transaminase (ALT, SGPT) and lactate 
dehydrogenase (LDH) have been observed during retinoid treatment.2 0 1 
Serum triglyceride and cholesterol may increase during etretinate therapy. 
During long-term treatment hyperostotic changes in the spine can be obser­
ved occasionally. It is important to be aware of the teratogenic potential of 
retinoids. Because etretinate and acitretin (after reesterification) have a long 
elimination half life, women should avoid pregnancy for at least 2 years after 
stopping the therapy.194 
Contraindications for both retinoids are active liver disease, pre-existing 
hyperlipidaemia, and pregnancy. 
Before starting systemic retinoids a blood chemistry analysis should be 
performed to exclude hyperlipidemia and hepatic or renal pathology. A clini­
cal examination once a month to ascertain clinical efficacy and to cheque for 
possible side-effects is required. An X ray of the spine should be performed 
before the start and after every year of treatment.1 9 4 
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1 5 2 5 Cyclosporin A 
Cyclosporin A is a relatively new drug in the management of psoriasis Its 
antipsonatical potential has been repeatedly confirmed 2 0 2 2 0 4 
The mode of action of cyclosporin A in psoriasis is supposed to be an inhi­
bition of CD4+ Τ lymphocyte function However, there are studies which 
show an effect of cyclosporin on other systems including the keratinocytes 35 
Because of potentially serious side-effects, such as nephrotoxicity and hyper­
tension, cyclosporin A should only be considered in case of refractory psoria­
sis As these adverse effects are dose-related the lowest possible dosage 
should be administered Other side effects, milder and reversible, are gingi­
val hyperplasia, tremor, hypertrichosis, headache, diarrhea, malaise and nau­
sea
 2 0 5 
Contraindications are concomitant treatment with potential nephrotoxic 
or cytotoxic agents, concomitant immunosuppressant or radiation therapy 
(including PUVA and UVB), other drugs which may interfere with the bioavai­
lability of cyclosporin A, previous or concomitant malignancies, infections, 
immunodeficiency, chronic severe organ dysfunction, drug or alcohol abuse, 
epileptic disorders, pregnancy, abnormal renal function or uncontrolled 
hypertension 
Before treatment, dermatological and physical examination (including 
measurement of bloodpressure on at least two occasions), and laboratory 
examinations (glomerular filtration rate, serum creatinine, bilirubin, liver 
enzymes, serum sodium and potassium, uric acid, serum lipids, white blood 
count and urinary protein) should be performed. Regular clinical and labora­
tory examinations are mandatory 2Uft 
1 5 2 6 New developments in the treatment of psoriasis 
Recently the vitamine D3 derivative calcipotnol has been registrated as a rou­
tine treatment for psoriasis Other vitamin D3 derivatives such as calcitnol 
(1,25 -(ОН)г-Оз) and tacalcitol (1,24 -(ОН)г-Оз) are in an experimental stage 
Development of more vitamin D3 analogues is worthwhile in order to achieve 
a compound with maximal antipsonatic efficacy and minimal side effects 
Once weekly application of a corticosteroid under hydrocolloid dressings is 
an extremely effective treatment and a hydocolloid dressing as a monothera­
py is effective to some extent Cyclosporin A recently has become available as 
a routine treatment in patients with severe psoriasis Currently this treatment 
is establishing its position between the other major treatments for psoriasis 
Also dérivâtes which are less toxic are tested 
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1.6 Hypothesis 
Without denying the significance of inflammation control on the pathogene-
sis of psoriasis, we formulate the working hypothesis that increased epider-
36 mal proliferation and abnormal epidermal differentiation represent major 
constituents of the pathogenesis of psoriasis. Evidence for this hypothesis is 
provided by the observation that epidermal profileration and various aspects 
of signal transducing pathways in the epidermis are abnormal already in the 
clinically uninvolved skin in the absence of clinical and histological signs of 
inflammation. Circumstantial evidence for this hypothesis is provided by the 
fact that all treatments which are available for psoriasis have been shown to 
interfere with epidermal proliferation. 
1.7 Aim of the thesis 
With respect to the investigations described in this thesis we restricted our 
research to epidermal growth and differentiation. In particular the recruit-
ment of cycling epidermal cells, the expression of filaggrin, involucrin and 
transglutaminase were studied. The recruitment of cycling cells has been 
the hyperproliferation principle in the psoriatic lesion. Transcription of 
involucrin and the cross-linking enzyme transglutaminase are an early as-
pect of and filaggrin transcription a late event in the process of keratiniza-
tion. 
The aim of this thesis is threefold: 
1. To study the dynamics of epidermal proliferation and keratinization in the 
transition zone between non-lesional and lesionai skin and a potential in 
vivo model for psoriasis. 
2. To study the clinical efficacy of new topical treatments for psoriasis and to 
establish the dynamics of epidermal proliferation and keratinization 
during the regression of the lesion induced by these treatments. 
3. To study the direct effect of systemic antipsoriatic treatments on epidermal 
proliferation and differentiation in vivo. 
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1.8 Experimental approach 
As stated in aim i, 2 and 3, we used several models to study the dynamics of 
epidermal proliferation and keratinization. To study the sequence of changes 
in the evolution of the psoriatic lesion, we investigated the margin zone of the 37 
spreading psoriatic lesion. The regression of the psoriatic lesion was studied 
using different therapies. To find out whether these features are specific for 
psoriasis we also performed the tape stripping model. 
1.8.1 MODELS 
1.8.1.1 The margin zone of a spreading of the psoriatic lesion 
To study the sequence of changes in the evolution of the psoriatic lesion we 
used the model of the margin zone of a spreading plaque. It has been sugges-
ted that the nature of the psoriagenic stimulus is maximally manifest at the 
leading edge of centrifugally extending lesions.207 
1.8.1.2 The tape stripping model 
In 1951 Pinkus made the discovery that following the application of multiple 
strips of cellophane tape to normal skin, a predictable mitotic response of 
epidermal cells occurs. After applying successively multiple strips of tape to 
the same area the corneocytes were removed, layer by layer. 48-72 Hours after 
tape stripping he observed a burst of mitoses in the basal layer and in the 
lower region of the stratum spinosum.208 The peak of the mitotic response is 
usually after 48 hours.209 The stratum granulosum is lost after 12 hours.210 
After 24 hours, a parakeratotic layer starts to form and the stratum granulo-
sum starts to regenerate beneath the parakeratotic cells.204 Human epider-
mis following tape stripping shows a wave of cell divisions with a maximal 
percentage of cells in the mid-S-phase at about 39 hr after stripping. Thus, 
tape stripping provides a usefull model to study synchronized epidermal 
growth. As such it offers an accurate method to study influences of drugs on 
epidermal behaviour in the absence of a significant degree of inflammatory 
infiltrate.211 
1.8.1.3 The regression o/the psoriatic lesion during therapy 
The psoriatic lesion may regress spontaneously or during treatment with 
antipsoriatic drugs. 
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In spontaneously resolving lesions of psoriasis, the inflammatory cells are 
the first cells to disappear The granular layer returns to normal and the epi­
dermis becomes less acanthotic The suprapapillary plates remain thin for 
long, whereas the marked tortuosity of the capillaries in the papillary dermis 
persists longest 2 1 2 
I 8 2 METHODS 
The mechanisms which are involved in vivo during the therapeutically indu­
ced regression of the lesion remain to be established 
A method to evaluate the in vivo effects of antipsonatic therapies is taking 
biopsies before and after treatment, followed by an immunohistochemical 
assessment with antibodies against cell biological aspects with respect to 
proliferation keratinization or inflammation 
1 8 3 IMMUNOHISTOCHI-MISTRY 
To investigate the dynamics of differentiation and epidermal proliferation 111 
psoriasis we used monoclonal antibodies against filaggnn, involucrin, epi­
dermal transglutaminase and against a nuclear antigen present in cycling 
epidermal cells 
I 8 4 MONOCLONAL ANTI BO Dil· S MARKING AS Ρ l· CTS OF THE 
KLRATINIZATION PROCESS 
ι 8 4 ι Inuolucnn 
1 he corneocyte can be thought of as an envelope of cross-linked proteins sur­
rounding a network of keratin intermediate filaments 2 1 Э Involucrin is a solu­
ble protein precursor of the cross-linked envelope of human stratified 
squamous epitheha 2 1 4 The name involucrin comes from the latin word inuol-
ucrum, which means envelope 2 1 5 I he protein sequence has a repeating struc­
ture, while the molecular weight is 68,000 daltons 2 1 f t The structure of invol­
ucrin shows a uniform distribution of glutamine residues at equal intervals 
along the axis of the α-helical involucrin rod Thus involucrin should be able 
to cross-link proteins in multiple spatial planes 2 1 7 The initiation of the syn-
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thesis of involucrin is correlated with cell enlargement and migration from 
the basal layer.218 The envelope assembly begins long before nuclear destruc-
tion is complete. The early and continued synthesis of involucrin in differen-
tiation suggests that involucrin molecules are likely to be deposited early in 
the process of envelope assembly and that the deposition of involucrin will 
continue during the keratinization process.213 The cornified envelope is sta- 39 
bilized by calcium-dependent transglutaminase cross-linking.87 
Using immunohistochemical methods involucrin can be detected in the 
maturing cells of the upper stratum spinosum and stratum granulosum in 
normal human skin.09 
Because involucrin is immunologically and biochemically unrelated to 
keratin, involucrin is a distinctive marker for a stage in keratinocyte matu-
ration that immediately preceeds the final events of terminal differen-
tiation.214·219-221 
To assess the involucrin expression we used MON-150, which is a mono-
clonal antibody against involucrin.222 
1.8.4.2 Filaggrin 
Filaggrin (fi! ament agg regating prote ine) is a histidine-rich basic protein 
which is synthesized as a high molecular weight, heavily phosphorylated, 
precursor protein (> 300,000 daltons), called profilaggrin, which is depo-
sited in the keratohyalin granules.223 Simultaneously with the transition of 
the granular cell into a stratum corneum cell, profilaggrin is dephosphoryla-
ted and proteolytically cleaved into filaggrin molecules (35,000 daltons).224 
One of the functions of filaggrin is the aggregation of keratin filaments, the-
reby forming the keratin pattern as can be seen in the lower stratum cor-
neum.22,5 
Breakdown of filaggrins leads to the formation of a very concentrated pool 
of free amino acids and derivatives, such as pyrrolidone carboxylic acid, 
which has a water retaining function in the stratum corneum.226 The latter 
acts as a moisture binding compound allowing the stratum corneum to 
remain hydrated at low environmental humidities.227 The low level of amino 
acids found in the stratum corneum of ichthyosis vulgaris patients, a disease 
characterized by severe dryness of the skin, corresponds with the finding of a 
decreased or absence of profilaggrin.228 Also in senile xerosis the clinical 
severity correlates with decreased amino acid contents in the stratum cor-
neum. Thus low profilaggrin biosynthesis in the epidermis may be involved 
in the pathogenesis of xerotic skin conditions.224 Another breakdown pro-
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duct of filaggnn is urocanic acid, which mav have a role as ultraviolet blocker 
and possibly a photoimmune receptor 23° 2 3 1 Moreover, it was shown that 
filaggnn is also a component of the epidermal-cell envelope in vivo and a glu-
tamine-donor substrate of epidermal transglutaminase in the newborn 
r a t 2 3 2 
40 In normal human skin filaggnn expression can be observed in the stratum 
granulosum and in the stratum corneum 9 8 
We used a monoclonal mouse anti-filaggnn antibody to asses filaggnn 
expression 
1 8 4 3 Transglutaminase 
Ihe reaction of the cross-linking of loncrin, involucnn, keratolmin and pro­
bably also filaggnn in the cornified envelope is catalyzed by transglutaminase 
1 (TGase 1 or transglutaminase K), a calcium-requiring enzyme, through the 
formation ofe-(y-glutamyI)Iysine isopeptide bonds 2 1 8 2 " 2 3 6 IGase 1 is acti­
vated as the keratinocyte matures in the granular layer of the epidermis 2 3 7 
The cellular TGase 1 can be activated prematurely by introducing Ca++ into 
the cytoplasm 2 1 4 The elevation of medium calcium levels in cultured mouse 
epidermal cells increases both the activity of transglutaminase and subse­
quently the formation of ε-(γ glutamyl)lysine cross links 2 3 8 Using anti-
lGase 1 antibodies the expression of! Gase 1 has been demonstrated in the 
granular and the upper spinous cell layer2 3 , ; 2 3 7 
We used anti-human keratinocyte transglutaminase to assess transgluta­
minase expression 
1 8 5 M O N O C L O N A L ANTIBODY M A R K I N G R E C R U I T M E N T OF 
CYCLING CELLS 
ι 8 5 ι Ki-67 
Ihe K1-67 antibody recognizes a nuclear antigen present in cycling cells, 
which is absent in resting cells 2 3 9 It has been shown that the Ki-67 nuclear 
antigen is present in S, G2, and M phase, but not in Go Also Gi cells, after 
mitosis, are Ki-67 positive Cells entering the cell cycle from a Go state beco­
me positive before entering the S-phase but after increased RNA amounts, 
typical for Gì In addition to nuclear staining, cytoplasmic staining of the 
basal layer can also be observed, which is dramatically reduced in hyperpro-
liferative psoriatic lesion and in tapestnpped epidermis compared with heal-
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thy skin. Thus, it seems that there is a negative relation between cytoplasmic 
staining and proliferation. In normal epidermis only a small minority of 
nuclei are positive in the basal layer.240 
We used two different antibodies to visualize Ki-67 positive nuclei. The 
monoclonal Ki-67 is a monoclonal mouse antibody to human proliferating 
cells from Dakopatts. The monoclonal MIB 1 is directed against a cell prolife- 41 
ration associated nuclear antigen, the same antigen as is recognized by Ki-67 
(Immunotech SA AMAC Ine).241 
1.8.6 PHASING 
In chapter 2. the transition between non-lesional and lesionai skin was inves-
tigated using the margin zone of the spreading psoriatic plaque as experi-
mental approach. In order to find out to what extent the dynamics and magni-
tude of epidermal changes are specific for psoriasis, the same markers were 
studied in the skin of normal controls following tapestripping. 
In chapter 3 clinical improvement and interference with epidermal changes 
were studied during treatment with two new classes of topical therapy: the 
topical vitamin D3 analogues Calcitriol and Tacalcitol, and hydrocolloid 
occlusion. 
In chapter 4 the effect of two classes of systemic antipsoriatic treatments on 
epidermal proliferation and differentiation was studied in vivo. In these stu-
dies the response to sellotape stripping of uninvolved skin was used as a 
model for epidermal proliferation and differentiation. 
In chapter 5 the conclusions which have been reach in the various studies of 
this thesis will be discussed. 
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2.1 Recruitment of cycling epidermal cells and expression of 
filaggrin, involucrin and tenascin in the margin of the active 
psoriatic plaque, in the uninvolved skin of psoriatic patients 
and in the normal healthy skin 
58 
2.1.1 SUMMARY 
The peripheral changes in the uninvolved skin adjacent to the extending 
psoriatic lesions may represent early events. The sequence of these events 
remains controversial In the present study we evaluated epidermal and der-
mal aspects of the margin of the progressive psoriatic plaque, the distant 
uninvolved skin and normal healthy skin, using immunohistochemistry with 
markers for keratimzation, proliferation and connective tissue, filaggrin, 
involucrin, K1-67 and tenascin. 
1 he results showed that· 
1. Processes in distant uninvolved skin were comparable with the observa-
tions in normal skin. 
2 In the margin zone of the spreading psoriatic lesion, following the in-
creased appearance of tenascin, the transition into parakeratosis, abnor-
mal expression of filaggrin, involucrin and recruitment of cycling epider-
mal cells, happened simultaneously. 
Based on the present ïesults and earlier findings, we would like to propose a 
triple stage model for the development of the psoriatic lesion Stage I, invol-
vement of the stroma; stage II, inflammatory infiltrate formation, penetration 
into the upper layers of the epidermis, with suprabasal expression of keratin 
16; stage III, recruitment of cycling epidermal cells and abnormal terminal 
differentiation 
Further studies are required on the regulation of tenascin expression, 
focussing on factors derived from the stroma affecting both recruitment of 
cycling epidermal cells, involucrin and filaggrin expression An intermediairy 
step in the dermo-epithehal interrelation is the inflammatory infiltrate, pene-
trating into the most superficial zone of the epidermis, and the suprabasal 
expression of keratin 16 
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2.1.2 INTRODUCTION 
Initial changes in psoriasis differ from those in the fully developed psoriatic 
plaque. 
At the cellular level the established psoriatic lesion is characterized by epi­
dermal changes consisting of an increased proliferation, an incomplete kera- 59 
tinization, and dermal changes such as inflammation and an increased 
expression of the extracellular matrix glycoprotein tenascin. In contrast to 
the histological changes found in the mature psoriatic plaque, the pin-point 
papules show only slight epidermal proliferation, whereas the changes in the 
corium, consisting of inflammatory infiltrates, are more pronounced.1"14 
The sequence of events however remains controversial. 
An approach to this problem is the investigation of the margin of the 
spreading psoriatic lesion.15"18 Studying the following events van de Kerkhof 
et al reported that changes in the capillary may precede those in the epidermis 
during the spread of the psoriatic lesions.15 Using laser-doppler flowmetry 
and immunocytochemical techniques Hull et al postulated that the earliest 
change in the developing psoriatic plaque is an increased blood flow possible 
associated with a diffusable humoral initiating factor that accumulates at the 
active edge, stimulating transformation of normal skin to psoriatic pla­
ques. l f t De Mare et al reported that the suprabasal Кь8.і2 binding was the ear­
liest change they observed in the epidermis.17 De Jong et al found evidence 
that the dermal compartment is involved early in the pathogenesis of psoria­
sis.18 
In the present study we compared the immunohistological findings in the 
normal human adult skin of healthy volunteers, the uninvolved skin of 
psoriatic patients and the margin of spreading psoriatic lesions. 
In the epidermis parameters for keratinization and proliferation were stu­
died. Keratinization was characterized using markers for filaggrin and invol-
ucrin. Filaggrin and ¡nvolucrin are important proteins in the process of 
differentiation.19"24 Ki-67 was used as a proliferation marker, as it is a mono-
clonal antibody which recognizes a nuclear antigen present in cycling epider-
mal cells. In the dermis we studied the expression of the extracellular matrix 
glycoprotein tenascin.14· 25"2Û 
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2 1 3 MATFRIAL A N D M E T H O D S 
2 ι з ι Patients 
Fifteen patients (eight male and seven female, mean age 49 4 (28-69 years)) 
suffering from plaque psoriasis participated in this study They did not recei-
60 ve any topical treatment for at least two weeks and no systemic treatment for 
at least one month In all patients the total body extent varied between 5-10 
percent From ten patients suffering from an unstable progressive plaque 
psoriasis 6 mm punch biopsies were taken across the margin of a spreading 
lesion From five patients also a 3 mm punch biopsy was taken from the unin-
volved skin at exactly ю cm from the psoriatic lesions From the other five 
psoriatic patients with stable disease we only took 3 mm punch biopsies from 
the uninvolved skin, also at exactly 10 cm from a psoriatic lesion 
From eight healthy volunteers (three female and five male, mean age 26 1 
(23-33 years)) 3 mm punch biopsies were taken 
All biopsies of the uninvolved skin of psoriatic patients and normal human 
adult skin of the healthy volunteers were take from the skin of an arm 
bvery biopsy was embedded in Tissue lek OCT Compound (Miles Scientific, 
Napcrville, USA), snap-frozen in liquid nitrogen and stored at -80 °C until 
use 
From each biopsy consecutive sections were cut (6 μιτι), airdried and fixed 
in acetone-ether (60/40%) in case of K1-67 staining and in acetone for the 
staining with the other monoclonal antibodies 
2 1 3 2 Monoclonal antibodies 
1 о approximate the number of cycling cells we used the monoclonal antibody 
K1-67, which recognizes a nuclear antigen present in cycling cells (1 10, 
Ki-07, Dakopatts, Copenhagen, Denmark) 2 7 3 υ 
To assess epidermal differentiation a monoclonal antibody against fil-
aggrm (1 500, antifilaggrm, BTI, BT576) and a monoclonal antibody against 
involucrin (Mon-150,1 2 5 ) n were used 
A monoclonal antibody against tenascin (T2H5, 1 2000) was obtained 
from AA Verstraeten, The Netherlands Cancer Institute, Amsterdam, the 
Netherlands Tenascin is an extracellular matrix glycoprotein In vitro studies 
suggest that proliferating epithelium induces the production of tenascin by 
mesenchymal cells 3 7 
CHAPTER 2 
2.1.3-3 Staining procedure 
An indirect ïmmunoperoxidase technique was used. For ten minutes the 
slides were fixed in acetone-ether (60/40 vol%) (Ki-67/filaggrin staining) or 
acetone (involucnn and tenascin). After these slides were air-dried they were 
put in a phosphate-buffered stock solution (PBS solution: 360 ml ЫагНРСи 
(7.9 g Na2HP04, Merck in 500 ml deminerahzed water) plus 70 ml NabhPCU 61 
(13.8 g NaH2P04, Merck, in 500 ml deminerahzed water) plus 70 ml demi­
nerahzed water). For 60 minutes the slides were incubated with the mono­
clonal antibodies After washing in phosphatebufFer the slides were incuba­
ted with rabbit anti-mouse immunoglobulin conjugated with peroxidase (1. 
50, RAMPO). After washing in the phosphate-buffered stock solution and 
pre-incubation with sodium-acetate buffer (pH 4.9), a solution of з-агшпо-9-
ethylcarbazole (AEC) in sodium-acetate buffer containing 0.01% H2O2 was 
added for 10 minutes 
All slides were counterstained with Mayer's Haematoxyhn (Sigma, St. 
Louis MO USA) and mounted in glycerol gelatin. 
2.1.3.4 Histological examination 
Epidermal proliferation was measured by counting the number of K1-67 posi­
tive nuclei per mm length of the section. In exactly the same area the filaggrin 
expression was assessed by measuring the percentage of the length of the 
stratum corneum and stratum granulosum which was stained.32 
The involucnn expression was assessed by calculating the ratio positive 
cell layers/total cell layers of the living epidermis, this was done on two sites, 
at the tip of a dermal papil and between two dermal papillae.32 
The distribution of tenascin in the papillary dermis was assessed using the 
following grading system· 
1. Continuous expression adjacent to the basal lamina (C) versus disconti­
nuous expression adjacent to the basal lamina (D). 
2 Staining intensity (0-3).33 
The lmmunohistochemical findings in the biopsies taken from the margin of 
an active psoriatic lesion were compared with the localization of parakerato­
sis to assess the transition point into uninvolved skin These biopsies were 
examined on four spots: on 20% and 40% (involved part), 60% and 80% 
(uninvolved part) of the length of the sections 
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2.1.3-5 Statistical evaluation 
We used the Mann-Whitney test for statistical analysis of the results from the 
biopsies of the uninvolved skin of psoriatic patients and from the normale 
human adult skin. For statistical analysis of the results from the biopsies of 
the margin zone we used the Wilcoxon test for matched pairs. 
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2.I.4 RESULTS 
2.1.4.ι Normal healthy adult skin and uninuolued skin of psoriatic patients 
We did not observe a statistically significant difference between the results 
from the normal skin of healthy volunteers and the uninvolved skin of the 
psoriatic patients (table 2.1). 
Table 2.Ί Histological results from the normal healthy and from the distant un­
involved skin of psoriatic patients (mean ± standard error of the mean ( M ± SEM)) 
and the p-values. Healthy skin η = 8; distant uninvolved skin η = io. 
Filaggrin str. cormeum 
Filaggrin str. granulosum 
Ki-67 positive nuclei 
Involucrin mterpapillar 
Involucrin tip 
Tenascin 
Healthy skin 
100% ± 0 
100% ± 0 
10.5 ±2.5 
20.9% ±2.7 
25.4% ±1.2 
1.3 ±0.2 
Uninvolved skin 
100% ± 0 
100% ± 0 
9 2 ± 2 6 
17 4% ± 1 6 
26 1% ± 1 3 
12 + 0 1 
p-value 
1 00 
1 00 
0.69 
075 
0.23 
0 7 8 
In the normal healthy skin the number of Ki-67 positive nuclei per mm length 
of the section was n ± 2.6 (Μ ± SEM), whereas in the uninvolved skin the 
number was 9 ±2.6 (ρ > 0.65). As well as in the normal healthy skin as in the 
uninvolved skin the filaggrin expression in the stratum granulosum and in 
the stratum corneum was 100% ± о (p =1.00; figure 2.1). The involucrin 
expression at the interpapillar region and at the tip of a dermal papilla in the 
uninvolved skin and in the healthy skin were within the same range (p i n t e r p a . 
p,ntir > 0.75 and p n p > 0.2; figure 2.2). Seven out of eight sections of the biop­
sies from the normal healthy skin did show a discontinuous tenascin expres-
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Figure 2.7 Filaggrin and Ю-67 expression in the distant uninvolved skin of a psoriatic 
patient. The filaggrin expression shows a continuous staining pattern in the stratum 
granulosum and stratum corneum. A minimal expression of nuclear Ki-67 is shown in 
the basal layer. 
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Figure 2.2 Involucrin expression in the distant uninvolved skin of a psoriatic patient. 
The involucrin expression shows a continuous staining pattern in the stratum granu­
losum and upper part of the stratum spinosum. 
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Figure 2.3 Tenascin expression in the normal healthy skin. The tenascin expression 
is discontinuously distributed adjacent to the basal lamina. 
sion adjacent to the basal lamina, whereas one section did show a continuous 
and more intense staining pattern in the upper dermis. In the biopsies from 
the uninvolved skin eight out of 10 slides did show a discontinuous expres-
sion. In two sections we observed a continuous expression. The staining 
intensity of the tenascin expression in the normal healthy skin and the unin-
volved skin did not show a statistically significant difference (p > 0.78; figure 
2.3). 
2.1.4.2 Margin of progressive psoriatic plaques 
In eight out often biopsies taken from the margin of a progressive psoriatic 
lesion the transition of the parakeratotic horny layer into an orthokeratotic 
stratum corneum was abrupt. In the involved areas of these biopsies a mar-
ked acanthosis was observed, whereas in the uninvolved parts the acanthosis 
disappeared. In the remaining biopsies we did not observe parakeratosis. In 
one of these two biopsies however we observed acanthosis. 
The histological examination in the biopsies of the margin zone was per-
formed at 20%, 40%, 60% and 80% of the length of the sections (table 2.2, 
2.3, 2.4 and 2.5), 20 and 40% representing the involved part and 60 and 80% 
representing the uninvolved area of the biopsy. 
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Table 2 2 The histological results from the 20% zone of the margin of spreading 
psoriatic plaques (the involved part). 
1 2 3 4 5 6 7 8 9 10 
Filagg str corneum 0% 0% 0% 100% 80% 20% 0% 0% 0% 20% 
Filagg str gran 40% 30% 100% 100% 100% 10% 50% 100% 50% 80% 65 
Κι 67 positive nuclei 84 84 184 16 80 92 304 72 248 156 
Involucrm mterpap 36% 60% nd 33% 27% 28% 47% nd 28% 38% 
Involucrm tip 72% 50% nd 56% 40% 42% 70% nd 56% 64% 
Tenascin C/3 C/3 C/2 C/3 C/3 C/3 C/3 C/2 C/3 nd 
Numbers 1-10 represent trie 10 biopsies token from the margin of a spreading psoriatic lesion 
nd= not done 
Table 23 The histological results from the 40% zone of the margin of spreading 
psoriatic plaques (the involved part) 
1 2 3 4 5 6 7 8 9 10 
Filagg str corneum 0% 60% 0% 100% 80% 20% 0% 0% 0% 20% 
Filagg str gran 50% 40% 100% 100% 100% 100% 80% 100% 100% 100% 
Κι 67 positive nuclei 40 52 204 16 60 28 96 48 120 140 
Involucrm mterpap 32% 30% nd 29% 32% 48% 53% nd 36% 32% 
Involucrm tip 60% 30% nd 56% 53% 70% 62% nd 33% 83% 
Tenascin C/3 C/3 C/2 C/3 C/3 C/3 C/2 C/2 C/3 nd 
Numbers 1 10 represent the ю biopsies taken from the margin of a spreading psoriatic lesion 
nd= not done 
At 20% of the sections the filaggnn expression in the stratum corneum and 
stratum granulosum was observed as a discontinuous or absent staining pat­
tern. Comparing the uninvolved part of the margin zone (at 80% of the length 
of the section) with the involved part (at 20% of the length of the section) the 
filaggnn expression was significantly different ( p
c o m e u m
 ^ ο·°ι, p g n n u | 0 S u m < 
0.02) and comparable with the filaggnn staining as can be observed in 
normal healthy skin. 
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Table 2.4 The histological results from the 60% zone of the margin of spreading 
psoriatic plaques (the uninvolved part). 
1 2 3 4 5 6 7 8 9 10 
Filagg str corneum 100% 100% 60% 100% 50% 100% 100% 100% 100% 100% 
66 Filagg. str. gran. 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Ki-67 positive nuclei 16 12 128 16 44 8 32 40 40 12 
Involucrminterpap 26% 18% nd 38% 29% 21% 22% nd 37% 29% 
Involucri tip 63% 25% nd 56% 47% 33% 38% nd 50% 83% 
Tenascm C/2 D/1 C/2 C/3 C/3 C/2 D/2 C/2 C/3 nd 
Numbers I-ÎO represent the ю biopsies taken from the margin of a spreading psoriatic lesion 
nd= not done 
Table 2.5 The histological results from the 8 0 % zone of the margin of spreading 
psoriatic plaques (the uninvolved part). 
1 2 3 4 5 6 7 8 9 10 
Filagg str corneum 100% 100% 60% 100% 100% 100% 100% 100% 100% 100% 
Filagg str. gran. 100% 100% 100% 100% 100% 100% 100% 100% 100% 100% 
Ki-67 positive nuclei 20 8 156 8 28 0 20 12 12 8 
Involucrminterpap. 15% 11% nd 42% 23% 14% 44% nd 25% 23% 
Involucrin t ip 40% 11% nd 50% 41% 22% 44% nd 43% 44% 
Tenascin C/2 D/1 C/2 C/3 C/3 D/2 D/2 C/2 C/3 nd 
Numbers 1-10 represent the 10 biopsies taken from the margin of a spreading psoriatic lesion 
nd= not done 
The number of Ki-67 positive nuclei in the involved areas of the sections 
(areas with evident parakeratosis) was markedly elevated and statistically 
significant different from the number we found in the uninvolved part of the 
sections (p < 0.005). In the two sections without parakeratosis the number of 
Ki-67 positive nuclei did show a minimal increase. Figure 2.4 demonstrates 
the Ki-67/filaggrin staining in 40-60% zone. 
In the involved parts (at 20 and 40%) the involucrin expression was also 
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Figure 2.4 Filaggrin and Ю-67 expression in the 40-60% zone of the margin of a 
spreading psoriatic lesion. The 40% zone (left) shows a markedly decreased filaggrin 
expression in the granular layer and stratum corneum and an increased number of Ki-
67 positive nuclei in the lower region of the epidermis. In the 60% zone (right) a nor­
mal filaggrin expression can be seen, while the number of Ki-67 positive nuclei has 
markedly decreased, compared with the 40% zone. 
seen in the lower region of the epidermis, whereas the expression in the unin-
volved areas was observed in the granular layer and the upper part of the stra­
tum spinosum. Comparing the involucrin expression at 20% and 80% of the 
length of the section the results were statistically significant different [p-
mtei. 
papular - °-°4; Ptip ^ 0.01). Figure 2.5 demonstrates the involucrin expression 
in the 40-60% zone. 
In eight biopsies clearly parakeratosis was observed in the involved areas. 
A transition point was seen at about 40-60% of the length of the sections. 
These biopsies did also show a transition point for filaggrin and involucrin 
expression at 40-60%, at which the expression changed into a staining pat­
tern as can be observed in normal healthy skin. 
In the involved areas tenascin expression was observed as a continuous and 
intense staining pattern in the dermis adjacent to the basal lamina. Comparing 
the tenascin expression we observed in the normal healthy skin, the staining 
in the involved areas was also present in the upper dermis (figure 2.6). 
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Figure 2.5 Involucrin expression in the 40-60% zone of the margin of a spreading 
psoriatic lesion. On the right (40% zone, involved part) the involucrin expression is 
intense and extended to the lower cell layers of the stratum spinosum, whereas in the 
60% zone (left) the involucrin expression is comparable with the expression as can be 
seen in normal healthy and distant uninvolved skin. 
In six out of nine sections we also observed a continuous but less pronounced 
staining pattern in the uninvolved parts. The other three sections showed a 
changing into a more discontinuous pattern in the uninvolved areas. The stai­
ning intensity of the tenascin expression in the involved and uninvolved areas 
did not show a statistically significant difference (p = 0.67), while the staining 
intensities of the uninvolved areas did show a statistically difference with the 
expression observed in the normal healthy and the uninvolved skin at 10 cm 
of a lesion (p = 0.02 and ρ = 0.005). 
2.1-5 DISCUSSION 
Margins of spreading psoriatic lesions permit the investigation of the 
sequence of events in the development of psoriasis. The peripheral chan­
ges in the uninvolved skin adjacent to the extending lesions may represent 
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Figure 2.6 Tenascin expression in the 40-60% zone of the margin of a spreading 
psoriatic lesion. On the right (40% zone, involved part) the tenascin expression is 
extended to the upper dermis, whereas in the 60% zone (left) the tenascin expression 
shows an intense and continuous distribution adjacent to the basal lamina. 
early changes. In the present study we confirm that changes in dermal expres-
sion of tenascin preceed epidermal changes. Tenascin was the only parame-
ter which did not show a statistically significant difference between the invol-
ved and the uninvolved areas of the margins of progressive psoriatic lesions. 
These findings confirm the observations of de Jong et al.18 In the uninvolved 
skin at 10 cm from a psoriatic lesion the tenascin expression was within the 
same range as the staining pattern we observed in the normal healthy skin, 
whereas the staining intensity of the tenascin in the uninvolved part of the 
margins (at 80%) was statistically significant different from the expression 
we observed in the normal healthy and the uninvolved skin at 10 cm. 
In the epidermis the transition point of parakeratosis was observed 
between 40 and 60% of the length of the section. In the same region we 
observed a transition point of the number of Ki-67 positive nuclei, filaggrin 
and involucrin expression towards normalization. These parameters in the 
involved and in the uninvolved parts were statistically significant different. 
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In the un involved parts the number of K1-67 positive nuclei, the filaggrm and 
involucrin expression were not statistically significant different from the 
results we found in the normal healthy and in the uninvolved skin (at 10 cm of 
a lesion). 
The early expression of tenascin in the dermal compartment of the unin-
70 volved skin adjacent to the spreading psoriatic lesion together with the nor-
mal staining pattern of K1-67, filaggrm and involucrin in the uninvolved epi-
dermis of the marginal zone suggest that the dermis is involved in early 
events in the evolution of psoriasis Several observations suggest that activa-
ted epithelium, wound healing and disease (cancer, psoriasis) induces tenas-
cin expression in the human dermis Mackie et al suggested that migrating, 
proliferating epidermis induces the production of tenascin.34 The present 
results imply that tenascin expression is an earlier event than the recruitment 
of cycling cells. 
Our investigation reveals that the expression of the epidermal proteins 
filaggrm and involucrin in psoriatic epidermis differs from the expression in 
the uninvolved parts (60 and 80%), 111 the normal healthy skin and in the 
unvolved skin at 10 cm from a psoriatic lesion These observations suggest 
that an abnormal keratmization process must be secondary to other changes. 
The fact that the transition points of parakeratosis, recruitment of cycling 
epidermal cells, filaggrm and involucrin expression between uninvolved and 
involved psoriatic skin was observed between 40 and 60% of the length of the 
section might point out a close relationship between epidermal hyperprohfe-
ration and abnormal keratmization. Our observations confirm the results of 
van de Kerkhof et al.15 They observed a simultaneously changing of enzyme 
markers for proliferation and keratmization in the margin zone of a sprea-
ding psoriatic lesion. The simultaneously normalization of these epidermal 
processes might be a consequence of a signal which is simultaneously trans-
duced to the basal and suprabasal cell layers of the epidermis. 
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2.2 Repeated tape stripping of normal skin: a histological 
assessment and comparison with events seen in psoriasis 
2 2.1 SUMMARY 
The aim of the present study was to investigate the response of normal 
human skin to repeated courses of Sellotape stripping The skin of healthy 
volunteers was stripped five times at 24 h intervals Skin biopsies were taken 
before stripping (day o) and on days 2, 4, 7 and 10. Ihe responses were stu-
died using H&E staining, and immunohistochemical analysis of several 
aspects of epidermal proliferation and keratinization. 
Although increased proliferation (nuclear binding to the K1-67 antibody), 
acanthosis and parakeratosis were observed, the overall histological picture 
did not resemble psoriatic histology completely: no micropustules of Kogoj 
and no thinning of the suprapapillary plate were observed Involucnn stain-
ing followed the recruitment of cycling epidermal cells, showing a statistical-
ly significant elevation of positive cell layers from day 2 onwards Filaggrin 
expression showed an increase from day 2 onwards, which was statistically 
significant on day 7 and day 10. Using the anti-keratin antibodies Ks8 12 (K13 
and K16) and RKSE60 (Kio) we observed a fast induction of K13/K16 expres-
sion, while the staining of keratin 10 showed the same overall intensity at 
different time intervals. 
In conclusion, the response to repeated courses of tape stripping provides 
an adequate model for studies on epidermal proliferation, hypergranulosis 
and hyperkeratosis. This approach causes a more prolonged induction of 
these phenomena than a single course of stripping In contrast to the situa-
tion following a single course of stripping, repeated tape stripping induced 
the expression of filaggrin. Iherefore the repeated tape stripping model is 
less compatible with psoriasis than a single course of stripping. 
2 2.2 I N T R O D U C T I O N 
Psoriatic lesions are characterized by inflammation, epidermal proliferation 
and abnormal keratinization, and show topographical heterogeneity with 
'hot spots' and 'cold spots'.1 2 In a disorder as complex as psoriasis an in vivo 
model may provide a more simple approach to the study of the dynamics of 
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certain aspects of the disease A psoriatic lesion may be induced by surface 
trauma, and therefore the response to injury represents a classical model for 
studies of psoriasis.3 
From 1951 onwards many investigators have used single courses of Sello-
tape stripping as an in vivo method for studying epidermal proliferation and 
74 keratimzation 4 ь Interestingly, Sellotape stripping also has been used as a 
model for investigating the intraepidermal accumulation of polymorphonu­
clear leucocytes (PMN) 9 1 0 Intraepidermal accumulation of PMNs as micro-
pustules of Kogoj and microabscesses of Munro is a highly characteristic 
feature of psoriasis n 1 2 However, single Sellotape stripping as a model for 
psoriasis has serious limitations. The topography of acanthotic rete ridges 
and thinning of the suprabasal plate is missing in this model. Parakeratosis, 
a consistent histological feature of psoriasis, is seen only transiently for a few 
days and epidermal proliferation shows a sharp peak at 48 h after tape strip­
ping m this model.13 7 
1 he aim of the present study was to characterize a modification of the clas­
sical Sellotape stripping model repeated applications of Sellotape on 5 con­
secutive days In particular the following questions were addressed· 
1. What are the responses of normal human skin to repeated courses of Sello­
tape stripping of consecutive days with respect to epidermal proliferation 
and keratimzation7 
2 To what extent is this model compatible with psoriasis-' 
3. To what extent does repeated Sellotape stripping provide an advantage 
over the single stripping approach7 
At various time intervals during and following repeated courses of Sellotape 
stripping, razor-blade biopsies were taken and analyzed using well-esta­
blished immunohistochemical markers of differentiation (expression of 
keratin 10, keratin 16, filaggrm and involucrin) and proliferation (nuclear 
binding of the monoclonal antibody K1-67). 
Keratin 10 is a marker of normal differentiation, and is expressed in the 
suprabasal cell layers In psoriatic lesions its expression shows a focal distri­
bution pattern.2 Keratin 16 is a marker of a hyperproliferative epidermis.14 In 
psoriatic epidermis a marked suprabasal expression of this keratin is obser­
ved.15 Filaggrm is produced by the keratohyahn granulas and constitutes the 
matrix permitting the aggregation of the intermediate filaments.1''I7 Involu­
crin is the soluble precursor of the cornified envelope.18 
Recruitment of resting cells into the cell cycle is perhaps the most ímpor-
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tant regulatory mechanism of epidermal growth. Nuclear binding to the 
monoclonal antibody Ki-67 is a well established approach to estimate the 
number of cycling cells.19 
2.2.3 MATERIALS AND MhTHODS 75 
2.2.3.1 Subjects 
Three males and three females, aged between 18 and 29 years, participated in 
this investigation, after having given informed consent. The subjects were 
seen seven times for Sellotapc stripping and the biopsy procedures. 
2.2.3.2 Sellotapc stripping and biopsy procedure 
A plastic template with four round windows (1 cm diameter) was applied to 
the back. The exposed areas were at least 2.5 cm apart. Sellotape (Tesafilm^) 
was applied with gentle pressure to the exposed areas, and then removed. 
This procedure was repeated with fresh consecutive areas of the tape, and one 
course of stripping was regarded as complete when the skin was glistened. In 
order to find out whether the removed stratum corneum contained nuclei, 
some pieces of used tape were stained with the DNA-specific dye propidium 
iodide (Cellbiochem, San Diego, Calif., USA) and assessed by fluorescent 
microscopy. 
The Sellotape stripping procedure was performed on exactly the same sites 
in each individual on days o, 1, 2, 3 and 4. Preliminary experiments had 
demonstrated that these time intervals were appropriate for observing the 
most significant changes. 
Biopsies were taken freehand using a razor-blade in conjunction with a 
metal guard. The biopsies were performed on day о from an unstripped area 
and on days 2, 4, 7 and 10 from the four stripped areas, respectively. The 
biopsy specimens were embedded in Tissue Тек II OTC compound (Miles, 
Naperville, 111., USA), immediately snap-frozen in liquid nitrogen and stored 
at-8o°C. 
2.2.3.3 Irnmunohistochemistry 
The biopsy specimens were sectioned at 7 μιτι on a cryostat microtome at -25 
°C, mounted on poly-L-lysine-coated slides, air dried, and fixed in cold aceto­
ne (for staining with Ki-67 in acetone/ether, 60:40 v/v). The prepared sections 
were again stored at -80 °C except for two sections from each specimen which 
were stained immediately with H&E. 
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After air drying again at room temperature and refixing in the same fixative 
the other cryostat sections were stained immunohistochemically using an 
indirect immunoperoxidase technique. 
Table 2.6 summarizes the details on the individual markers for keratiniza-
tion. 
Table 2.6 List of keratinization markers with the localization in normal epidermis 
and in psoriatic epidermis. 
Monoclonal 
RKSE60 
Biochemical Localization in Localization in Dilution Reference 
specifìty normal epidermis psoriatic epidermis 
Keratin 10 Suprabasal Suprabasal 1:10 19 
layers layers 
Ks8.i2 Keratin 13 Keratin·^ Keratin 16 1 20 11 
and 16 not present is present in 
suprabasal 
layers 
Anti-involucrin Involucrin Granular layer Suprabasal 1:8 16 
and upper layers 
third of stratum 
spinosum 
Anti-filaggrin Profilaggrm Granular layer Granular layer 1 500 12 
and filaggrin 
The number of cycling cells in the epidermis was determined by binding 
of Ki-67 (Dakopatts, Copenhagen, Denmark), a monoclonal anti-nuclear 
mouse anti-human antibody with specific adherence to the nuclei of cycling 
cells from the late Gi phase onwards.2'"24 
2.2.3.4 Assessments 
Biopsy sections were evaluated light microscopically with respect to the stai-
ning pattern of the antibody used. In each section two representative areas 
were chosen to calculate the expression of the antibody. Ki-67 staining was 
expressed as the number of positive nuclei per millimetre length of the sec-
tion. It is well known that Ki-67 staining can also be seen in the cytoplasm of 
the epidermal cells. We counted only the number of Кі-67-positive nuclei. In 
the case of staining with anti-involucrin and anti-filaggrin for each evaluated 
CHAPTER 2 
section the percentage of positive staining of the living epidermis was calcu-
lated. This was done at the tip of a dermal papilla and at an interpapillary 
location. The varying suprabasal distribution pattern of RKSE60 and Ks8.i2 
did not permit such a quantitative assessment. Therefore the distribution pat-
tern of these markers was described qualitatively. 
2.2.3.5 Statistical evaluation 
For the statistical analysis the Wilcoxon's test for matched pairs was applied. 
2.2.4 RESULTS 
2.2.4.1 Clinical appearance 
The clinical responses of the six volunteers were remarkably similar. In the 
first few days a sharply demarcated area of erythema with a fine scaling was 
observed. Gradually the scaling became more substantial and was complica-
ted by some crust formation. On days 3 and 4 all subjects experienced in-
creasing tenderness of the areas during and after stripping. From day 3 
onwards pinpoint bleeding was seen reminiscent of the Auspitz pheno-
menon in psoriasis. 
2.2.4.2 H&E starnine) 
Parakeratosis and hypergranulosis were observed in all subjects on day 2, and 
persisted for the whole observation period. On day 10, however, the most 
superficial part of the stratum corneum was parakeratotic whereas the deeper 
layers were orthokeratotic. Figure 2.7 illustrates these findings. Acanthosis 
was observed on day 4, and subsequently increased gradually. A mixed 
inflammatory infiltrate was seen in the dermis and epidermis, without the 
formation of spongiform pustules. However, local debris formation was 
observed between parakeratotic foci. 
2.2.4.3 Propidium iodide staining 
On day 0 sporadic positively staining corneocytes containing nuclei could be 
shown on the strips. In contrast, from day 1 until day 4 (last tape stripping 
course) a considerable increase in such stained cells was seen (figure 2.8). 
2.2.4.4 Immunohistochemical stainimjs 
RKSE60 binding (keratin 10 expression) — The expression of keratin 10 showed 
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the same gross overall intensity at different time intervals. However, foci 
without any staining were seen in the biopsy specimens taken on day 4 and 
later (figure 2.9). This phenomenon seemed to be related to the presence of 
celldebns in the upper epidermis. 
Ю.8 12 binding (keratin 13 and 16) — In the basal zone continuous staining was 
78 observed in the unstripped skin. On day 2 the basal staining was diminished, 
whereas the suprabasal compartment showed some staining. On day 4 the 
stratum basale showed no staining and the staining intensity of the supraba­
sal zone increased. From day 7 onwards the suprabasal staining was restric­
ted to the more superficial cell layers leaving the lower layers unstained. On 
day 10, in three of the six subjects basal staining was again observed (figure 
2.10). 
Anti-filaggnn — The expression of filaggnn (table 2.7) showed a slight but 
fairly consistent increase during the early phase of tape stripping. From day 7 
onwards a pronounced and statistically significant increase in the number 
of filaggnn-containing cell layers in the epidermis was seen (figure 2.11). 
Anti-muolucnn — Before tape stripping a condensed anti-involucrin staining 
was observed exclusively in the stratum granulosum (table 2.7) A marked 
and statistically significant increase in positive staining of the living epider­
mis was reached on day 2 and remained until day 10. Figure 2 12 illustrates 
this phenomenon. 
K1-67 staining — The K1-67 binding results are also summarized in table 2.7. 
It can be seen that a maximum increase was reached on day 2 and persisted 
until day 7. On day 10 the number of K1-67 positive nuclei showed a tendency 
towards normalization. 
Table 2.7 Statistical evaluation of the expression of filaggnn, involucrin an K1-67 
positive nuclei, expressed as mean ± SEM. 
Day 0 Day 2 Day 4 Day 7 Day 10 
Filaggnn tip 46 0% ± 4 3 50 6% ± 3 6 49 0% ± 4 9 64 0% ± 5 2* 76 5% ± 2 7* 
Filaggnn mterp 330% ±2 5 40 2% ±4 2 42 0% ± 1 1 46 2% ± 5 8* 62 3% ± 6 5* 
Involucrin tip 343% ±16 67 5% ±2 9* 67 2% ± 3 9 * 61 5% ± 1 2 ' 55 8% ± 4 6* 
Involucrin mterp 20 5% ± 1 5 583% ± 4 0 * 60 0% ± 5 2* 44 5% ± 4 6* 39 8% ±4 9* 
Ki-67 pos nuclei 1 7 0 1 4 1 14721262* 12731251* 1108 + 194* 5 6 5 1 8 0 
* Values are statistically significant different compared with the results observed at day 0 
(p<o 05) 
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Figure 2.7 HE staining of biopsies ta­
ken at intervals during and following 
tape stripping. 
(a) 
(b) 
(c) 
(à) 
day 0 (before stripping) 
day 2 
day 7 
day 10 
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Figure 2.8 Propidium iodide staining 
of strips of corneocytes. 
(a) 
(b) 
day о 
day 4 
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Figure 2.9 RKSE-бо binding (keratin 
10 expression) at intervals during and 
following tape stripping. 
о (before stripping) (a) 
(b) 
(c) 
day ι 
day 4 
day 7 
Figure 2.Ю Ks8.i2 staining (keratin 16, 
13 expression) at intervals during and 
following tape stripping. 
(a) day о (before stripping) 
(b) day 4 
(c) day 10 
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Figure 2.12 Anti-involucrin staining at 
intervals during and following tape 
stripping. 
(a) day о (before stripping) 
(b) day 4 
Figure 2.11 Anti-filaggrin staining at 
intervals during and following tape 
stripping. 
(a) 
(b) 
(c) 
(d) 
day о (before stripping) 
day 4 
day 7 
day io 
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2 2 5 DISCUSSION 
Repeated courses of Sellotape stripping on consecutive days is a new ap-
proach for inducing a chronic inflammatory response The disruption of the 
skin barriere is thought to be the main cause of the recovery following tape 
82 stripping, alternatively this response might be triggered by injury to the spi-
nous layer Indeed, it has been demonstrated by Proksch et al that total occlu-
sion following tape stripping prevents recovery 2S 
The induction phase is grossly comparable to the changes induced by a 
single course of tape stripping After 48h a hyperprohferative response was 
seen (nuclear binding of K1-67) which is comparable with the response follo-
wing a single course of stripping " T h e expression of keratin 16 following a 
single course of tape stripping, has been reported previously and is compara-
ble to the expression as observed in the present study 8 1S An important 
difference between single and repeated courses is the induction of a 'plateau' 
of at least 2 davs duration for all markers After discontinuation of tape strip-
ping (day 5) the recruitment of cycling epidermal cells (nuclear binding to Ki-
67), some aspects of keratimzation (expression of keratin 10 and 16), and 
hyperkeratosis showed a tendency towards normalization within 5 days, 
whereas the filaggnn and involucrin expression remained in the 'plateau' 
phase 
H&E staining indicated similarities with psoriatic lesions Acanthosis, 
parakeratosis and a mixed inflammatory infiltrate are also observed in psoria-
tic lesions Parakeratosis in psoriasis is accompanied by a thin granular layer, 
whereas parakeratosis in the present model was accompanied by hypergra-
nulosis The intraepidermal micropustules of Kogoj and microabscesses of 
Munro - characteristic features of psoriasis - are absent in repeatedly strip-
ped skin 1J 12 
Except for filaggnn, the expression of the lmmunohistochemical markers 
for keratimzation (involucrin and keratins 10 and 16) showed similar changes 
in the present model to those in psoriatic lesions 2 1 5 1 7 21 22 2b In contrast to 
a reduced filaggnn expression after a single course of tape stripping, the pre-
sent investigation showed an induction of filaggnn expression after repeated 
tape stripping which was statistically significant from dav 7 onwards Howe-
ver, in psoriatic lesionai skin filaggnn expression is decreased Thus, with 
respect to this aspect of keratimzation the present model is not compatible 
with psoriatic skin It has been suggested that involucrin expression is related 
to the rate of epidermal turnover I7 The present investigation confirms this 
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hypothesis, showing that, as well as involucrin expression the number of 
cycling cells is significantly increased from day 2 onwards. The nuclear bin­
ding to K.1-67 reached values similar to those observed in psoriatic lesions. 
Although these immunohistochemical markers are representative of changes 
in the various compartments of the epidermis, they are by no means specific 
for psoriasis. In this respect studies on calmodulin or skin-associated-anti- 83 
leukoprotease might be more relevant.27 2 S 
As psoriasis and wound healing show a number of features in common 
(reduced filaggnn expression, increased expression of involucrin, transgluta­
minase, EGF-Rand keratins 6 and 16, an increased number of cycling epider­
mal cells and the presence of ψ-3 antigen) it is not surprising that the same 
model (tape stripping or response to suction blistering) may represent 
psoriasis and wound healing.2'13<) The observed hypergranulosis with an in­
creased expression of filaggnn make the present model unsuitable for the 
study of normal wound healing However, it remains speculative whether the 
distinct features of wound healing during repeated injury make it possible to 
distinguish between normal and disturbed wound healing (for example with 
respect to artefacts). 
The present model provides an experimental approach for studying the 
induction and maintenance of epidermal hyperprohferation and adaptive 
keratinization. The advantage compared to a single course of tape stripping 
is the prolonged induction of changes which makes it an better model to use 
in drug research. 
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2.3 Plasma Membrane Bound Transglutaminase 
¡η psoriatic skin 
2 3 I SUMMARY 
86 
Plasma membrane bound transglutaminase is a key enzyme in the formation 
of the cornified envelope In lesionai skin of psoriatic patients it has been 
demonstrated that the activity of this enzvme is increased 
1 he aim of the present study was to investigate the topographical distribu­
tion of plasma membrane bound transglutaminase in lesionai skin, distant 
clinically uninvolved skin and the margin zone of spreading lesions in 
patients with psoriasis 
In lesionai epidermis the number of transglutaminase positive cell layers 
was markedly increased compared to the distant clinically uninvolved skin In 
patients with stable psoriasis the number of transglutaminase positive cell 
layers was more increased compared to patients with spreading psoriatic pla­
ques In the transition zone between symptomless and lesionai skin, the 
number of transglutaminase positive cell layers showed a gradual increase in 
contrast to the sharp on/off transition with respect to parakeratosis, involu-
enn, filaggnn and recruitment of cycling epidermal cells Transglutaminase 
proved to increase further proximally to the transition point of the latter para­
meters 
2 3 2 I N T R O D U C I ION 
I he cornified envelope is a characteristic feature of the stratum corneum The 
plasma membrane-associated transglutaminase is responsible for the cross-
linking of the precursor proteins (1 e ìnvolucrin, filaggnn) by Σ (γ-glutamyl) 
lysine isopeptide bonds, into the cornified envelope 1 Michel et al investiga­
ted the localization and in vivo activity of epidermal transglutaminase These 
authors observed expression of epidermal transglutaminase in the upper 
stratum spinosum and granulosum of normal human epidermis The activity 
of transglutaminase, however, was restricted to one or two cell layers at the 
transition between the granular layer and the stratum corneum As the cross-
linking process, and the activity of transglutaminase is Ca2+ dependent, it is 
feasible that the activation of this enzvme in these cell lavers is the conse­
quence of the liberation of Ca2 + ions from intracellular organelles 2 
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It has been demonstrated that membrane-associated transglutaminase activi­
ty and the number of cross-linked envelopes are markedly increased in 
lesionai skin of psoriatics, respectively 5-fold and 10-fold э 
A monoclonal antibody, directed against plasma membrane bound trans­
glutaminase, became available which permits the visualization of the distri­
bution pattern in normal and diseased epidermis 4 6 87 
The aim of this investigation is to study the distribution pattern of trans­
glutaminase in biopsies taken from lesionai skin, distant clinically uninvol-
ved skin and the interphase of the margin zone of spreading psoriatic pla­
ques 
2 3 3 MATERIAL A N D M E T H O D S 
2 3 3 1 Subjects 
Fifteen patients suffering from chronique plaque psoriasis participated in 
this study lhey did not receive any topical treatment for at least two weeks 
and no systemic treatment for at least one month In all patients the total 
body extent varied between 5-ю percent Six of these patients noticed that 
some of the psoriatic lesions were progressive in the last week From the six 
patients suffering from unstable progressive plaque psoriasis 6 mm punch 
biopsies were taken across the margin of a spreading lesion Ihe biopsies 
comprized approximately 50% uninvolved and 50% lesionai skin From five 
of these patients also a 3 mm punch biopsy was taken from the uninvolved 
skin at exactly 10 cm from the margin of the psoriatic lesion 
From si\ patients with stable psoriasis we took 3 mm punch biopsies from 
the lesionai skin,and from four psoriatic patients with stable disease we took 
3 mm punch biopsies from the uninvolved skin, also at exactly 10 cm from the 
border of the psoriatic lesion 
From two healthy volunteers 3 mm punch biopsies were taken 
All biopsies taken from the distant uninvolved skin of psoriatic patients 
and from the normal human adult skin of the healthy volunteers were take 
from the upper arm 
All biopsies were embedded in Tissue lek ОС Г Compound (Miles Scien­
tific, Naperville, USA), snap-frozen in liquid nitrogen and stored at -80 °C 
until use 
From each biopsy consecutive sections were cut (6 μηι), airdried and fixed 
acetone 
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2.3-3-2 Monoclonal antibody 
To visuale transglutaminase type I which is expressed during the differentia-
tion of epidermis we used an anti-human keratinocyte transglutaminase 
(Mouse Monoclonal Antibody, IgG2¿).46 The antibody was obtained from 
Biomedical Technologies Inc. 
88 
2.3.3.3 Starnine) procedure 
An immunoperoxidase technique was used. After the slides were air dried 
they were fixed for 5 minutes in acetone at -20 °C. After they were dried again 
they were put in a phosphate-buffered stock solution (PBS solution: 360 ml 
ЫагНРСи (/.g g ЫагНРО-», Merck in 500 ml dcminerahzed water) plus 70 ml 
NaH2P04 (13.8 g NabhPO^ Merck, in 500 ml deminerahzed water) plus 70 
ml deminerahzed water, pH 7,4) during ten minutes. The slides were incuba­
ted with 10% normal rabbit serum diluted in PBS solution, during 15 minutes 
at roomtemperature. Afterwards the anti-human keratinocyte transglutami­
nase (1:25 with 1:20 human AB serum in PBS solution) was added and the 
slides were incubated for 1 hour at room temperature. After two washing in 
PBS solution the slides were incubated with rabbit anti-mouse immunoglo­
bulin conjugated with peroxidase (1:25 RAMPO with 1-20 human AB serum). 
Again after two washings during ten minutes the slides were put in a sodium-
acetate buffer (pH 4,9), a solution of з-аітнпо-9-ethylcarbjzole (AEC) in sodi­
um-acetate buffer containing 0,01% H2O2 was added for ten minutes. After 
washing in deminerahzed water the slides werd counterstained with Mayer's 
Haematoxyhn (Sigma, St. Louis MO USA) and mounted in glycerol gelatin 
2 3.3.4 Histological examination 
Ihe histological examination was performed blinded I he transglutaminase 
expression was assessed by calculating the ratio positive cell layers/total cell 
layers of the living epidermis. This was performed at two sites: at the tip of a 
dermal papilla and in the interpapillar region. In every slide two representati­
ve spots were examined and the mean of these observations was computed. 
The immunohistochemical findings in the biopsies taken from the margin 
of an active psoriatic lesion were related with the topographically localization 
of parakeratosis to assess the transition point into uninvolved skin. In all 
biopsies the transition point was localized between 40 and 60% of the length 
of the sections. 1'he biopsies were examined on four spots on 20%, 40%, 
60% and 80% of the length of the sections. The 20 and 40% zones were loca­
lized in the involved parts and the 60 and 80% zones were localized in the 
uninvolved parts of the margin of the lesions 7 
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2.3-3-5 Statistical evaluation 
For statistical analysis of the results from the biopsies the Wilcoxon test for 
matched pairs and the Mann Whitney test was used. 
2.3.4 RESULTS 89 
Distant umnuolued skin of psoriatic patients and the normal healthy adult slan 
In the uninvolved skin of the psoriatic patients (n=cj) the relative transgluta-
minase expression was 26.2 ± 1.4 at the tip of the dermal papilla, and 22.1 ± 
1.2 in the interpapillar region. No significant difference could be demonstra-
ted comparing the patients with stable psoriasis with patients suffering from 
unstable psoriasis. In the normal healthy skin (n=2) the relative transgluta-
minase expression was 22.5 ± 2.4 at the dermal papilla, and 18.5 ± 1.5 in the 
interpapillar zone. The distribution of transglutaminase is demonstrated in 
figure 2.13,2.14, and 2.15. 
Margin zone cjfspreadtmj psoriatic plaques 
The transglutaminase expression in the involved areas of the progressive 
lesions (20 and 40%) was markedly increased, respectively 65.815.3 and 60.5 
± 3.0 at the tip and 39.7 ± 2.7 and 35.8 ± 2.5 in the interpapillar region. In the 
uninvolved areas of the progressive plaque (60 and 80%) the ratio of the 
transglutaminase expression was 50.8 ±5.9 and 37.5 ± 6.9 at the tip and 28.2 
± 3.9 and 22.7 ± 5.3 in the interpapillar region. The transglutaminase expres-
sion as was observed in the 20% and in the 80% zones was statistically 
significant different at the tip (p = 0.04), and almost statistically different in 
the interpapillar region (p < 0.075). The distribution of the transglutaminase 
is demonstrated in figure 2.16 and 2.17. 
Lesionai skin 
Lesionai skin showed a marked extension of the number of transglutaminase 
positive cells compared to distant uninvolved and normal skin. In 6 patients 
with stable plaque psoriasis transglutaminase expression was as high as 80.2 
± 2.6 suprapapillary and 40.0 ± 3.3 at the intrapapillary locations (figure 
2.18). Comparing the transglutaminase expression in the stable psoriatic 
skin with the involved part of the spreading psoriatic lesions we observed a 
significant higher expression in the stable psoriatic epidermis suprapapillar 
(p < 0.03). In the intrapapillar region we did not observe a significantly higher 
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F/gure 2.13 Plasma membrane bound transglutaminase ¡η the distant uninvolved 
skin, located beneath the stratum corneum. 
Â i f f . ' 
Figure 2.14 Plasma membrane bound transglutaminase in the normal healthy skin, 
located beneath the stratum corneum. 
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Figure 2.15 Plasma membrane bound 
transglutaminase in distant clinically unin-
volved skin (DU at the tip and DU interpa-
pillar) and normal healthy skin (NS tip and 
NS interpapillar) expressed as M ± SEM 
(mean ± standard error of the mean). 
9' 
Figure 2.16 Plasma membrane bound transglutaminase in the margin zone of the 
spreading psoriatic lesion. On the right the involved, and on the left the uninvolved 
part of the transition zone are demonstrated. 
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Figure 2.17 Transglutaminase in the margin zone of spreading psoriatic plaques, 
expressed as M ± SEM (mean ± standard error of the mean) 
(a) suprapapillary distribution pattern; 
(b) interpapillary distribution pattern. 
Figure 2.78 Transglutaminase in the lesio-
nai psoriatic skin, expressed as Μ ± SEM 
(mean ± standard error of the mean). 
suprapapillar intrapapillar 
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expression in lesionai skin of stable plaque psoriasis compared to the sprea-
ding psoriatic lesions. 
2.3.5 DISCUSSION 
The present observation confirms an increased presence of plasma membra-
ne bound transglutaminase in lesionai epidermis of psoriatic patients. The 
increased capacity of this enzyme is characterized by an increased enzyme 
activity and by an extension of the number of cell layers comprizing this enzy-
me.1 This increase is of importance to encompass in terms of differentiation 
with the 20-fold increase of the production rate of epidermal cells in the 
psoriatic plaque/ 
In the margin zone of spreading psoriatic plaques (figure 2.15) a steady 
increase of the number of transglutaminase positive cell layers can be obser-
ved from the clinically uninvolved towards and into the lesionai skin. The 
dynamics of transglutaminase is strikingly different from other markers for 
epidermal differentiation. At the transition point between the uninvolved 
skin (low involucrin, marked filaggrin, orthokeratotic, normoproliferative 
epidermis) and lesionai skin (high involucrin, decreased or absent filaggrin, 
parakeratotic and hyperproliferative epidermis) the difference is an on-off 
phenomenon for these markers.7 Transglutaminase demonstrates a more 
gradual, step by step transition between uninvolved and lesionai skin. For 
comparison figure 2.19 illustrates the distribution of involucrin on the same 
biopsies as used in the present studies on transglutaminase. 
As transglutaminase positive cell layers are more abundant in stable com-
pared to unstable plaque psoriasis and as the number transglutaminase posi-
tive cell layers increase beyond the transition point between uninvolved and 
involved lesionai skin it is feasible that the expression of transglutaminase is 
an adaptation to psoriatic dysregulation and not a cause. In this respect it is of 
relevance that treatment with active vitamin D3 dérivâtes enhance transgluta-
minase activity in vitro whilst exerting a potent antipsoriatic effect in vivo.4'11 
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Figure 2.19 Involucrin ¡η the margin zone of spreading psoriatic plaques expressed as 
M ± SEM (mean ± standard error of the mean) 
(a) suprapapillar distribution pattern; 
(b) interpapillar distribution pattern. 
The observation is taken from Gerritsen et al (7) 
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study. Br J Dermatol 1993; 128· 666-673. 
M.J.P. Gerritsen, J.B.M. Boezeman, I.M.J.J. van Vlijmen-Willems, 
P.C.M. van de Kerkhof 
The effect of Tacalcitol (1,24 (OH)j D3) on cutaneous inflammation, epidermal 
proliferation and keratinization in psoriasis, a placebo-controlled, double-blind study. 
Br J Dermatol 1994; 131· 57-63 
M.J.P. Gerritsen, P.E.J, van Erp, P.C.M. van de Kerkhof 
Transglutaminase positive cells in psoriatic epidermis during treatment with calcitnol 
(ια,25 dihydroxy vitamin D3) and tacalcitol (10,24 dihydroxy vitamin D3) Accepted 
BrJ Dermatol. 
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P.C.M. van de Kerkhof 
The effect of a hydrocolloid occlusive dressing (DuoDERM E) on keratinization in 
psoriasis vulgaris. Accepted Acta Dermato Venereol (Stockholm). 
3-1 Topical treatment of psoriatic plaques with 1,25-dihydroxyvi-
tamin O3: a cell biological study 
3 I I SUMMARY 
98 
Calcitino], m,25 dihydroxycholecalciferol (101,25 (ОН)г DÌ) IS a natural active 
vitamin Di metabolite, which has been shown to have an antipsonatic 
efficacy In vitro studies have demonstrated that calcitnol interferes with 
various aspects of inflammation, epideimal proliferation and keratinization 
The aim of the present investigation was to find out to what extent 10,25 
(OH)2 D3 (3 μg/g in white petrolatum) interferes with these aspects in vivo 
during treatment with calcitnol 
Using an immunohistochemical assessment of recruitment of cycling epi­
dermal cells filaggrin and involucrm expression, Τ cell accumulation, PMN 
accumulation, amount of endothelium and ICAM-i expression the following 
observations were made 
1 Modulation of all these aspects occurred during calcitnol treatment 
2 Earlv reduction of epidermal proliferation and PMN accumulation was 
shown 
3 1 he ordei of changes was comparable with the response to treatment with 
calcipotiiol 
In conclusion, at the cell biological level calcitnol (3 μg/g in white petrola­
tum) has a substantial effect on various aspects of the psoriatic lesion. 
3 I 2 INTRODUCTION 
i,25"(OH)2 Di and other vitamin D=t derivatives have been shown to have an 
antipsonatic potential Monmoto and Kumahara1 observed in a patient with 
senile osteoporosis complicated by psoriasis vulgaris, that the psoriasis was 
cured from oral administration of ioc-hydroxyvitamm D? In an open study 
they observed an improvement of psoriasis after treatment with 10-hydroxy-
vitamin D3 orally, ia,25-dihvdro\witamm Di orally and 10,25 dihydroxvvita-
min D3 topically 2 Kato et al3 reported successful treatment of 11 psoriatic 
patients with topical ία 24-dihvdroxychoIecalciferoI Smith et al4 suggested 
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that orally or topically administered і,25-(ОН)г D Ì may be a safe and effective 
alternative therapy for the treatment of psoriasis. In a double blind study 
Kragballe et al5 found that calcipotriol (a vitamin Ώ3 analogue) resulted in a 
statistically significant decrease in erythema, thickness and scaling of the 
psoriatic lesions. They suggested that the vitamin D3 analogue calcipotriol is 
an effective and safe topical treatment for psoriasis. 99 
In a previous study6 we have demonstrated that the analogue calcipotriol 
inhibits several cell biological phenomena of relevance in psoriasis. In that 
study, calcipotriol (50 μg/g ointment) applications to psoriatic plaques resul­
ted in a reduction of the number of neutrophils already after one week treat­
ment; from two weeks treatment onward epidermal proliferation showed a 
significant reduction; Τ lymphocytes and markers for abnormal keratiniza-
tion (expression of keratin 16) showed the first significant reduction after 
four weeks treatment. 
The aim of the present investigation is to further elucidate how and to what 
extent inflammation, proliferation and differentiation are modulated by topi­
cal treatment with 1,25 (ОН)г DÌ, the natural active vitamin D3 metabolite. 
The following questions were addressed: 
- Can we observe a statistically significant modulation of relevant aspects of 
inflammation, epidermal proliferation and keratinization during treat-
ment with m,25 (ОН)г D3 (3 μg|g in white petrolatum)? 
- What is the order in which these processes normalize during treatment 
with ш,25 (OH)2 D3? 
3.I.3 MATERIAL AND METHODS 
3.1.3.1 Patients 
Ten patients suffering from psoriasis were treated with 1,25 (ОН)г D^ oint­
ment (3 μg/g) twice daily (Solvay Duphar BV, Weesp, The Netherlands). The 
patients were included in an open-design multicentre trial covering 78 weeks 
of treatment. Each patient was informed about the experiment and gave writ­
ten consent. Prior to the study they had received no local treatment for at least 
two weeks or systemic therapy for at least one month. The clinical improve­
ment was assessed using the PASI-score. Before and during treatment clini­
cal chemistry, hematological blood investigations and safety parameters with 
respect to calcium and phosphorus metabolism were assessed. 
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3 ι з 2 Biopsies 
Punch biopsies (3 mm diameter) were taken from the psoriatic lesion of 10 
patients before treatment and after 1,2 and 4 weeks treatment The biopsies 
were embedded in 'Iissue Тек OCT compound (Miles Scientific, Naperville, 
IL, USA), snap frozen in liquid nitrogen and stored at -80 °C, untili use. 
100 Sections of 5 μπι were cut, air dried and fixed for ten minutes in aceton-aether 
60/40 vol.°/o (K1-67 staining) or in aceton (other stainings) and stored again at 
-80 °C untili use 
3 1 3 3 Monoclonal antibodies 
To assess epidermal differentiation we used a monoclonal antibody against 
filaggnn (1 500, monoclonal mouse anti-filaggnn, ВТ I, BT576) and învolu-
cnn Mon-150 (1.50, monoclonal antibody against involucrin)7 In normal 
adult skin positive staining for filaggnn is observed in the granular and horny 
layers of the epidermis.84 Involucrin shows a characteristic distribution in 
normal human skin, being present in the upper spinous layer and the granu-
lar layer of the epidermis.4 u ' To characterize the epidermal proliferation we 
used monoclonal antibodies against a nuclear antigen present in the cycling 
cells (1 20, K1-67, Dakopatts, Copenhagen, Denmark) 
lo assess the inflammatory infiltrate staining we used antibodies against 
leucocyte-elastase to visualize PMN (1 100, monoclonal mouse antibody to 
human neutrophil elastase, DAKO-elastase, Dakopatts) and Τ lymphocytes 
(1:100, monoclonal mouse antibody to human T-cells, DAKO-T11, Dako­
patts) To visualize the endothelium of the microvasculature, the monoclonal 
antibody PAL-E (1 50, Department of Pathology, University Hospital Nijme­
gen the Netherlands) was used " This monoclonal antibody specifically 
recognizes the vascular endothelium and doesn't stain the endothelial lining 
of lymphatic vessels 
1 о get information about the endothelial activation we used a monoclonal 
antibody against ICAM-i (1.100, anti-ICAM-i clone 84H10, Immunotech s.a., 
Marseille) 
3 1 3 4 Staining procedures 
For the staining with anti-filaggnn, anti-involucrin, K1-67, anti-elastase, 
PAL-Ε and anti-ICAM-i an indirect immunoperoxidase technique was used. 
The slides were put in a phosphate-buffered stock solution (PBS solution: 
ЗботШагНРСы (j cjgNa2HP04, Merck in 500 ml deminerahzed water) plus 
70 ml NaLhPCb (13 8 g Nal-hPCK Merck, in 500 ml deminerahzed water) 
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plus 70 ml demineralized water). Only the slides stained with anti-elastase 
had a pré-incubation for 20 minutes with methanol/0.1% H2O2 (30%). For 30 
minutes the slides were incubated with the monoclonal antibodies anti-
filaggrin, Ki-67, anti-involucrin and anti-elastase. For the remaining stai-
nings the slides were incubated for one hour. After washing with phosphate-
buffer the slides were incubated with rabbit anti-mouse immunoglobulin 101 
conjugated with peroxidase (1: 25, RAMPO). After washing in the phosphate-
buffered stock solution and pré-incubation with sodium-acetate buffer 
(pH 4.9), a solution of з-атіпо-9-ethylcarbazole (AEC) in sodium-acetate 
buffer containing 0.01% H2O2 was added for 10 minutes. 
Staining with Tu was performed using an indirect peroxidase-anti-peroxi-
dase technique (PAP). After washing the slides forro minutes in PBS solution 
the slides were incubated for 20 minutes with 50% NRS (normal rabbit 
serum). Again after washing the slides in PBS solution twice, the slides were 
incubated for an hour with the antibody. After washing in PBS solution an 
incubation procedure followed with rabbit anti-mouse immunoglobulin (1: 
25, RAM-Ig, Dakopatts) for 20 minutes, two washings in PBS solution and 20 
minutes incubation with PAP-complexes (шоо, Peroxidase monoclonal 
mouse anti peroxidase complexes, Dakopatts, P850). After two washings in 
PBS solution this cycle was repeated and after incubation of the slides in sodi­
um acetate buffer (pH 4.9) they were stained with the AEC solution (see 
above). All slides were counterstained with Mayer's Haematoxylin (Sigma, 
St. Louis MO USA) and mounted in glycerol gelatin. 
3.1.3.5 Histological examinations 
The histological examination was performed with blinding. Epidermal pro­
liferation was measured by counting the number of K1-67 positive nuclei per 
mm length of the section. The filaggrin expression was assessed by measu­
ring the percentage of the length of the stratum corneum and stratum granu-
losum which was stained. The involucrin expression was assessed by calcula­
ting the ratio positive cell layers/total cell layers of the living epidermis. This 
was performed at two sites: at the top of a dermal papilla and between two 
dermal papillae. Dermal inflammation (PMN and Τ lymfocytes) was semi-
quantitatively enumerated by expressing the number of positively stained 
cells as a percentage of the total number of infiltrative cells12 : o, no positive 
cells;i, sporadic; 2, 1-25%; 3, 26-50%; 4, 51-75%; 5, 76-99%; 6, 100%. 
Inflammatory cells in the epidermis were assessed using a five-point scale: 
o, no staining; 1, sporadic staining; 2, minimal staining; 3. moderate stain­
ing; 4, pronounced staining. 
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Ihe expression of the seaming with PAL-Ε and anti-ICAM-i was assessed 
using a four-point scale: o, no staining; i, minimal staining; 2, moderate 
staining; 3, pronounced staining. 
3.1.3.6 Statistical evaluation 
102 For statistical analysis the Wilcoxon test for matched pairs was used. 
3.1.4 RESULTS 
3.1 4.1 Clinical response 
In all patients the psoriatic lesions showed improvement. After two weeks 
this was significantly (p = 0.005). After four weeks the improvement continu­
ed (p =0.007). Figure 3 1 summarizes the PASI scores in the ten patients. 
3.14.2 Histological response 
The number of K1-67 positive nuclei (figure 3.2) showed a significant decrea­
se after one week of treatment (p - 0.01). After two weeks the impiovement 
was also significant (p = 0.005). After four weeks there was still a significant 
decrease (p = 0.03). In the untreated psoriatic lesion hlaggnn expression was 
markedly decreased compared with normal healthy skin. The filaggnn stain­
ing (figure 3.3) in the stratum corneum showed a significant increase after 
two weeks (p = o.o2). After four weeks the filaggnn expression in the stratum 
corneum was almost comparable with the normal skm.s 9 The filaggnn stain­
ing in the stratum granulosum increased significantly after two weeks 
(p = 0.04). After four weeks the hlaggnn staining in the granular layer had 
practically reached normalization.8 0 Ihe mvolucnn expression (figure 3.4) 
on the top of the dermal papilla showed a significant decrease after four 
weeks (p = 0.03). At the interpapillarv epidermis the mvolucnn expression 
did show a slight improvement but this decrease was not significant. Figure 
3.5 illustrates the expression of filaggnn and mvolucnn before and after cal-
citriol treatment. 
The staining of Г lymphocytes (figure 3.6) in the dermis altered signifi­
cantly after two weeks (p = 0.04). Within four weeks the diminishing was 
more significant (p = 0.007). ^ n e Tu staining in the epidermis showed a 
significant decrease after four weeks of treatment (p = 0.02). The PMN ex­
pression (figure 3 7) 111 the dermis showed a significant decrease after one 
week (p = 0.02). 'I he PMN staining in the epidermis did not alter significant-
Is, although there was a slight decrease during the foui weeks of treatment 
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Figure ¡.ι PASI scores before and 
during the treatment with calcitriol, 
expressed as means ± SEM. 
number/ 
mm 
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8 0 
о weeks 1 week 2 weeks 4 weeks 
Figure 3.2 Ю-67 (a marker for epider­
mal growth) before and during treat­
ment with calcitriol expressed as 
means ± SEM. 
Figure3.3 Filaggrin (marker for differentiation) before and during treatment with 
calcitriol, expressed as means ± SEM. 
• stratum corneum cells • stratum granulosum cells 
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Figure 3.4 Involucrin (marker for differentiation) before and during treatment with 
calcitriol, expressed as means ± SEM. 
• on adermal papilla • between dermal papillae. 
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Figure 3.5.1 Filaggrin staining before treatment. 
Figure 3.5.2 Filaggrin staining after four weeks of treatment with calcitriol. 
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Figure 3.5.3 Involucrin staining before treatment. 
• 
Figure 3.5.4 Involucrin staining.after four weeks of treatment with calcitriol. 
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Figure 3.6 Tu (marker of Τ lymphocytes) before and during treatment with calci-
triol, expressed as means ± SEM. 
• epidermal cells • dermal cells. 
2,5 
1.5 
0,5 
0 weeks 
Figure 3.7 Anti-elastase (marker of PMN) before and during treatment with calci-
triol, expressed as means ± SEM. 
• epidermal cells • dermal cells. 
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The endotheliummarkers PAL-E and anti-ICAM-i tended to decrease during 
this period. In the untreated lesions a minimal to moderate staining of the 
keratinocytes was observed with anti-ICAM-i. After four weeks there was a 
slight decrease of the ICAM-i expression of these cells. 
Table 3.1 illustrates the mean values of the PASI scores and the histological 
108 responses. 
Table 3.1 Mean values of the PASI scores and the histological examinations during 
the four weeks of treatment. 
PASI score 
Ki-67 
Filaggrin 
stratum corneum 
stratum granubsum 
Involucrin 
on a dermal papilla 
between dermal papillae 
T11 
epidermis 
dermis 
Anti-elastase 
epidermis 
dermis 
Weeko 
6.6 
119 
26 
55 
64 
31 
2-4 
4-5 
1-3 
1.6 
Week 7 
72 
45 
50 
66 
28 
23 
4-1 
1.2 
1.0 
Week 2 
4-3 
55 
66 
73 
57 
31 
2.0 
37 
0-7 
1.0 
Week 4 
3-2 
35 
83 
88 
51 
28 
1.6 
2.8 
0.2 
0.7 
3.1.4.3 Relation between clinical and histological scores 
A significant improvement of the number of Ki-67 positive nuclei and the 
PMN in the dermis seems to preceed the decrease in clinical scores. However 
it was not until week 2 that the clinical score was done. This makes it difficult 
to make a correct interpretation of these data. The filaggrin staining in the 
stratum corneum and stratum granulosum , the Τ lymphocytes in the dermis 
simultaneously improved with the PASI scores. Involucrin staining, expres­
sion of PAL-Ε and ICAM-i decreased more slowly. 
C H A P T E R 3 
3-1.5 DISCUSSION 
A statistically significant modulation of various aspects of inflammation, epi­
dermal proliferation and keratinization was demonstrated in vivo during 
treatment of psoriatic plaques with calcitriol. The order in which these aspects 
reduce during calcitriol treatment suggests that epidermal proliferation and 109 
PMN accumulation constitute important targets for the antipsoriatic effect 
of calcitriol. Remarkably a similar order of events was shown during treat­
ment with calcipotriol with reduction of epidermal proliferation and PMN 
accumulation in the early phase (first two weeks) and reduction ofT cell accu­
mulation in the late phase (third and fourth week).b Based on the dynamics of 
changes during treatment it is attractive to hypothesize that interference with 
common pathways for cutaneous inflammation and epidermal proliferation 
constitutes an important aspect of the mode of action. In this respect inter­
ference with phosphoinositide metabolism and expression of various proto-
oncogenes might be of relevance.13'15 Alternatively a direct effect on calcium 
metabolism has been hypothesized. It has been well established that epider­
mal keratinocytes and dermal fibroblasts have a specific receptor for ία,25 
(OH)2 D3. 1 6" 1 9 Franceschi et al 2 0 and Eil et al2 1 describe a cytosolic receptor 
that is transported to the nucleus after binding with 10,25 (ОН)г Ö3 and ini-
tiates the transcription of those genes involved in hormonal response. 
An effect of 10,25 (ОН)гОз on intracellular calcium could be relevant to the 
response of keratinocytes to this hormone. 10,25 (ОН)г D3 has been shown 
to increase intracellular calcium in other cell types.2 2 '2 3 These two studies 
report on a relatively acute effect of 10,25 (ОН)г Ü3 on intracellular free calci-
um. Bittiner et al24 conclude in their report that 10,25 (ОН)г Ü3 acts directly 
on keratinocytes to increase intracellular free calcium and that this may be 
relevant to its mode of action in psoriasis. 
A direct effect on the PMN has been suggested. The release of arachidonic 
acid, an important mediator in inflammation in the pathogenesis of psoriasis 
is inhibited by 1,25 (ОН)г Di, whereas Chemotaxis and activation of the PMN 
are not influenced.2' Relatively late in the treatment with calcitriol Τ cell accu­
mulation decreases. It has also become clear that 10,25 (OH)2 D3 has an 
immunomodulating effect with interference on T-cell proliferation.26-30 1,25 
(OH)2 D3 not only blocks IL-2 production but it also seems to interfere with 
IL-2 thymocyte interaction, which in turn results in inhibition of thymocyte 
proliferation.26·28 1,25 (ОН)г Бз inhibits the IL-i induced activities which 
results in inhibition of Τ lymphocyt proliferation, and inhibition of the pro-
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auction of IL-2, IL-6 and IFN-γ 3 1 3 2 Further studies are indicated to find out 
to what extent modulation of signal transducing pathways and cytokine 
expression during the first week of treatment might have occurred Remark­
ably relatively minor changes were observed with respect to amount of endo­
thelium (PAL-Ε binding) and expression of intei cellular adhesion molecules 
n o (anti-ICAM-i staining) In contrast to the dramatic reduction induced by 
cyclosporin treatment33 calcitnol does not seem ro mteifere via endothelial 
gate control 
A stimulation of normal keratinization is a well established in vitro effect 
of calcitnol. However, using involucrin and filaggrin as markers such seems 
to proceed following reduction of epidermal proliferation 
From a clinical point of view the question is relevant to what extent calci­
tnol ointment might constitute an antipsonatic treatment In our ten patients 
no safety problems with 3 pg/g calcitnol ointment occuned The reduction of 
the PASI scores during calcitnol treatment confirm a clinical relevant efficacy 
of the drug in line with previous workers and in contrast to an earhei commu­
nication of our group 3 4 In the latter study clearly bioavailability was not 
sufficient for an antipsonatic effect of calcitnol (2 μg/g in medium chain tri­
glycerides) 3 3 At the cell biological level it is of interest that concomitantly 
with clinical improvement recruitment of cycling cells in the epidermis accu­
mulation of I cells and PMN reduced markedly during calcitnol treatment It 
is intriguing that calcipotnol at a concentration of 50 μg/g induced a reduc­
tion of these aspects to a similar extent as obtained bv calcitnol at 1 <, oncen-
tration as low as 3 ug/g However comparative studies betwee ι both vitamin 
D3 dérivâtes are not available so far Ihe described changes of maimers tor 
proliferation, differentiation, inflammation and I lymphocytes are compara-
ble to those found with other anti-psonatic treatments and other vitamin 0 
analogues It remains to be determined whether the changes of the biological 
markers are directly caused bv the drug 01 whether the drug ïmnroves the dis-
ease by totally different mechanisms 
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3-2 The effect of Tacalcitol (1,24 (OH)2 D3) on cutaneous 
inflammation, epidermal proliferation and keratinization 
in psoriasis, a placebo-controlled, double-blind study 
114 Presented at the EADV (European Academy of Dermatology and Venereology) 1993 in 
Kopenhagen 
3.2.1 SUMMARY 
Vitamine D3 dérivâtes have been shown to exert an antipsonatic effect. In 
vitro investigations clearly showed an antiproliferative effect in various cell 
lines including human keratinocytes. Other studies demonstrated an enhan-
cement of normal keratinization and interference with inflammation In vivo 
data on the interference of vitamin D3 analogues with respect to epidermal 
proliferation, keratinization and inflammation are fragmentary. Moreover, 
interference of 1,24 (ОН)г Û3 with markers for inflammation and keratiniza-
tion have never been studied in vivo. 
I he aim of the present study was to find out to what extent 1,24 (OH)2 D3 
ointment (4 μg/g) can modulate several aspects of inflammation, epidermal 
proliferation and keratinization. 
I en patients with psoriasis vulgaris were included in a placebo-controlled 
double-blind study on 1,24 (ОЩ2 D3 ointment (4 μg/g). Before and af­
ter 8 weeks of treatment, punch biopsies were taken from verum and pla­
cebo treated lesions. An immunohistochemical study was carried out using 
monoclonal antibodies against the hyperprohferation associated keratin 16, 
against cycling nuclei, filaggnn, involucrin and against Τ lymphocytes, 
Langerhans cells, CD14 and PMN. For statistical analysis the Wilcoxon test 
for matched pairs was used. 
The biopsies from the verum treated lesions showed a statistically 
significant modulation towards normalization of all these aspects of 
inflammation, epidermal proliferation and keratinization, except for the Lan­
gerhans cells. The only parameter which showed a significant alteration in 
the placebo treated lesions was the number of cycling nuclei in the epidermis 
(p < 0.02). However, the biopsies from the verum treated plaques did show a 
higher decrease of cvchng cells (decrease : Mvcrum = 70, Mplaccbo = 53) and a 
lower statistically significant p-value (< 0 01). 
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Therefore we concluded that at the cell biological level 1,24 (OH)2 D3 oint­
ment (4 μg/g) has a substantial effect on features of several cell types with 
respect to inflammation, epidermal proliferation and keratinization, except 
on the Langerhans cells. 
3.2.2 INTRODUCTION 
Active vitamin D3 dérivâtes have been shown to be effective in psoriasis. An 
antipsoriatic potential has been demonstrated for 10,25 (ОН)г vitamin D3 
((1,25 (OH)2 D3, also designated as Calcitriol), Calcipotriol (a side chain 
modification of 10,25 (ОН)г vitamin D3) and 10,24 (ОН)г vitamin D3 (1,24 
(OH)2 D3, also designated as Tacalcitol).1's In vitro investigations clearly 
showed an antiproliferative effect in various cell lines including human kera-
tinocytes. Further studies demonstrated an enhancement of normal keratini­
zation and interference with inflammation.6"9 
In vivo data on the interference of vitamin D3 analogues with aspects of 
epidermal proliferation, keratinization and inflammation are fragmentary.10 
In a previous study it was shown that the analogue calcipotriol (50 μglg) 
applied to psoriatic plaques diminished epidermal proliferation and accumu­
lation of polymorphonuclear leukocytes whilst decreasing slightly the accu­
mulation of Τ cells and the expression of keratin 16.4 Remarkably the number 
of Langerhans cells and monocytes did not change during treatment. 
Currently we reported on the effect of 1,25 (ОН)г Эз (з μ g/g in white petro­
latum) on inflammation, epidermal proliferation and keratinization." We 
noted an early reduction of epidermal proliferation and PMN accumulation. 
We also observed modulation of filaggrin and involucrin expression, Τ cell 
accumulation, amount of endothelium and ICAM-i expression during topical 
treatment of psoriatic plaques with 1,25 (ОЩ2 Di. 
Previous investigations have demonstrated that 1,24 (OH)' D3 profoundly 
inhibits growth of keratinocyte in vitro.12 Also during treatment of psoriatic 
plaques an inhibition of epidermal growth was demonstrated.13 So far, inter­
ference of 1,24 (OH)2 D3 with markers for inflammation and keratinization 
never have been studied in vivo. The remarkable clinical efficacy of 1,24 (ОН)г 
Ü3 in pustular psoriasis suggests a potent anti-inflammatory capacity of this 
new analogue.14 The efficacy in disorders of keratinization such as ichthyosis 
on the other hand suggests a direct and efficacious target at the process of 
keratinization in vivo.ls 
CHAPTER 3 
The aim of the present investigation is to find out to what extent 1,24 (ОН)г 
D Ì ointment (4 μg/g in paraffinum subhquidum, dusopropyladipat, vaseline 
album) can modulate several aspects of inflammation, epidermal prolifera­
tion and keratinization. 
116 We addressed the following question-
Does 1,24 (OH)2 D3 ointment (4 μglg) induce a more general effect on 
inflammation, epidermal proliferation and keratinization or alternatively 
does this treatment has a preferential interference with one of these aspects7 
3 2 3 MATERIAL AND METHODS 
Ten patients with psoriasis vulgaris were included in a placebo-controlled, 
double-blind right-left comparative study on 1,24 (OH)2 D? ointment. They 
had received no topical treatment for at least four weeks or systemic treat­
ment for at least two months. All patients gave written consent. During 8 
weeks the patients were treated, once daily, with 1,24 (OH)i Di ointment for 
one body half and placebo for the other body half 
Before and after 8 weeks punch biopsies (3mm) were taken, embedded in 
tissue Тек OCT compound, snap frozen in liquid nitrogen and stored at -80 
°C, untili use. Clinical improvement was assessed using the PASI scores.16 
Before start and during treatment blood samples were taken every two weeks. 
32.3.1 Monoclonal antibodies 
To characterize epidermal proliferation and keratinization we performed a 
staining procedure, thereby using a mixture of a monoclonal antibody 
against a nuclear antigen present in cycling cells (1.10, K1-67, Dakopatts, 
Copenhagen, Denmark)1 7 and a monoclonal antibody against filaggnn 
(1:500, monoclonal mouse anti-filaggnn, BTI, BT576). lo assess other rele­
vant aspects of the keratinization process we furthermore used antibodies 
against involucrin (1:25, MON-i5o) l s and against keratin 13 and 16 (1:20, 
Ks8.i2, Sigma, St. Louis, MO, USA). Keratin 16 is present in the epidermis of 
hyperprohferative skin,14 while keratin 13 cannot be found in human adult 
skin.2 0 
To characterize the inflammatory infiltrate staining was performed with 
antibodies against leucocyte-elastase to visualize PMN (1.50, monoclonal 
mouse antibody to human neutrophil elastase, DAKO-elastase, Dakopatts, 
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Copenhagen, Denmark), Τ lymphocytes (ι 50, monoclonal mouse antibody 
against human i -cells, DAKO-T11, Dakopatts, Copenhagen, Denmark), 
monocytes and macrophages(i 100, WT14, Department of Medicine, Divi­
sion Nephrology, University Hospital of Nijmegen, the Netherlands)21 and 
against Langerhans cells (1,100, monoclonal mouse antibody against human 
cortical thymocyte, DAKOT6, Dakopatts, Copenhagen, Denmark) 117 
3 2 3 2 Staining procedure 
For the staining with anti-filaggrin, anti-involucrin K1-67, anti-elastase and 
Ks8 12 an indirect immunoperoxidase technique was used For ten minutes 
the slides were fixed in acetone-ether (60/40 vol%) (Ki-67-hlaggrin staining) 
or acetone (involucri», anti-elastase and Ks8 12 staining) After these slides 
were air-dried they were put in a phosphate-buffered stock solution (PBS 
solution 360 ml ЫагНРСи (79 g ЫагНРСм, Merck in 500 ml demineralized 
water) plus 70 ml NabhPCu (13 8 g ЫаНгРОч, Merck, in 500 ml deminerali­
zed water) plus 70 ml demineralized water) The slides for the Ks8 12 stai­
ning were put in a PBS solution combined with Tween 80 (polyethylene sorbi-
tan mono oleate) Only the slides stained with anti-elastase had a pré-incuba-
tion for 20 minutes with methanol/o 1% Η-Ό2 (30%) For 60 minutes the 
slides were incubated with the monoclonal antibodies After washing in 
phosphatebuffer the slides were incubated with rabbit anti-mouse immuno­
globulin conjugated with peroxidase (1 50, RAMPO) After washing in the 
phosphate-buffered stock solution and pre-incubation with sodium-acetate 
buffer (pH 4 9), a solution of з-агшпо-9-ethylcarbazole (AEC) in sodium-
acetate buffer containing о oi% H2O2 was added for 10 minutes 
Staining with Ti 1 OK Г6 en W114 was performed using an indirect peroxi-
dase-anti-peroxidase technique (PAP) After washing the slides for 10 minu­
tes in PBS solution the slides were incubated for 20 minutes with 50% NRS 
(normal rabbit serum) Again after washing the slides in PBS solution twice, 
the slides were incubated for an hour with the antibody. After washing in PBS 
solution an incubation procedure followed with rabbit anti-mouse immu­
noglobulin (1 25, RAM-lg, Dakopatts) for 20 minutes, two washings in PBS 
solution and 20 minutes incubation with PAP-complexes (1 100, Peroxidase 
monoclonal mouse anti-peroxidase complexes, Dakopatts, P850) After two 
washings in PBS solution this cvcle was repeated and after incubation of the 
slides in sodium acetate buffer (pH 4 9) they were stained with the AEC solu­
tion (see above) All slides were counterstained with Mayer's Haematoxyhn 
(Sigma, St Louis MO USA) and mounted in glycerol gelatin 
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3.2.3.3 Histological examination 
The histological examination was performed with blinding. Epidermal pro­
liferation was measured by counting the number of Ki-67 positive nuclei per 
mm length of the section. In exactly the same area the filaggrin expression 
was assessed by measuring the percentage of the length of the stratum cor-
118 neum and stratum granulosum which was stained.22 The Ks8.i2 staining in 
the epidermis was assessed using a five-point scale: 0, no staining; 1, spora­
dic staining; 2, minimal staining: 3, moderate staining; 4, pronounced stai­
ning.9 
The involucrin expression was assessed by calculating the ratio positive 
cell layers/total cell layers of the living epidermis. This was done on two sites: 
at the tip of a dermal papilla and between two dermal papillae. ' ' 
Dermal inflammation (PMN, Τ lymphocytes, CD14 (monocytes/macro­
phages) and Langerhans cells) was semiquantitatively enumerated by expres­
sing the number of positively stained cells as a percentage of the total number 
of infiltrate cells23: o, no positive cells; 1, sporadic positive cells; 2,1-25%; 3, 
26-50%; 4, 51-75%; 5, 76-99%; 6, 100%. In the epidermis inflammatory cells 
were assessed using a five-point scale: 0, no staining; 1, sporadic staining; 
2, minimal staining; 3, moderate staining; 4, pronounced staining. 
3.2.3.4 Statistical evaluation 
For statistical analysis the Wilcoxon test for matched pairs was used. 
3.2.4 RESULTS 
3.2.4.1 Clinical response 
Eight patients did show a marked improvement. The mean pretreatment 
PASIs were 3.7 ± 0.4 for the 1,24 (ОН)г DÌ treated lesions and 3.8 ± 0.3 for the 
placebo treated plaques (figure 3.9). After two weeks of treatment with 1,24 
(OH)2 Di the improvement was significant (p < 0.01). The lesions treated 
with placebo also showed a significant improvement after two weeks (p < 
0.03). After 8 weeks both body halves showed a more significant improve-
ment with the same p-value (< 0.01). The mean posttreatment PASIs were 1.9 
± 0.4 for the 1,24 (OH)2 Di treated psoriatic plaques and 2.8 ± 0.4 for the 
placebo treated lesions (figure 3.9). Evaluating the PASI scores we found that 
both treatments gave an improvement of induration, desquamation, and on 
erythema. However, the verum treated lesions showed a much higher decrea-
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Figure ¡.g The PASI scores of the verum 
and placebo treated lesions, expressed as 
M ± S E M . 
*p < 0.05 * *p < 0.025 * * *p < 0.01 
Wko Wk8 Wko Wk8 
verum placebo 
se in severity scores. The mean value with respect to erythema in the verum 
treated lesions changed from 3 ± 0 before, into 1.7 ± 0.2 after 8 weeks, where-
as the mean value of the placebo treated plaques decreased from 3 ± о to 2.5 ± 
0.2. The mean value for induration in the verum treated body halves changed 
from 3 ± 0 into 1.1 ± 0.3, the mean value of the placebo treated plaques chan­
ged from 2.9 ± 0.02 before, into 2.0 ± 0.2 after 8 weeks treatment. With 
respect to desquamation the mean value of the verum treated lesions changed 
from 3 ± 0 into 1.3 ± 0.4, while the mean value of the placebo treated plaques 
decreased from 2.95 ± 0.04 to 1.8 ± 0.3 after 8 weeks. Moreover the extension 
of the placebo treated areas did not show a significant improvement (p < 
0.14), whereas the 1,24 (ОН)г D? treated lesions did (p < 0.01). 
During treatment with 1,24 (ОН)г Ü3 one patient got an exacerbation of 
her psoriasis vulgaris. She had used corticosteroid ointments for several 
years and did stop with this treatment one month prior to the study start. 
After stopping the psoriasis got worse, even during the 1,24 (OH)2 D3 treat-
ment. The psoriasis appeared to be very unstable so we decided to withdraw 
the patient from the study. 
No side effects were seen. Laboratory analysis (blood calcium, phosphate, 
albumin, creatinine, alkaline phosphatase, aspartate amino transferase, lac-
tate dehydrogenase, white and red blood cell counts, haemoglobin, platelets 
and erythrocytes) did not show any significant change. 
119 
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3.2.4-2 Histological results 
In the lesions treated with 1,24 (ОН)г Оз the number of Ki-67 positive nu­
clei showed a statistically significant decrease after 8 weeks of treatment 
(p < 0.01). The placebo treated lesions showed a lesser but also significant 
decrease of Ki-67 positive nuclei (p < 0.025). 
120 In the untreated psoriatic lesion filaggrin expression is markedly de­
creased in the stratum corneum and stratum granulosum, compared with 
healthy skin.24 The filaggrin staining in the stratum corneum did show a 
significant increase in the verum treated lesions (p < 0.05), whereas the 
stratum corneum staining of filaggrin in the placebo treated group did not 
(p>o.io). 
The filaggrin staining in the stratum granulosum in the verum treated 
lesions showed a significant improvement after 8 weeks (p < 0.025), t n e 
placebo treated plaques did not show a significant increase (p > 0.6). 
In the normal healthy skin involucrin expression is seen in the stratum gra­
nulosum and in the upper part of the stratum spinosum. In the psoriatic 
lesions involucrin expression is also seen in the lower region of the epider­
mis. 2 4 The involucrin expression (assessed at the tip of a dermal papilla) in 
the verum treated lesions did show a statistically significant decrease (p < 
0.01). In the placebo treated group we did not find signicant improvement (p 
> 0.4). In the interpapillar region the involucrin expression did not show a 
significant decrease in both treatments (p
vcr
um
>0
-3> Ppiacebo>0-3)· 
The Ks8.i2 staining (keratin 16) was high in the suprabasal layers of the 
epidermis (figure 3.10.1). In the verum treated lesions the Ks8.i2 expression 
altered significantly after 8 weeks (p < 0.01; figure 3.10.2), whereas the 
expression in the placebo treated lesions did not (p = 1.0; figure 3.10.3). 
However, the staining of keratin 16 did not alter into the characteristic pattern 
of the clinically uninvolved psoriatic skin (sporadic staining of the basal lay­
ers and no staining in the suprabasal compartment). 
In the pretreatment psoriatic plaques PMN (anti-elastase positive cells) 
were presentas micro-abscesses in the stratum corneum and dispersed in the 
epidermis and dermis. In the verum treated lesions the PMN in the epidermis 
as well as the PMN in the dermis reduced significantly (p
e
pidermis < °-°5) (Pder-
mis<°.Ol ) . 
The placebo treated plaques did not show a significant reduction of PMN 
in the epidermis nor in the dermis (p
epi(jermib > °·1) (Pdermis > °-5)· 
Τ lymphocytes (Tn positive cells) were moderately present in the epider­
mis, but numerous in the dermis (about 76-99% of the dermal infiltrate). 
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Figure 3.10.1 The Ks8.i2 expression before treatment, keratin 16 is seen high in the sup­
rabasal layers of the epidermis. 
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Figure 3-10.2 The Ks8.i2 expression after 8 weeks of treatment with Tacalcitol, keratin 
16 did show a significant reduction, but did not alter into the characteristic pattern of 
the clinically uninvolved skin of psoriatic patients. 
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-, 
Figure 3.10.3 The Ks8.i2 expression after 8 weeks of treatment with placebo is compa­
rable with the expression we observed before the treatment period. 
The verum treated psoriatic lesions showed a significant reduction of Τ lymp­
hocytes in the epidermis as well as in the dermis, while the placebo treated 
plaques dit not (Verum: p
epidermis - ° ·
0 1 ; Pdermis < °-°3; Placebo: Pepidermis > 
0.5; Pdermis > 0 .7) . 
CD14 positive cells were seen in the epidermis and in the dermis. In the 
verum treated lesions we estimated a significant decrease of CD14 positive 
cells in the epidermis (p < 0.01) and a almost significant decrease in the der­
mis (p > 0.05). The placebo treated lesions did not show a significant altera­
tion with respect to the CD14 positive cells in the epidermis (p > 0.15) and in 
the dermis (p > 0.15). 
In psoriatic epidermis Langerhans cells have demonstrated clustering.25" 
2 7
 Whether their numbers are decreased or increased remains controver­
sial.25' 2 S " 2 9 We observed Langerhans cells (OKT6 positive cells) in the epider­
mis as well as in the dermis. The verum treated psoriatic plaques did not 
show a significant modulation in Langerhans cells in the epidermis (p > 0.2) 
and in the dermis (p > 0.6). The Langerhans cells in the placebo treated 
lesions also did not alter significantly in the epidermis (p > 0.5) nor in the 
dermis (p = i.oo). 
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Tables 3.2 and 3.3 demonstrate the mean-values ± SEM of the immuno-
histochemical results. 
Table 3.2 Mean values of the markers for proliferation and differentiation ± SEM. 
Ki-67 (pos nuclei/mm) 
Filaggrin (%) 
str. corneum 
str. granulosum 
Involucrin (%) 
fop 
interpapillar 
Ks8.i2 (5-point 
*ρ < 0.05 
scale) 
**p<o. 025 
Verum 
weeko 
99.2 ± 20.7 
1.0І1.0 
60.0 ±13.3 
67.1 ±5.7 
26.3 ±2.2 
2.8 ±0.2 
***p <0.01 
Verum 
week 8 
29.8 ± 9.5*** 
44.0 ±15.7* 
100.0 ± 0.0** 
46.I ± 2.6*** 
23.3 ± 2 . 8 
1.4 ± Ο.3*** 
Placebo 
weeko 
123.8127.7 
1.0І1.0 
62.5 + 11.1 
62.7 + 3.5 
28.2 ±2.1 
2.9 ± 0.2 
Placebo 
week 8 
69.8 ±11.7** 
23.0 ±13.2 
70.0 ± 12.0 
64.312.7 
26.213.1 
2.9 1 0.2 
Table 3.3 Mean values of the markers for inflammation ± SEM. 
PMN 
epidermis 
dermis 
Τ lymphocytes 
epidermis 
dermis 
CDi4pos. cells 
epidermis 
dermis 
Langerhans cells 
epidermis 
dermis 
Verum 
weeko 
1.3 ±0.5 
1.1 ± 0.2 
2.3 ± 0 . 2 
4.5 ± 0.3 
1.3 ± 0.2 
2.5 ± 0.2 
2.8 ± 0 . 3 
1.7 ± 0 . 2 
Verum 
week 8 
0.З + 0.3* 
0.1 ± 0.1*** 
1.5 ±0.3*** 
3.7 ± 0 . 4 * 
0.2 ±0.2*** 
2.0 ± 0 . 2 * 
2.1 ± 0 . 3 
1.6± 0.2 
Placebo 
weeko 
1.010.3 
1.11 0.2 
2.2 + 0.1 
4.6 1 0.2 
i . o l 0.3 
2.1 ± 0.1 
2.4 ± 0 . 2 
1.8 + 0.2 
Placebo 
week 8 
0 . 6 1 0.2 
0 . 9 1 0 . 2 
2.4 1 0.4 
4 . 7 I 0.2 
0.4 + 0.2 
1.9 + 0.1 
2.2 + 0.2 
1.81 0.3 
123 
*p<o.os **ρ<0.02ζ **"ρ<ο.σί 
CHAPTER 3 
3 2 5 DISCUSSION 
The aim of the present study was to investigate the in vivo effect of 1,24 (ОНЬ 
D Ì ointment (4 pg/g) on inflammation, epidermal proliferation and keratini-
zation In the verum treated lesions we observed a statistically significant 
124 modulation in the expression of the inflammation markers fori lymphocy-
tes, CD14, and PMN, the proliferation markers for cycling nuclei in the epi-
dermis and keratin 16, and the differentiation markers for filaggnn and învol-
ucnn The Langerhans cells did not show any statistically significant altera-
tion after 8 weeks of treatment The only parameter which showed a statisti-
cally significant modulation during placebo treatment was the number of 
cycling nuclei in the epidermis However, the verum treated lesions did show 
a higher decrease of cycling nuclei (verum Mde(.rejsc = 70, placebo Mdecrcisc = 
53) and a lower statistically significant p-value (pvtrlim < о 01 р
р
|1сеЬо < 
о 025) Iherefore, 1,24 (ОН)г DÌ ointment resulted in broad spectrum of cell 
biological effects in vivo during topical application on psoriatic plaques 
fable 3 4 summarizes the in vivo effects of the present analogue, calcitnol 
(1,25 (OH)2 Ds) and calcipotnol ч " 
It can be concluded that the various compounds, at the concentrations 
used, have a different spectrum of responses in the in vivo situation, 1,25 
(OH)2 D3 and 1,24 (OH)2 D Ì having a more substantial effect on the 
inflammatory aspects In vitro, a similar concentration range was observed 
for the three compounds with respect to interference with epidermal 
growth 1S 30 31 
All three vitamine D Ì dérivâtes, listed in Table з 4, have an antipsonatic 
efficacv However the concentrations are very different Calcitnol, 1,25 (OH)z 
DÌ was applied twice dailv as 3 μg|g petrolatum and calcipotnol twice dailv as 
50 μg/g in an ointment The low calcipotropic effect of calcipotnol permitted 
the relatively high concentration of 50 μg/g Remarkably, each of the three 
compounds at these very different concentrations had a remarkable clinical 
effect and a substantial cell biological effect So far, however, no comparative 
efficacy studies and no comparative data on transcutaneous penetration are 
available 
With respect to irritancy of the skin it has been documented that 8-19 5% 
of the patients treated with calcipotnol 50 μg/g experienced irritancy 2 b With 
respect to calcitnol (1,25 (ОН)г DÌ) our information is limited With respect 
to 1,24 (OH)2 D Ì a very low irritancy potential has been claimed,32 although 
no comparative studies are available In the light of the findings summarized 
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Table 3.4 Comparison of the effect of calcipotriol (50 Mg/g)9, calcitriol (1,25 (ОН)г 
D3> 3 u g/g)" a " d tacalcitol (1,24 (ОН)г DÌ, 4 Mg/g) at the cell biological level on featu-
res of several cell types with respect to inflammation, epidermal proliferation and 
keratinization. 
Ю-67 
K16 
Involucnn 
Filaggrin 
PMN accurru 
Tcellaccumu 
ilation 
ilation 
WT14 accumulation 
OKT6 accumulation 
Calcipotno/ 
50 fig/q twice dc 
+ 
± 
nd 
nd 
+ 
+ 
-
-
i/ly 
Calcitriol 
3 ¿/g/g twice dc 
+ 
nd 
+ 
+ 
+ 
+ 
nd 
nd 
nly 
Tacalcitol 
4^g/g once daily 
+ 
+ 
+ 
+ 
+ 
+ 
+ 
-
± = positive, but not significant effect + = significant effect - = no effect nd = not done 
in table 3.4 it is attractive to hypothesize that the broader in vivo effects of 
1,24 (OH)2 DÌ on cutaneous inflammation are responsible for the low irritan-
cy potential of this treatment. 
The present study demonstrates an improvement of the psoriatic plaque 
during treatment with 1,24 (ОН)г D^ ointment at various levels of the epider­
mis and dermis. 
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3-3 Transglutaminase positive cells in psoriatic epidermis during 
treatment with calcitriol (101,25 dihydroxy vitamin D3) and 
tacalcitol (10,24 dihydroxy vitamin D3) 
128 3.3.I SUMMARY 
Plasma membrane bound transglutaminase is responsible for the cross-lin-
king of precursor proteins (e.g. involucrin, filaggrin) into the corn ¡fled enve-
lope by I(y-glutamyl) lysine isopeptide bonds. In lesionai skin of psoriatic 
patients both the activity and the number of transglutaminase positive cells 
has been reported to be increased compared to normal skin. In vitro, active 
vitamin D3 analogues have been reported to enhance transglutaminase activi-
ty of keratinocytes. 
The aim of the present investigation was to investigate the effect of two 
vitamin D3 analogues -calcitriol (ία, 25 dihydroxy vitamin D3) and tacalcitol 
(ία, 24 dihydroxy vitamin D3)- on the expression of transglutaminase in 
psoriatic epidermis. 
Both analogues induced a clinical improvement of the lesions and at the 
cellular level reduced the number of transglutaminase positive cell layers sub­
stantially. This reduction is interpreted to be the result of compartmentaliza-
tion of the epidermal cell population following inhibition of the recruitment 
of cycling epidermal cells. 
3.3.2 INTRODUCTION 
The keratinization process of human epidermis involves the formation of an 
insoluble cross-linked protein envelope. Involucrin, filaggrin, and other 
major precursor proteins of the cornified cell envelope are expressed late 
during epidermal differentiation.1 Involucrin expression starts in the upper 
spinous cell layers in normal human skin.2 Filaggrin expression is restricted 
to the granular layer and the stratum comeum.' These and other precursor 
proteins become cross-linked by the activity of transglutaminase K, the rate 
limiting enzyme in the formation of the cornified envelope, via e-ty-glutamyl) 
lysine isopeptide bonds.4 
It has been demonstrated that membrane-associated transglutaminase 
activity and the number of cross-linked envelopes are markedly increased in 
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psoriatic skin.5 It is also well established that in psoriatic epidermis involu­
c r i expression is significantly increased, whereas the filaggrin expression is 
decreased or even absent.6 
In keratinocytes in vitro it has been demonstrated that cornified envelope 
formation and transglutaminase activity are enhanced by calcitriol (ία, 25 
dihydroxy vitamin D3), tacalcitol (ία, 24 dihydroxy vitamin D3) and calcipo- 129 
triol.7-4 
Recently, we reported that calcitriol (1,25 (ОН)г Бз) and tacalcitol (1,24 
(OH)2 D3) reduce the expression of involucrin and increase the filaggrin 
expression in psoriatic skin.6 '1 0 
The aim of the present investigation is to examine the effect of 1,25 (ОН)г 
Ü3 and of 1,24 (OH)2 D3 on the expression of the human keratinocyte trans-
glutaminase in vivo during treatment of psoriatic plaques with these deriva-
tes. 
3.3.3 MATERIAL AND METHODS 
3.3.3.1 Patients 
Twenty patients with stable psoriasis vulgaris were included in this study. 
Ten patients were treated with calcitriol in petrolatum (3 μg/g) twice daily. 
Before, after 1, 2 and 4 weeks of treatment punch biopsies (3 mm) were taken 
from the psoriatic lesions. Calcitriol was obtained from Solvay Duphar, 
Amsterdam, The Netherlands. 
The other ten patients were treated with tacalcitol ointment (4 Mg/g) once 
daily for one body half and ointment without tacalcitol for the other body half 
during 8 weeks. Before and after 8 weeks of treatment punch biopsies (3 mm) 
were taken from both body halves. 
The punch biopsies were embedded in Tissue Тек OCT compound and 
snap frozen in liquid nitrogen and stored at -80 °C until use. Sections of 6 μπι 
wer cut, air dried and fixed for ten minutes in acetone and stored again at 
-80 °C, until use. 
In these 20 patients the clinical improvement during treatment with calci­
triol and tacalcitol, assessed by using the PASI scores, and the modulation of 
the expression of involucrin, filaggrin, composition of the inflammatory 
infiltrate and recruitment of cycling epidermal cells have been reported befo­
re 6,11) 
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3 3·3· 2 Monoclonal antibody 
To visuale transglutaminase type I, which is expressed during differentiation 
of epidermis we used an anti-human keratinocyte transglutaminase (Mouse 
Monoclonal Antibody, IgG2 0 α ι 1 3 The antibody was obtained from Biomedi­
cal Technologies Inc. 
130 
3 3.3.3 Staining procedure 
An lmmunoperoxidase technique was used. After the slides were air dried 
they were fixed for 5 minutes in acetone at -20 °C After thev were dried again 
they were put in a phosphate-buffered stock solution (PBS solution: 360 ml 
Na2HP04 (7.9 g Na2HP04, Merck in 500 ml deminerahzed water) plus 70 ml 
NaFhPCU (13 8 g Naf-hPO·*, Merck, in 500 ml deminerahzed water) plus 70 
ml deminerahzed water, pH 7,4) during ten minutes The slides were incuba­
ted with 10% normal rabbit serum diluted in PBS solution, during 15 minutes 
at roomtemperature Afterwards the anti-human keratinocyte transglutami­
nase (1:25 with i-го human AB serum in PBS solution) was added and the 
slides were incubated for 1 hour at room temperature. After two washings in 
PBS solution the slides were incubated with rabbit anti-mouse immunoglo­
bulin conjugated with peroxidase (1:25 RAMPO with 1.20 human AB serum). 
Again after two washings during ten minutes the slides were put in a sodium-
acetate buffer (pH 4,9). A solution of з-аішпо-9-ethylcarbazole (AEC) in 
sodium-acetate buffer containing 0,01% H2O2 was added for ten minutes. 
After washing in deminerahzed water the slides werd counterstained with 
Mayer's Haematoxyhn (Sigma, St. Louis MO USA) and mounted in glycerol 
gelatin. 
3.3.3.4 Histological examination 
The histological examination was performed blinded. The transglutaminase 
expression was assessed by calculating the ratio positive cell layers/total cell 
layers of the living epidermis. This was performed at two sites: at the tip of a 
dermal papilla and in the interpapillar region. In every slide two representati­
ve spots were examined and the mean of these observations was assessed.6 
3.3.3.5 Statistical eualuation 
For statistical analysis the Wilcoxon Ranking Test for matched pairs was 
used. 
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3-3-4 RESULTS 
The calcitriol treated biopsies did show a statistically significant reduction of 
transglutaminase expression at the tip of a dermal papilla after 4 weeks of 
treatment (p < 0.03). In the interpapillar region the transglutaminase stain­
ing showed a tendency to decrease after 4 weeks treatment with calcitriol 131 
(p< 0.075). 
The tacalcitol treated lesions also showed a statistically significant decrea­
se of the transglutaminase expression at the tip of a dermal papilla (p < 0.03), 
while the reduction of the expression in the interpapillar zone was not 
significantly modulated by this treatment(p < 0,125). The transglutaminase 
expression of the biopsies of the lesions treated with placebo did not change 
significantly (p = 0.2 in both areas). 
Figure 3.11 and 3.12 demonstrate the mean values ± SEM. 
Figure 3.13.1 and 3.13.2 show the distribution of transglutaminase before 
and after 4 weeks of treatment with calcitriol. 
100% 
Figure3.11 Plasma membrane bound 
transglutaminase before treatment and 
90 % after 4 weeks treatment with calcitriol 3 
80% 
70% 
60% 
50% 
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30% 
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CHAPTER 3 
132 
100% 
9 0 % 
80% 
70% 
60% 
50% 
40% 
30% 
20% 
10% 
0% 
W k o W k 8 W k o W k 8 W k o W k 8 W k o W k 8 
Figure3.72 Plasma membrane bound transglutaminase before treatment and after 8 
weeks treatment with tacalcitol ointment (4 μg/g) once daily and placebo ointment 
once daily. (Left: suprapapillary distribution pattern; Right: interpapillary distribution). 
'JËÜ 
1 
Figure 3.13.1 The distribution of plasma membrane bound transglutaminase before 
treatment. 
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43 
Figure3.13.2 The distribution of plasma membrane bound transglutaminase after 4 
weeks of treatment with calcitriol. Figure 3.13.1 and 3.13.2 have been made with the 
same magnitude. 
3.3.5 DISCUSSION 
In has been demonstrated that membrane-associated transglutaminase acti-
vity and the number of cross-linked envelopes are markedly increased in 
psoriatic skin, respectively 5-fold and 10-fold.5 Recently we demonstrated 
that the number of transglutaminase positive cells is markedly increased in 
lesionai skin compared to the clinically uninvolved skin of psoriatic patients 
using immunohistochemistry.14 The distribution pattern of transglutamina-
se comprised relatively more cell layers compared to the distribution pattern 
of involucrin. So far the trigger for the premature expression of transglutami-
nase in psoriatic skin remains to be identified. It is remotely possible that 
involucrin expression stimulates the expression of its cross-linking enzyme 
directly. Alternatively the increased phosphatidyl-inositol turnover in lesionai 
psoriatic skin enhances liberation of calcium from the intracellular calcium 
stores.15 In an in vitro study an increase of involucrin expression and trans-
glutaminase activity was observed following a high level of extracellular calci-
um.12 So far, however, increased transcription of transglutaminase by an 
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increase of the intracellular calcium concentrations has not been proven. 
In vitro, active vitamin Di analogues enhance transglutaminase activity.7"4 
In this respect it is of interest that active vitamin D3 enhances calcium entry 
from the extracellular compartment.16 Haussler found evidence that binding 
of calcitriol to keratinocyte receptors results in intracellular calcium mobili-
134 zation.17 In vivo, the effect of active vitamin D3 on the activity of transglutami-
nase remains unsubstantiated. However, the present study demonstrates that 
the number of transglutaminase positive cell layers is reduced markedly 
during treatment with active vitamin D3. 
As transglutaminase activity is enhanced by active vitamin D3 in vitro, the 
reduced number of transglutaminase positive cells in vitamin D3 treated 
psoriatic skin is likely to be the result of a modification of compartmentaliza-
tion of epidermal cell population by this treatment. In untreated lesionai skin 
of psoriatics, the number of cycling cells has a 30-fold increase compared to 
normal skin. The increased recruitment of cycling epidermal cells in the ger-
minative pool results in a 20-fold increase of cell production.17 The number 
of differentiating cells is increased 3-fold compared to normal skin. l s The 
increased transglutaminase capacity in untreated lesionai skin could well be a 
compensatory phenomenon related to the increased production rate of epi-
dermal cells. It has been shown that the increased recruitment of cycling epi-
dermal cells is inhibited in an early stage of the treatment with calcitriol, and 
tacalcitol.k10 Redistribution of the number of cycling- and differentiating 
cells is associated with a decrease of the number of transglutaminase positive 
cells. 
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3-4 The effect of a hydrocolloid occlusive dressing (DuoDERM E) 
on keratinization in psoriasis vulgaris 
3.4.1 SUMMARY 
Various studies have reported on a beneficial effect of occlusion therapy in 
the treatment of psoriasis. The precise mechanism remains unknown. 
The aim of the present investigation was to evaluate the effect of a hydro-
colloid dressing (Duoderm E) on markers for keratinization (filaggrin and 
involucrin). Nine patients were treated for three weeks with Duoderm E. 
Before and after three weeks of treatment punch biopsies were taken and 
immunohistochemical stainings were performed. 
The filaggrin expression in the granular layer did show a statistically 
significant increase, while the involucrin expression showed a marked decre-
ase. 
Our results confirm the antipsoriatic potential of HCD as monotherapy. As 
the function of filaggrin is to maintain a normal hydrating state of the stra-
tum corneum, the increase of the filaggrin expression could lead to an incre-
ased permeability of the stratum corneum. This could explain the pronoun-
ced antipsoriatic effect of corticosteroids applied under plastic occlusion as 
was observed by other investigators. It has been suggested that involucrin 
synthesis is correlated with the degree of epidermal turnover. The decrease of 
the involucrin expression after three weeks treatment could indicate a down 
regulation of the proliferation rate of the epidermal keratinocytes. 
We concluded that as immunological parameters remain unaffected 
during HCD treatment, it is feasible that this mode of occlusion directly 
interferes with epidermal growth and differentiation. 
3.4.2 INTRODUCTION 
Previous studies have reported on a beneficial effect of occlusion therapy in 
the treatment of psoriasis. Friedman reported that the efficacy of an occlusive 
hydrocolloid dressing was comparable to topical fluocinolone acetonide in a 
ten weeks clinical trial. Also at the cellular level a reduction of the abnormali-
ties have been documented.1 Baxter et al observed a decrease of the mitotic 
index in the psoriatic lesion after a four days treatment with an occlusive dres-
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sing.2 Fry et al also noted lowered epidermal mitotic counts in psoriatic pla­
ques treated for two weeks with an occlusive dressing.3 They also found that 
application for one weekwas superior to repeated daily applications. Gottlieb 
et al investigated the efficacy of Actiderm alone in the treatment of psoriatic 
plaques using immunohistochemical and clinical measurements. Their 
results suggest that the dermatological patch is effective in treating psoriatic 
plaques, but does not affect underlying immunopathological mechanisms 
after two weeks of treatment.4 
I he purpose of the present study was to evaluate the effect of the hydrocol-
loid dressing DuoDERM E (Convatec1^) on markers for keratinization (anti-
filaggnn and anti-involucrin). Filaggnn is a basic protein normally present 
in the stratum corneum of the epidermis. Profilaggrin, the precursor of fil­
aggnn, is synthezised at the level of the granular layer, where it is stored in 
the keratohyahne granules.5 ° After dephosphorylation and proteolysis by 
specific enzymes profilaggrin is processed into filaggnn, during the cor-
nification of the keratinocytes.7 1 0 Filaggnn has a major function in aggrega­
ting keratin filaments and maintaining a normal hydratmg state of the stra­
tum corneum.11 1 2 Involucnn is normally present in the upper third of the 
epidermis of the healthy skin The protein becomes incorporated in the 
cornified envelope under the cellular plasmamembrane. 1 3 1 4 Involucnn is 
not related to keratins, immunological nor biochemical, and it is a distinct 
marker for terminal differentiation.1315 
3.4.3 MATERIAL A N D M E T H O D S 
3.4 3.1 Subjects 
Nine patients suffering from psoriasis vulgaris were included in this study. 
All patients gave written consent. They did not receive any topical treatment 
for at least two weeks or systemic treatment for at least si\ months A hydro-
colloid occlusive dressing (DuoDERM E, ConvatecR) was applied on one 
psoriatic lesion. 1 he dressing was renewed every seven days Clinical impro­
vement was assessed using the severity scores for erythema, induration and 
scaling 
Before treatment and after three weeks of treatment with DuoDERM E 
punch biopsies (3 mm) were taken from the psoriatic lesions, embedded in 
Tissue Тек OCT compound, snap frozen in liquid nitrogen and stored at 
-80 °C, until use 
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3-4-3·2 Monoclonal antibodies 
To assess epidermal differentiation we used a monoclonal antibody against 
filaggrin (1:500, antifilaggrin, BTI, BT576) and a monoclonal antibody 
against involucrin (MON-150, 1:25, monoclonal antibody against involu-
crin).16 
3.4.3.3 Staining procedure 
An indirect immunoperoxidase technique was used. For ten minutes the 
slides were fixed in acetone. After these slides were air-dried they were put in 
a phosphate-buffered stock solution (PBS solution: 360 ml Na2HP04 (7.9 g 
Na2HP04, Merck in 500 ml demincralized water) plus 70 ml NabhP04 (13.8 g 
NafhPCh, Merck, in 500 ml demineralized water) plus 70 ml demineralized 
water). For 60 minutes the slides were incubated with the monoclonal antibo-
dies. After washing in phosphatebuffer the slides were incubated with rabbit 
anti-mouse immunoglobulin conjugated with peroxidase (1: 50, RAMPO). 
After washing in the phosphate-buffered stock solution and pré-incubation 
with sodium-acetate buffer (pH 4.9), a solution of з-атіпо-9-ethylcarbazole 
(AEC) in sodium-acetate buffer containing 0.01% H2O2 was added for 10 
minutes. 
All slides were eounterstained with Mayer's Haematoxylin (Sigma, St. 
Louis MO USA) and mounted in glycerol gelatin. 
3.4.3.4 Histological examination 
Filaggrin expression was assessed by measuring the percentage of the length 
of the stratum corneum and stratum granulosum which was stained.17 
The involucrin expression was assessed by calculating the ratio positive 
cell layers/total cell layers of the living epidermis. This was done on two sites: 
at the tip of a dermal papil and between two dermal papillae.17 
3.4.3.5 Statistical evaluation 
We used the Wilcoxon test for matched pairs for statistical analysis. 
3.4.4 RESULTS 
3.4.4.1 Clinical response 
All patients showed an improvement of the psoriatic plaques. After one week 
of treatment we observed a statistically significant reduction with respect to 
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desquamation (ρ < 0.02) and induration (ρ < o.o2). After three weeks of treat­
ment erythema showed a considerable decrease (p = 0.07; table 3.5). We did 
not observe any side effect in our patients. 
140 
Table 3.5 Severity scores, expressed as M + SEM 
Erythema 
Induration 
Desquamation 
Weeko 
2.0 ± 0 . 2 
1.810.2 
2.0 ± 0 . 2 
Week ι 
1.8 ±0.1 
1.1 ± 0.2 
0.9 ± 0 . 2 
Week 2 
1.7 ± 0 . 3 
0.4 ± 0.1 
0.8 ±0.1 
еекз 
1.3 ± o . i 
0.2 ±0.1 
0.3 ± 0.1 
3.4.4.2 Histological response 
In the normal healthy skin filaggrin staining is observed as a continuously 
intense staining pattern of the stratum corneum and stratum granulosum.18 
In the biopsies of the psoriatic lesions before treatment filaggrin expression 
was absent or showed a discontinuous pattern in the stratum corneum and 
Figure 3.14 The filaggrin expression in a psoriatic lesion before treatment. The stra­
tum corneum is hyperkeratotic. The filaggrin expression in the stratum corneum as 
well as the expression in the stratum granulosum is almost absent. 
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Figure 3.15 The filaggrin expression in a psoriatic lesion after three weeks treatment 
with Duoderm E. The filaggrin expression has almost normalized in the stratum cor-
neum and in the stratum granulosum. The stratum corneum is also less hyperkeratotic. 
granulosum. After a three weeks treatment with Duoderm E we noted a statis-
tically significant increase with respect to the filaggrin expression in the gra-
nular layer (p < 0.01), while the expression in the stratum corneum showed a 
borderline significant increase (p < 0.06). Figure 3.14 and 3.15 demonstrate 
the filaggrin expression before and after three weeks of treatment with Duo-
derm E. 
Involucrin expression in the normal human skin can be observed in the 
granular layer and the upper third of the stratum spinosum.18 Before treat-
ment the involucrin expression in the psoriatic lesions extended to the deeper 
cell layers of the stratum spinosum. After treatment with Duoderm E the 
interpapillar involucrin expression showed an almost statistically significant 
improvement (p < 0.07). The involucrin expression observed above the der-
mal papillae did show a minimal decrease (p = 0.5; table 3.6, page 142). 
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Table 3.6 Histological results of the filaggrin and ¡nvolucrin expression, expressed 
as M ± SEM. 
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Week о еекз Ρ-values 
Filaggrin 
stratum corneum 17.518.7 
stratum granulosum 30.6110.5 
Involucrin 
tip dermal papillae 59.7 ± 4.5 
interpapillar 36.0 + 5.2 
66.9 ±12.7 
77-5 ±9-0 
56.4 ±3.2 
27.1 ± 2 . 2 
0.06 
0.01 
0-5 
0.07 
3.4.5 DISCUSSION 
Our results confirm the antipsoriatic potential of HCD (Duoderm E) as 
monotherapy. With respect to scaling and induration we observed a statisti­
cally significant improvement after one week of treatment. Erythema showed 
a borderline significant decrease after three weeks of treatment. 
Previous studies already revealed that occlusion by prolonged application 
of tape or an occlusive dressing is effective in the treatment of plaque psoria­
sis.1"4·1 9 '2 0 The mechanisms of the effects of occlusion, however, have not 
been elucidated. 
Psoriatic epidermis is characterized by an absent or only partially formed 
stratum granulosum, a feature we also observed in the biopsies taken before 
treatment. After three weeks of treatment we observed a re-establishing of 
the granular layer in most of the biopsies. This observation is in agreement 
with the finding of Fry et al who also noted a reappearance of the granular 
layer in psoriatic epidermis after occlusive therapy with plastic film.3 Moreo­
ver, we also noted a statistically significant increase of the filaggrin expres­
sion in the granular layer after three weeks of treatment. Besides the capacity 
of aggregating keratin filaments, filaggrin also has a major function in main­
taining a normal hydrating state of the stratum corneum. After having 
fullfilled its role in aggregating keratin fibres and catalysing the formation of 
disulphide bonds between these fibres, filaggrin becomes enzymatically 
modified. An increasing acidity of the filaggrins loosens the keratin/filaggrin 
complex, allowing proteolytic attack on the filaggrins, which leads to the 
complete proteolytic destruction of these proteins. The free amino acids, 
resulting from the proteolysis of filaggrin, are retained within the corneocy-
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tes. Their role is maintaining a normal hydration state of the stratum cor-
neum despite increasing dryness of the environment.21 Hydration increases 
the permeability of the stratum corneum.2 2 The increase of the filaggrin 
expression, as was observed in the present investigation after three weeks of 
treatment with HCD, and hence resulting in a normalization of the hydration 
state of the stratum corneum with an increased permeability, could explain 143 
the pronounced antipsoriatic effect of corticosteroids applied under plastic 
occlusion as is reported by other investigators.2,2b~27 
In the biopsies taken before treatment the involucrin expression was 
extended to lower cell layers of the stratum spinosum. In normal human skin 
involucrin expression can be observed in the stratum granulosum and in the 
upper third of the stratum spinosum. After three weeks of treatment with 
Duoderm E the interpapillar involucrin expression showed an almost statisti­
cally significant improvement. Banks-Schlegel et al proposed that early onset 
of involucrin synthesis is due to accelerated terminal differentiation.2Э Kani-
takis et al suggested that involucrin expression is correlated with the degree 
of epidermal turnover.24 Most lesions in their study that showed an increased 
expression of involucrin are characterized by an accelerated epidermal turn­
over.
24
"
2
'' Taking these hypotheses into account, our observation that the 
involucrin expression in psoriatic epidermis is decreased after three weeks 
occlusion therapy with HCD is in agreement with the findings of Baxter et al 
and Fry et al who noted a decrease of the mitotic index in psoriatic plaques 
after occlusion therapy.2,3 
The present study demonstrates that abnormalities with respect to epider­
mal differentiation are reduced during HCD treatment. As immunological 
parameters remain unaffected during HCD treatment4 it is feasible that this 
mode of occlusion directly interferes with the epidermal growth and differen­
tiation. 
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Chapter 4 
RESPONSE OF THE C L I N I C A L L Y U N I N V O L V E D 147 
S K I N OF P S O R I A T I C P A T I E N T S TO TAPE 
S T R I P P I N G D U R I N G S Y S T E M I C T R E A T M E N T 
This chapter was based on the following publications 
AA.J.P. Gerritsen, H.F.C. Rulo, W.P. Arnold, P.C.M, van de Kerkhof 
Response of the clinically unmvolved skin of psoriatic patients to tape stripping during 
cyclosporin A treatment. Br J Dermatol 1994, [130] 181-188. 
M.J.P. Gerritsen, H.P.A. van Pelt, P.C.M. van de Kerkhof 
Response of the clinically uninvolved skin of psoriatic patients to tape stripping during 
Acitretin treatment. Submitted. 
4·ΐ Response of the clinically uninvolved skin of psoriatic patients 
to tape stripping during cyclosporin A treatment 
Presented at the ESDR (European Society for Dermatolcujical Research) in 1993 in 
Amsterdam 
4.1.1 SUMMARY 
It is well established that cyclosporin A, a widely used immunosuppressant in 
human organ transplantation, is an effective drug in the treatment of psoria­
sis. Although it has been postulated that the effect of cyclosporin A in psoria­
sis is mediated through anti-lymphocyte activity, there is also evidence sug­
gesting cyclosporin A exerts a direct cytostatic effect on epidermal keratino-
cytes. However the results so far are contradictory. 
Using immunohistochemical methods we investigated the influence of 
systemic cyclosporin A on proliferation and differentiation in the tape strip­
ped uninvolved skin of psoriatic patients. This model provides the opportuni­
ty to study epidermal regeneration in the absence of significant accumulation 
ofT lymphocytes. 
The following question was addressed: 
Does cyclosporin A (3-5 mg/kg/day) modulate epidermal proliferation and 
differentiation following standardized injury in uninvolved skin of psoriatic 
patients? 
Ten patients with severe psoriasis participated in this study. The dosages the 
patients used were sufficient to induce a marked and statistically significant 
improvement (PASI week o: 20.5 ±4.4; PASI week 16:4.3 ±0.6). Before cyclo­
sporin A treatment and during week 16 of treatment sellotape stripping was 
carried out on a 2 cm2 area of the uninvolved skin of psoriatic patients. After 
48 hours punch biopsies were taken. Immunohistochemical assessment of 
recruitment of cycling cells (Ki-67), filaggrin, involucrin, Τ lymphocytes and 
tenascin was carried out. We did not find any significant alteration before and 
during treatment in the tape stripped uninvolved skin of psoriatic patients. 
We concluded that epidermal hyperproliferation and abnormal keratiniza-
tion is not modulated directly by cyclosporin A at therapeutic doses in vivo. 
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Furthermore our study provides indirect evidence that the antipsonatic effect 
of cyclosporin A is mediated by the immune system. 
4.I.2 INTRODUCTION 
Psoriasis is a common chronic disease and is characterized by inflammatory 
changes, epidermal proliferation with an increased recruitment of cycling 
cells and incomplete differentiation. It is well established that cyclosporin A, 
a widely used immunosuppressant in human organ transplantation13, is an 
effective treatment of psoriasis.4 15 Although it has been postulated that the 
effect of cyclosporin A in psoriasis is mediated through anti-lymphocyte acti-
vity16 18, there is ample evidence suggesting cyclosporin A exerts a direct 
cytostatic effect on epidermal keratinocytes.14 31 However the results obtai-
ned so far are contradictory. Several in vitro studies have reported on a direct 
antiproliferative effect of cyclosporin A in cultures of proliferating epidermal 
keratinocytes.14 25 Urabe et al described a direct in vivo antiproliferative effect 
of cyclosporin A on human epidermal keratinocytes grafted onto nude 
mice 26 Gschwendt et al demonstrated that cyclosporin A inhibits induction 
of DNA synthesis, ornithine decarboxylase, alkaline phosphate activity, and 
8-hydroxyeicosatetraenoic acid (8-HETE) in mouse epidermis following topi-
cal application of the tumor promoting phorbol ester 12-0-tetrodecanoyl-
phorbol-13-acetate (1PA).2724 Elder et al supported the hypothesis that 
cyclosporin A can have potent and direct effects upon epidermal cells activa-
ted in vivo by topical exposure to the tumor promoting phorbol ester TPA.30 
Gupta et al demonstrated that cyclosporin A is a potent inhibitor of the TPA-
ìnduced inflammatory hyperplastic response, lhey also observed inhibition 
of the induction of ornithine decarboxylase (a marker for proliferation) and 
inhibition of membrane-associated TGase activity (transglutaminase: a mar-
ker for terminal differentiation) in the skin of hairless mice. They suggest 
that cyclosporin A may directly affect keratinocytes in vivo 31 
On the other hand Kato et al reported that they did not find an inhibition of 
epidermal growth in pig skin expiant cultures by cyclosporin A at therapeutic 
levels.32 lhey concluded that cyclosporin is therefore unlikely to act in 
psoriasis by a direct effect on epidermal cells. Gottlieb et al found that kerati-
nocyte growth activation was less sensitive to the inhibitory effects of cyclo-
sporin A in biopsies from the psoriatic plaques compared to the decrease in 
immune activation.33 
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Epidermal hyperproliferation and abnormal keratinization of psoriatic pla­
ques revert to normal during systemic treatment with cyclosporin A 
The aim of the present investigation was to find out whether systemic treat­
ment with cyclosporin A at therapeutic doses affects epidermal behaviour 
directly 
150 For a model to study epidermal hyperproliferation and proliferation asso­
ciated keratinization and inflammation we used the tape stripping model, 
which was first described in 1951 by Pinkus 3 4 After removing almost all of 
the horny layer by repeated application of sellotape Pinkus observed a regene­
rative respons of the human epidermis " Human epidermis after tape strip­
ping provides a useful model of synchronized growth, thus allowing us to 
study drug influences on cell kinetics accurately.36 
Before initiation of treatment with cyclosporin A and at the end of a four 
months treatment period tape stripping was carried out at the symptomless 
skin of psoriatic patients. 
Fisher et al determined the amount of cyclosporin in lesionai and nonle-
sional epidermis of psoriasis patients undergoing cyclosporin treatment. Ihe 
concentration of cyclosporin in psoriatic involved epidermis was not 
significantly different from the concentration found in the uninvolved epider-
4 1 3 MATERIAL A N D M E T H O D S 
4.1 3 ι Patients and biopsies 
Ten patients with severe chronic psoriasis participated in this study. Each 
patient was informed about the experiment and gave written consent Prior to 
the study they had received no local treatment for at least one week and no 
oral antipsonatic therapy for at least two weeks 1 he cyclosporin A treatment 
was started after the the first biopsy was taken The starting dose was 3 
mg/kg/day of cyclosponne A (CsA) and depending on the clinical results the 
dose was increased with 1 mg/kg/day to a maximum of 5 mg/kg/day At week 
0, 2,4, 8,12,16, and week 20 the patients were examined for psoriatic lesions 
and side-effects Before and during treatment clinical chemistry with respect 
to CsA levels and blood samples to monitor side-effects were assessed The 
clinical improvement was assessed using the PASI score.37 Before cyclo­
sporin A treatment and during the last week of cyclosporin A treatment (the 
first three days, two hours after the morning dose) sellotape stripping was 
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carried out on a 2 cm2 area of the uninvolved skin. By repeated applications 
of sellotape on the uninvolved skin of the psoriatic patients almost all of the 
stratum corneum was removed. After 48 hours, when epidermal proliferation 
was most pronounced3 8·3 9, punch biopsies (3 mm diameter) were taken from 
these lesions and embedded in Tissue Тек OCT compound (Miles Scientific, 
Naperville, IL, USA), snap frozen in liquid nitrogen and stored at -80 °C, 151 
until! use. 
Sections of 6 ц т were cut, air dried and fixed for ten minutes in aceton and 
stored again at -80 °C untili use. 
Normal skin biopsies from individuals with no history of psoriasis and 
uninjured uninvolved skin of psoriatic patients served as controls in the T u 
staining. 
4.1.3.2 Monoclonal antibodies 
To approximate the number of cycling cells we used the monoclonal antibody 
Ki-67, which recognizes a nuclear antigen present in cycling cells (1:10, Ki-
67, Dakopatts, Copenhagen, Denmark). Nuclear binding with Ki-67 indica­
tes that the cell is cycling and has passed the transition point from the Go 
phase.4 0·4 1 
To assess epidermal differentiation a monoclonal antibody against fil-
aggrin (1:500, antifilaggrin, ВТ!, BT576) and a monoclonal antibody against 
involucrin (Mon-150, 1:5ο)42 were used. Filaggrin is a basic protein normally 
present in the stratum corneum of the epidermis. Profilaggrin, the precursor 
of filaggrin, is synthezised at the level of the granular layer, where it is stored 
in the keratohyaline granules.43-44 During the comification of the keratinocy-
tes profilaggrin is processed into filaggrin after phosphorylation and proteo­
lysis by specific enzymes.45"48 Filaggrin has a major function in aggregating 
keratin filaments and maintaining a normal hydrating state of the stratum 
corneum.
4 4
·
5 0
 In normal adult skin and in the uninjured uninvolved skin of 
psoriatic patients positive staining for filaggrin is seen in the granular and 
horny layers of the epidermis.5 1·5 2 In the healthy adult and in the uninjured 
uninvolved skin of psoriatic patients involucrin is normally present in the 
upper third of the epidermis.51 This protein becomes incorporated in the 
"cornified envelope" under the cellular plasmamembrane.5 3·5 4 Involucrin is 
not related to kératines, immunological nor biochemical, and it is a distinct 
marker for the last phase of the maturation of the keratinocytes.53"55 
To visualize Τ lymphocytes we used a monoclonal mouse antibody to 
human T-cells (1:100, DAKO-T11, Dakopatts). 
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A monoclonal antibody against tenascin (T2H5) was obtained from A.A. Ver-
straeten, The Netherlands Cancer Institute, Amsterdam, the Netherlands.50 
Tenascin is an extracellular matrix glycoprotein. In vitro studies suggest that 
proliferating epithelium induces the production of tenascin by mesenchymal 
cells.57 In normal human skin tenascin expression is found diffusely in the 
152 subepidermal dermis and adjacent to the basement membranes of sweat 
glands.5 8 
4.1.3.3 Staining procedure 
For the staining with anti-filaggrin, anti-involucrin, Ki-67 and the anti-tenas-
cin an indirect immunoperoxidase technique was used. The slides were air 
dried and fixed for ten minutes in aceton-ether 60/40 vol.°/o (Кі-67/filaggrin) 
or in aceton (involucrin, tenascin). The slides were put in a phosphate-
buffered stock solution (PBS solution: 360 ml ЫагНРСы (7.9 g ШгНРСи, 
Merck in 500 ml demineralized water) plus 70 ml Nal-hPCU (13.8 g NafhPOi, 
Merck in 500 ml demineralized water) plus 140 ml demineralized water). The 
slides were incubated for an hour with a mixture of the monoclonal antibo­
dies Ki-67 and anti-filaggrin. For 30 minutes the slides were incubated with 
the other monoclonal antibodies. After two washings with phosphate buffer 
the slides were incubated with rabbit anti-mouse immunoglobulin conjuga­
ted with peroxidase (1:25, RAMPO). After two washings in the phosphate-
buffered stock solution and a pré-incubation with sodium acetate buffer (pH 
4.9), a solution of з-атіпо-9-ethylcarbazole (AEC) in sodium-acetate buffer 
containing 0.01% H2O2 was added for 10 minutes. Staining with Tu was per­
formed using an indirect peroxidase-anti-peroxidase technique (PAP). The 
slides were air-dried and fixed in aceton for 10 minutes. After washing during 
10 minutes in PBS solution, the slides were incubated for 20 minutes with 
50% NRS(normal rabbit serum) in PBS solution. Again after washing the 
slides in PBS solution (twice) the slides were incubated for an hour with the 
antibody Tu. After washing in PBS solution an incubation procedure follo­
wed with rabbit anti-mouse immunoglobulin (1:25, RAM-Ig, Dakopatts) for 
20 minutes, two washings in PBS solution and 20 minutes incubation with 
PAP-complexes (1:100, Peroxidase monoclonal mouse anti peroxidase com­
plexes, Dakopatts, P850). After two washings in PBS solution this cycle was 
repeated and after incubation in sodium acetate buffer (pH 4.9) the slides 
were stained with an AEC solution (see above). 
After two washings in demineralized water all slides were counterstained 
with Mayer's Haematoxylin (Sigma, St. Louis MO USA) and mounted in gly­
cerol gelatin. 
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4.1.3.4 Histological examination 
Epidermal proliferation was measured by counting the number of Ki-67 posi­
tive nuclei per mm length of the section. In exactly the same area the filaggrin 
expression was assessed by measuring the percentage of the length of the 
stratum corneum and the stratum granulosum which was stained.59 The 
involucrin expression was assessed by calculating the ratio positive cell lay- 153 
ers/total cell layers of the living epidermis. This was done on two spots: on 
the dermal papilla and between two dermal papillae.59 The Τ lymphocytes in 
the dermis were semiquantitatively enumerated by expressing the number of 
positive stained cells as a percentage of the total number of infiltrative cells60: 
0. no positive cells; 1, sporadic; 2,1-25%; 3, 26-50%; 4, 51-75%; 5, 76-99%; 6, 
100%. The Τ lymphocytes in the epidermis were assessed using a five-point 
scale: o, no staining; 1, sporadic staining; 2, minimal staining; 3. moderate 
staining; 4, pronounced staining.60 
The distribution of tenascin in the papillary dermis was assesed using the 
following grading system: 
1. continuous expression adjacent to the basal lamina (C) versus disconti­
nuous expression adjacent to the basal lamina (D); 
2. staining intensity (0-3).01 
4.1.3.5 Statistical evaluation 
For statistical analysis (Ki-67 staining, filaggrin, involucrin and T n expres­
sion) the Wilcoxon test for matched pairs was used. 
4.1.4 RESULTS 
4.1.4.1 Clinical response 
We observed a marked and statistically significant improvement of the 
psoriatic lesions in OUr patients (PASIweek 0: 20.5 ± 4.4; PASIweek 16 4.3 ± 0.6). 
Before as well as during cyclosporin A treatment we did not observe a posi­
tive Koebner response in the patients after tape stripping of the uninvolved 
skin. It is, however, possible that the cyclosporin A treatment, directly started 
after the first biopsy and which was continued during at least 20 weeks, inhi­
bited a possible Koebner response. 
4.1.4.2 Histological response 
Remarkably none of the used markers did show a significant alteration after 
16 weeks of systemic treatment with cyclosporin A compared to the expres-
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sion before treatment in tape stripped epidermis, 48 hours after tape strip­
ping (table 4.1). Expression of Ki-67 was seen in the nuclei in the basal layer, 
but also in a few cells in the stratum spinosum cytoplasmic staining was seen. 
The number of Ki-67 positive nuclei tended to increase during this period 
(week ο: M = 86.4; week 16: M = 89.4). 
Table 4.1 Scores (expressed as mean ± SEM) and statistical evaluation of the mar­
kers for proliferation (Ki-67), differentiation (filaggrin and involucrin) and inflamma­
tion (T11) before and during cyclosporin A treatment from the tape stripped uninvol-
ved skin of psoriatic patients 48 hours after tape stripping. 
Markers 
Ki-67 (positive nuclei) 
Filaggrin 
stratum corneum 
stratum granulosum 
Involucrin 
top 
interpapillar 
T11 positive cells 
dermis 
epidermis 
Scores at 
weeko 
86.41157 
15.0110.7 
94.0 ± 6 0 
58 7 ±3-3 
3 7 . 0 1 2 8 
2 2 1 0.19 
O.6 + O.16 
Scores at 
week 16 
89.4 + 21.3 
1 0 0 1 1 0 . 0 
80.0 113.4 
53.4 ±2.8 
35.3 + 26 
2 1 1 0.23 
0.8 + 0.31 
P-value 
(Wilcoxon test) 
0779 
0.655 
0.109 
0.203 
0415 
0.590 
0.109 
In normal human adult skin and in the uninjured uninvolved skin of psoriatic 
patients filaggrin expression is seen in the stratum granulosum and in the 
stratum corneum as a discontinuous granular or homogeneous intense stai­
ning.5 2 In the tape stripped uninvolved skin of the psoriatic patients we found 
a minimal staining pattern in the stratum corneum but a continuous staining 
pattern in the granular layer, comparable to normal skin. The filaggrin stai­
ning in the stratum corneum and the stratum granulosum did show a tenden­
cy to decrease after 16 weeks of treatment (week оыг corneum: M = 15%; week 
ióstr.corneum: M — 10%; Week Ostr granulosum: M = 9 4 % ; w e e k l6¡>tr granulosum: 
M = 8o°/o; figure 4.1.1 and 4.1.2). 
Involucrin expression in normal human skin is seen in the upper malphi-
gian layer (Mtop : 19%; Mmterpapillar : 9%) (unpublished data). In the tape strip-
ped uninvolved skin of psoriatic patients expression of involucrin appeared 
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Figure 4.1.1 Staining of the tape-stripped skin with the anti-filaggrin antibody and Ki-
67, before treatment with cyclosporin A. The stratum corneum does show very mini­
mal filaggrin-expression. The stratum granulosum shows an almost normal staining 
pattern of filaggrin. In the lower layers an increased Ki-67 expression in the nuclei can 
be seen compared to uninvolved skin. 
\ 
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Figure 4.1.2 Staining of the tape-stripped skin with the anti-filaggrin antibody and Ki-
67, after 16 weeks of treatment with cyclosporin A. The stratum corneum does show 
minimal filaggrin expression. The stratum granulosum does show an almost normal 
filaggrin expression. In the nuclei in the lower layers of the epidermis an increased Ki-
67 expression can be seen compared to uninvolved skin. 
in lower epidermal cell layers. The involucrin expression on the top of the der­
mal papilla and on the interpapillary spot showed a slight but insignificant 
decrease after the treatment period (week otop: M = 58.7%; week i6top: 
M = 53.4%; week Ointcrpapillar: M = 37.0%; week ібілгсграрііілг: M = 35.3%). 
The staining pattern of the Τ lymphocytes in the tape stripped uninvolved 
psoriatic skin was almost comparable with the expression we observed in the 
uninjured normal human and uninvolved skin of psoriatic patients (table 
4.2). The staining of the Τ lymphocytes in the dermis did show a very minimal 
decrease after 16 weeks (week ο: M - 2.2; week 16: M = 2.1). In the epidermis 
we observed an increase ofT lymphocytes (weeko: M = 0.6; week 16: M = 0.8). 
Table 4.2 T11 staining in the psoriatic lesion, normal human skin, uninvolved skin, 
tape stripped uninvolved skin (before cyclosporin A) and ¡n the tape stripped uninvol-
ved skin (week 16 of cyclosporin A treatment) expressed as mean ± SEM 
Biopsies 
Psoriatic lesion (n = 10)* 
Normal human skin (n = 3) 
Uninvolved skin (n = 3) 
Tape stripped uninvolved skin 
week 0 (n = 10) 
Tape stripped uninvolved skin 
week 16 (n = 10) 
Τ lymphocytes 
4.5 ±0.7 
1.7 ±0.3 
2 o ± 0.0 
2.2 ± 0 2 
2.1 ± 0 2 
dermis Τ lymphocytes 
2.4 ± 0.5 
0 0 + 0.0 
1 0 ± 0 0 
0 6 + 0.2 
0.8 + o j 
' Values of psoriatic lesion are taken from Gerritsen et al, ref 5g 
In week 0 tenascin was discontuously distributed in the upper dermis 
adjacent to the basal lamina in 50% of the slides, 50% showed a continuous 
and more pronounced expression (figure 2a). In week 16 30% of the slides 
changed in staining pattern from D to C, 40% changed from С to D (table 4.3, 
page 158 and figure 4.2.2). 
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Figure 4.2.7 Tenascin expression in the tape-stripped skin before treatment. Adjacent 
to the basal lamina a continuous tenascin expression can be seen with a staining 
intensity of 3. 
|| •» 
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Figure 4.2.2 Tenascin expression in the tape-stripped skin after 16 weeks of cyclo­
sporin A treatment. Adjacent to the basal lamina a discontinuous expression can be 
seen with a staining intensity of 1. 
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Table 4.3 Tenascin expression in the tape stripped uninvolved skin before cyclo­
sporin A treatment and in week 16 of cyclosporin A treatment. 
Su 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
bject no Weeko 
2/D 
3/D 
i/D 
2/D 
2/C 
2/C 
3/c 
3/C 
2/D 
3/c 
Week 16 
3/c 
3/c 
2/D 
2/D 
2/D 
1/D 
2/C 
3/D 
2/C 
1/D 
С continuous expression adjacent to the basal lamina, D discontinuous expression adjacent 
to the basal lamina. Staining intensity (0-3) 
4.I.5 DISCUSSION 
The modification of epidermal behaviour as induced by tape stripping has 
been reported previously.34":)7·39·b2"63 In the present investigation we confirm 
that recruitment of cycling cells is enhanced, the expression of filaggrin is 
decreased and the expression of involucrin is increased following tape strip­
ping. With respect to these epidermal aspects the tape stripping model is 
compatible with epidermal dysregulation in the psoriatic lesion. The induc­
tion of the extracellular matrix glycoprotein tenascin is an aspect which is 
observed both following tape stripping and in the psoriatic lesion.5Ь'ЬЗ In 
contrast, as we have shown in table II, the number of Τ lymphocytes is not 
induced by tape stripping, whereas the accumulation of Τ cells in the psoria­
tic lesion is markedly increased. 
Although cyclosporin A had a marked effect on the psoriatic lesions we did 
not observe any statistic significant modulation of proliferation, differentia­
tion and inflammation during cyclosporin A treatment in the tape stripped 
uninvolved skin of psoriatic patients. No consistent change was observed of 
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tenascin expression in the stripped areas during cyclosporin A treatment. 
Our findings are in agreement with Kanitakis et al and extend to their obser­
vation the in vivo situation in psoriatic patients. In their study on normal 
human skin xenografted onto nude mice Kanitakis et al did not find any alte­
ration in expression of Ki-67, filaggrin and involucrin during cyclosporin A 
treatment.64 15 g 
As tape stripping did not enhance Τ lymphocyte accumulation in the unin-
volved skin of psoriatic patients in our model, it is not surprising that we did 
not observe the well known anti-lymphocyte effect of cyclosporin A in this 
model. 
From the observations reported in this communication we may conclude 
that epidermal hyperproliferation and abnormal keratinization is not modu­
lated directly by cyclosporin A at therapeutic doses in vivo. The present study 
provides indirect evidence that the antipsoriatic effect of cyclosporin A is 
mediated by the immune system. 
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4·2 Response of the clinically uninvolved skin of psoriatic patients 
to tape stripping during Acitretin treatment 
4 2 I SUMMARY 
The aromatic retinoids etretinate and acitretin are widely used in the systemic 
treatment of severe psoriasis The purpose of the present investigation is to 
further elucidate the mode of action of acitretin on abnormal keratinization 
and epidermal hyperproliferation in an in vivo model Studies on the interfe­
rence of acitretin with epidermal hyperproliferation and abnormal keratini­
zation in psoriatic plaques are difficult to interpret as acitretin induced chan­
ges might be due to direct effects of acitretin or be the indirect effect of reti­
noid induced modulation of cutaneous inflammation 
Using an immunohistochemical assessment we examined the in vivo 
effect of systemic acitretin (> 35 mg dailv) on the expression of filaggrm, 
involucrin, and on the recruitment of cycling epidermal cells, in the tape-
stripped uninvolved skin of psoriatic patients, a model which provides the 
opportunity to study epidermal regeneration in the absence of significant 
accumulation of Г-lymphocytes During acitretin therapy and three weeks 
after withdrawal of acitretin we took biopsies from the uninvolved skin follo­
wing tape-stripping in six patients with psoriasis Six patients with psoriasis 
who never used acitretin served as controls We did not observe a koebner-
response in our patients after tape-stripping Filaggrin expression was de­
creased, while the recruitment of cvchng epidermal cells and the involucrin 
expression were increased in the biopsies taken from the patients who did 
not use acitretin During acitretin treatment however, the filaggrin expres­
sion was similar, whereas the K1-67 positive nuclei and the involucrin expres­
sion showed a statistically significant decrease compared to those parameters 
in the patients who did not use acitretin Our findings indicate that epidermal 
hyperproliferation and abnormal keratinization are modulated directly by 
acitretin 
4 2 2 INTRODUCTION 
For more than 50 vears it is well known that vitamin A and its synthetic analo­
gues are usefull in the treatment of various skin diseases 1 he aromatic reti-
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noids etretinate and acitretin are widely used in the systemic treatment of 
severe psoriasis Since etretinate is the ester of acitretin, both dérivâtes can be 
expected to have comparable effects on psoriatic epidermis г One of the 
events seen during oral retinoid therapy is the inhibition of neutrophil migra­
tion into the psoriatic epidermis 2 э Ellis noted an early reduction in the anti­
body-dependent cell-mediated cytotoxity of polymorphonuclear leukocytes 
in psoriatic patients during etretinate therapy 4 Lowe et al observed an inhibi­
tion of epidermal ornithine decarboxylase during etretinate treatment in 
psoriatic patients s Dierhch et al reported on a reduction of epidermal cell 
proliferation in both lesionai and nonlesional skin in psoriatic patients after 
etretinate therapy ù Reduction of the expression of keratin 16 in psoriatic epi-
dermis is also described during etretinate therapy 7 
It has been demonstrated that retinole acid is capable of inhibiting 
profilaggrin synthesis in cultured human epidermis keratinocytes 8 Asseh-
neau reported that retinole acid prevents the conversion of profilaggrin into 
filaggrin in cultured human epidermal keratinocytes ч The transcription of 
the type I (epidermal) transglutaminase mRNA is downregulated by reti­
noids 1 0 Transglutaminase ι is responsible for the catalyzation of the 
crosslmking of involucnn during the synthesis of the cormfied envelope X 1 
In psoriatic plaques, epidermal hvperproliferation and abnormal keratim-
zation are associated with a pronounced infiltration ofvanous cell types The­
refore, in vivo studies on the interference with epidermal hyperprohferation 
and abnormal differentiation in psoriatic plaques are difficult to interpret as 
those changes might be due to direct effects of acitretin or be the indirect 
effect of retinoid induced modulations of cutaneous inflammation 
The purpose of the present investigation is to further elucidate the mode of 
action of acitretin on abnormal keratinization and epidermal hyperprohfera­
tion in an in vivo model We used the tape stripping model, which was first 
described by Pinkus 1 2 1 4 After repeated application of sellotape, thereby 
removing almost all of the hornv layer, Pinkus observed a regenerative 
respons of the human epidermis 1 5 Tape stripping is a useful model of syn­
chronized growth, thus allowing us to study drug influences on cell kinetics 
accurately, without significant infiltrate formation l ù 
Using an immunohistochemical assessment we examined the in vivo 
effect of acitretin on the presence of filaggrin and involucnn, and on the 
recruitment of cycling epidermal cells in the unmvolved skin of psoriatic 
patients following tape stripping 
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4-2.3 METHODS 
4.2.3.1 Patients 
Six patients with severe psoriasis vulgaris participated in this study. Each 
patient was informed about the experiment and gave written consent. The 
166 mean dose was 34,2 mg ± 4,0 daily and all patients did have mucocutaneous 
side-effects. Five patients had been treated already for a considerable time 
period with acitretin. Because the psoriasis showed a dramatic improvement, 
they were about to stop the treatment. In these patients, tape stripping was 
performed before stopping and 3 weeks after discontinuation of acitretin. 
Dierlich et al demonstrated that it takes three weeks of continuing medica­
tion with oral retinoids to affect the accelerated epidermal cell proliferation in 
psoriatic patients.6 This is the reason we took the biopsies with a three weeks 
interval. Table 4.4 overviews patients details. 
Table 4.4 Details about the patients, expressed as mean ± SEM 
Patient group Number Age Duration of Duration of 
psoriasis Ac. treatment 
Acetnn 6 53 7 ± 9 9 19 ±14.3 y 2.8 ± 1 9 y 
Untreated 6 54.8±ioo 8 ±6.7 y -
Ac- acetretm 
Tape stripping was performed at day о and day 23 on the uninvolved skin 
(back) of the psoriatic patients. After 48 hours when epidermal proliferation 
is most pronounced1 6"1 8 punch biopsies (3 mm) were taken, embedded in 
Tissue Тек Compound, snap frozen in liquid nitrogen and stored at -80 °C 
until use. After the biopsies were taken on day 2, the acitretin therapy was dis-
continuated. 
Six patients with psoriasis vulgaris and who did not use acitretin during 
the experiment and had not used acitretin in the past, served as controls. They 
were also tape-stripped at the uninvolved skin (back). Again after 48 hours a 
punch biopsy (3 mm) was taken from the tape-stripped area. 
Sections of 6 μιη were cut, air dried and fixed for ten minutes in acetone-
ether 60/40 vol.% (Ki-67 staining) or in aceton (other stainings) and stored 
again at -80 °C until use. 
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4.2.3.2 Monoclonal antibodies 
To assess epidermal differentiation we used a monoclonal antibody against 
filaggrin (monoclonal mouse anti-filaggrin, BTI, BT576) and involucnn 
MON-150 (monoclonal antibody against involucrin)19. To characterize the 
epidermal proliferation we used a monoclonal antibody against a nuclear 
antigen present in the cycling cells (MIB 1 (cellprol. assoc. nucl. antigen (Ki-
67), Immunotech SA AMAC Ine).2 0 
4.2.3.3 Staining procedures 
For the staining with anti-filaggrin, anti-involucrin, and Ki-67 an indirect 
immunoperoxidase technique was used. The slides were put in a phosphate-
buffered stock solution (PBS solution: 360 ml ЫагНРСЬ (y.g g ЫагНРСЬ, 
Merck in 500 ml demineralized water) plus 70 ml ЫаШРОі (13.8 g NabhPCU, 
Merck, in 500 ml demineralized water) plus 70 ml demineralized water) plus 
70 ml demineralized water. For 60 minutes the slides were incubated with the 
monoclonal antibodies MIB-i (1:50 diluted in phosphaste-buffered stock 
solution + azide + 1 % BSA), anti-filaggrin and anti-involucrin (1:500 and 1:50 
diluted in phosphate-buffered stock solution). After washing with phospha-
tebuffer the slides were incubated with rabbit anti-mouse immunoglobulin 
conjugated with peroxidase (1:25, RAMPO). After washing in the phosphate-
buffered stock solution and pre-incubation with sodium-acetate buffer (pH 
4.9), a solution of з-атіпо-9-ethylcarbazole (AEC) in sodium-acetate buffer 
containing 0.01% H2O2 was added for 10 minutes. 
All slides were counterstained with Mayer's Haematoxylin (Sigma, St. 
Louis MO USA) and mounted in glycerol gelatin. 
4.2.3.4 Histological examination 
Epidermal proliferation was measured by counting the number of Ki-67 posi­
tive nuclei per mm length of the section. The filaggrin expression was asses­
sed by measuring the percentage of the length of the stratum corneum and 
stratum granulosum which was stained. The involucrin expression was 
assessed by calculating the ratio positive cell layers/total cell layers of the 
living epidermis. This was performed at two sites: at the tip of a dermal papil­
la and between two dermal papillae.21 
4.2.3.5 Statistical evaluation 
For statistical analysis the Wilcoxon test for matched pairs and the Mann-
Whitney test were used. 
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4.2.4 RESULTS 
None of the patients did show a koebner-response. 
4.2.4.1 Histological results 
168 In normal human skin filaggrin expression can be observed as a continuous 
staining pattern in the stratum granulosum and corneum.2 2"2 3 After tape-
stripping anti-filaggrin was absent or showed discontinuous expression in 
both layers. The filaggrin expression in the stripped areas during acitretin 
treatment did not show a statistically significant change, compared to fil­
aggrin in the stripped areas after discontinuation of acitretin (p
str.gran -
 0 Л І > 
Pstr.corn>o-I5; figure 4.3). 
100% 
9 0 % 
8 0 % 
70% 
6 0 % 
50% 
4 0 % 
30% 
20% 
10% 
0% 
90% 
80% 
70% 
60% 
50% 
4 0 % 
30% 
20% 
10% 
0% 
Controls Ac- Асн Controls Ac-
Figure 4.3 Filaggrin expression 48 hrs after tape stripping in the control group, with­
out acitretin (-Ac) and during acitretin (+Ac), expressed as mean ± SEM. 
Left: stratum corneum; right: stratum granulosum. 
Whereas involucrin expression in normal human skin is present in the stra­
tum granulosum and upper third of the stratum spinosum,2 4"2 4 after tape-
stripping the involucrin expression is also observed in the lower region of the 
epidermis.25 This induction of involucrin decreased statistically significant 
during acitretin treatment (p t i p < 0.02, ρ mterpap. ; 0.04; figure 4.4). 
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Figure4.4 Involucrín expression 48 hrs after tape stripping in the control group, 
without acitretin (-Ac) and during acitretin (+Ac), expressed as mean ± SEM. 
Left: ¡nterpapillar; right: suprapapillar. 
* statistically significant difference. 
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It is well established that after tape-stripping the recruitment of cycling epi-
dermal cells is enhanced.16"18 The degree of stripping induced recruitment 
was statistically significant reduced during acitretin treatment, compared to 
the stripping induced recruitment three weeks following discontinuation of 
acitretin (p < 0.04; figure 4.5, figure 4.6 and 4.7, pages 170 and 171). 
The histological results of biopsies taken from the control group did not 
show a statistically significant difference compared to the observation in the 
group of patients who stopped the acitretin for three weeks (figure 4.8, 
page 171). 
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Figure4.5 K¡-67 positive nuclei in the tape-stripped uninvolved skin three weeks 
after withdrawal of acitretin. 
Figure 4.6 Ki-67 positive nuclei in the tape-stripped uninvolved skin during acitretin. 
CHAPTER 4 
171 
* * 
Figure 4.7 Ю-67 positive nuclei in the tape-stripped uninvolved skin of the control 
group. 
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Figure4.8 Numberof Ki-67 positive 
nuclei 48 hrs after tape stripping in the 
control group, without acitretin (-Ac) 
and during acitretin(+Ac), expressed as 
mean ±SEM. 
* statistically significant difference. 
Controls Ac - Ac + 
CHAPTER 4 
4-2.5 DISCUSSION 
The present investigation confirms earlier observations of our group that epi-
dermal dysregulation after tape-stripping and epidermal characteristics of 
the psoriatic plaque share important similarities with respect to recruitment 
172 of cycling epidermal cells, filaggrin and involucrin expression (table 4.5)." 
Following tape stripping, filaggrin expression had decreased markedly. 
The observation that filaggrin expression remains decreased during acitretin 
treatment is in line with the previous in vitro findings that retinoic acid is 
capable of inhibiting profilaggrin synthesis and preventing the conversion of 
profilaggrin into filaggrin in cultured human epidermal keratinocytes.8"4 Our 
results are also in agreement with the observation of Eichner et al, who 
demonstrated a reduction of filaggrin expression in epidermal cells of rhino 
mice after topical application with retinoic acid.20 On the other hand, Rosen-
thal et al noted an increased number of cell layers with involucrin and fil-
aggrin expression after topical retinoic acid treatment in healthy volun-
teers.27 However, the irritation of the skin following topical retinoid might be 
responsible for this effect. It is known that retinoids exert a different effect in 
normal human epidermis compared to psoriatic epidermis. Gillenberg 
observed an increase of epidermal proliferating cells in normal human epi-
dermis during therapeutic doses of oral aromatic retinoids.28 The reports of 
Lowe et al and Dierlich et al definitely demonstrate the antiproliferative effect 
of retinoids in psoriatic skin.5·6 In the present investigation using an in vivo 
model for epidermal proliferation, an inhibition of the recruitment of cycling 
cells could be substantiated. 
The observation that the stripping induced recruitment of cycling epider-
mal cells and involucrin expression arc both reduced during systemic acitre-
tin treatment (> 35 mg daily) lends support for the hypothesis that involucrin 
synthesis is related to the proliferation rate of epidermal keratinocytes. It has 
been reported that the number of T-cells is not induced by tape-stripping in 
patients who do not show a positive koebner-response.25 Indeed, only spora-
dic distributed infiltrate cells were observed following tape-stripping in our 
patients. Therefore the modulation of epidermal changes following tape-
stripping by acitretin are unlikely to be secondary to immune modulatory 
effects of the drug. 
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Table 4.5 Comparison of the expression of filaggrin, involucrin and Ki-67 positive nuclei in normal 
skin, psoriatic uninvolved skin (PUI) after tape-stripping (PS), psoriatic uninvolved skin (PUI) after 
tape-stripping (PS) before cyclosporin A (-CsA), and during CsA (+CsA)25, psoriatic uninvolved skin 
(PUI) after tape-stripping (PS) without acitretin (-Ac) and during acitretin (+Ac),and in the psoriatic 
lesion (PL)2i. Data expressed as mean ± SEM. 
Patient Normal PUI PUI (-CsA) PUI(+CsA) PUI(-Ac) PUI(+Ac) PL 
group skin ^8hrPS 48hl-PS 48hrPS 48hrPS 48hrPS 
Filaggrin (%) 
str. cor. 100 ± 0 58 + 4.9 15.0110.7 10.0 ±10.0 14.018.7 34 ±21 26 ±11.3 
str gran. 100 ± 0 80 ±10.5 94.0 ±6.0 80.0 ±13 4 64.0119.4 86 ±11 5 55 ±11.6 
Involucrin (%) 
tip 25.4 + 1.2 71.2 + 2.8 58.7 + 3.3 53.4 + 2.8 69.813.4 52.5 ±4.2 63 8 ± 3 5 
mterpap. 20 9 ± 2.7 54.8 ± 2.6 37.0 + 2.8 35312.6 51 713.5 41.0 + 3.3 31012.1 
Κι-67/mm 10 5 ± 2 5 1063 ±15.0 86 4 ±15 7 89.4121.3 996 + 148 76.2 ±15.2 1190 + 22.1 
pos. nuclei 
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Chapter 5 
G E N E R A L D I S C U S S I O N 177 
5-1 Introduction 
In the introduction of this thesis three major aims have been identified: 
i. To understand the dynamics of epidermal proliferation and abnormal 
keratinization during the transition of non-lesional into lesionai skin. 
2. To explore the efficacy of new principles for the treatment of psoriasis and 
to assess the dynamics of epidermal proliferation and differentiation in 
lesionai skin during these treatments. 
3. To study the interference of systemic antipsoriatic treatments with epider-
mal proliferation and differentiation in vivo. 
In this chapter the conclusions which have been reached in the various stu-
dies of this thesis will be discussed. 
Firstly these conclusions will be integrated with respect to the three gene-
ral aims in a section "general conclusions". 
In a section on "the dynamics of initiation, perpetuation and spontaneous 
involution of the psoriatic lesion" and in a section on "the epidermis as a tar-
get for antipsoriatic treatments" we will highlight to what extent the observa-
tions of this thesis contribute to a better understanding of pathogenesis and 
treatment of psoriasis. 
5.2 General conclusions 
5.2.I AIM I (CHAPTER 2) 
It was shown that the recruitment of cycling epidermal cells in the distant cli-
nically uninvolved skin of psoriatic patients was comparable to the recruit-
ment of cycling cells in the skin of normal volunteers; no significant differen-
ce between normal skin and clinically uninvolved skin of psoriatics was 
shown in the number of Ki-67 positive nuclei. Comparing both conditions no 
significant difference was shown as to the number of filaggrin and involucrin 
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positive cells and the density of the "hyperprohferation associated" extracel­
lular matrix molecule tenascin. 
In contrast, psoriatic lesionai skin is characterized by an increased recruit­
ment of cycling epidermal cells (K1-67 positive nuclei) and an increased num­
ber of cell layers containing involucrin and transglutaminase, whereas the 
number of filaggnn positive cell layers proved to be decreased The density of 179 
the extracellular matrix molecule tenascin is increased beneath the lesionai 
epidermis It is of interest that exactly the same distribution pattern of these 
markers was seen following one single course of tape stripping. However, 
repeated courses of tape stripping on consecutive days resulted in a marked 
increase of the number of filaggnn positive cell layers. With respect to the 
markers studied in this thesis, the psoriatic phenotype is well expressed in 
the tape stripping model (single course of stripping). This distribution pat­
tern is compatible with the hypothesis that the psoriatic epidermis is in a 
phase of regeneration motto perpetuo 
In the margin zone between symptomless and lesionai skin the abnormali­
ties of the stroma (tenascin expression and endothelial abnormalities) are the 
most peripheral changes, the appearance of the inflammatory infiltrate 
together with the expression of keratin 16 has an intermediate position1 - and 
an abrupt simultaneous epidermal change (increases of recruitment of 
cycling epidermal cells and of the number of involucrin positive cells, combi­
ned with a decrease of the number of filaggnn positive cells, chapter 2). 
Again a similarity with the tape stripping model exists. Ί he dynamics of these 
features in the margin zone of the psoriatic plaque appeared to approximate 
the phasing of events following tape stripping Within minutes to hours fol­
lowing tape stripping stromal changes and infiltrate formation occur, keratin 
16 expression appears after one day and increased epidermal proliferation 
and shift of the expression of filaggnn and involucrin positive cell layers are 
manifest 48 h after tape stripping 
5 2.2 AIM 2 ( C H A P T E R 3) 
Occlusion of the psoriatic lesion with plastic or a hydrocolloid dressing has 
been shown to induce a substantial improvement of the psoriatic plaque. In 
chapter 3 it was reconfirmed that application of the hydrocolloid Duoderm E 
results in a substantial improvement after 3 weeks treatment At the cell bio­
logical level an increase of the number of filaggnn positive cells and a decrea-
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se of the number of involucnn positive cells was observed. However, within 
the experimental treatment period of 3 weeks, the recruitment of cycling epi-
dermal cells and the number of infiltrate cells had not reduced significantly 3 
Treatment with the vitamin D3 dérivâtes calcitnol (ια,25 dihydroxyvitamin 
D3) and tacalcitol (101,24 dihydroxyvitamin D3) resulted in a substantial clini-
180 cal improvement following topical application during 4-8 weeks Treatment 
with these compounds did reduce the number of cycling epidermal cells and 
the number of involucnn and transglutaminase positive cells, whereas the 
number of filaggnn positive cells was increased Not only the number of neu­
trophils but also the number of monocytes and Τ lymphocytes decreased 
during treatment 
It can be concluded that occlusion with hydrocolloid dressings and that 
treatment with calcitnol and tacalcitol are promissing new additions to the 
existing scala of antipsoriatic treatments Both treatments have a striking 
difference as to the cell biological response, the hydrocolloid exerting its 
most impressive effect at the suprabasal compartment and vitamin D Ì analo-
gues having its most pronounced effect at epidermal proliferation and 
inflammation. 
5 2 3 AIM 3 (CHAPTER 4) 
The tape stripping model was applied as an in vivo model to study the modu-
lation of the induction of epidermal proliferation and psoriasiform keratini-
zation in patients treated with systemic antipsoriatic drugs. As the response 
to tape stripping (single course) is similar to the epidermal changes in the 
psoriatic lesion this model is adequate to study the induction of the epider-
mal changes. 
Cyclosporin A did not modulate the response to tape stripping in the unin-
volved skin of psoriatics as to the proliferation and differentiation markers, 
although the psoriatic lesions in these patients faded away Acitretin, howe-
ver, resulted in a reduction of the response to tape stripping· reduced respon-
se as to the induction of involucnn and of the recruitment of cycling epider-
mis cells. 
Systemic treatments may interfere in a selective way with the psoriatic pro-
cess From the observations in this thesis it is feasible that cyclosporin A does 
not interfere with epidermal proliferation and differentiation directly, where-
as acitretin does. 
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5-3 On the dynamics of initiation, perpetuation and involution 
of the psoriatic lesion 
5.3.I THE DISTANT CLINICALLY UNINVOLVED SKIN 
In chapter 2 it was shown that the recruitment process of cycling epidermal 
cells and the number of cell layers containing filaggrin, involucrin and trans-
glutaminase in the distant clinically uninvolved skin of psoriatic patients 
were not significantly different from the skin of normal volunteers. 
These data are at variance with observations using flow cytometry and 
thymidine labelling.4·5 However, it is of importance that these observations 
(table 5.1) were on relatively large groups, and the differences between psoria-
tic and normal skin were minimal, data showing a considerable overlap. 
Table 5.7 Growth and differentiation characteristics in normal skin and clinically 
uninvolved skin of psoriatics (mean ± standard deviation). 
IÖI 
Marker 
%S 
%CzM 
Thymidine units 
Ki-67 
Involucrin 
interpapiliar 
tip papilla 
Filaggrin 
str corn. 
str. gran 
Transglutaminase 
interpapiliar 
tip papilla 
Normal skin 
2.7 ±0.8 
η = 60 
1.3 + 06 
n = 6o 
29.9110.2 
η = 20 
io 5 + 7.0 
n = 8 
20.9% ±7.6 
25.4% ± 3.4 
n = 8 
100% ± 0 
100% ± 0 
n = 8 
18.5% ±4.2 
22.5% ±6.8 
η = 2 
Clinically uninvolved 
skin psoriatic patients 
3.8 ±1.4 
π =47 
1.8 ±0.8 
η = 47 
44 4 ±22.8 
η = i g 
9.2 ± 8.2 
η = 10 
17.4% ±5-0 
26.1% ±4.1 
η = ю 
100% ± о 
100% ± о 
η = 10 
22.1% ±3-6 
26.2% ±4-2 
η = 9 
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Another explanation for the observations by the other groups of a slight 
increase in the distant clinically uninvolved skin might be the fact that in 
patients with unstable psoriasis, prepinpoint lesions are present scattered 
over the body under the level that they can be identified by the naked eye. 
These prepinpoint lesions are biopsied and will yield to a pseudo-increase in 
182 the "clinically uninvolved skin". Another possibility for the discrepancy in 
literature might be the definition of clinically uninvolved skin. In the Nijme­
gen centre we define 'distant clinically uninvolved skin' and 'paralesional 
skin'. In many publications such has not been specified. However, we know 
from personal communications that various authors claiming increased va­
lues, did biopsy the paralesional areas. Based on the studies presented in 
chapter 2 it can be concluded that the distant clinically uninvolved skin of 
psoriatic patients is essentially normal, with respect to epidermal growth and 
differentiation. 
At the molecular level, however a definite increase of the activity of phos-
pliolipase A2 has been reported by three groups.6 '8 In our centre and at the 
University of Keele (U.K.), the assessments were performed in distant clini­
cally uninvolved skin. Another group claimed that the release of arachidonic 
acid - phospholipase A2, which is the rate limiting enzyme for this metaboli­
te - is increased in clinically uninvolved skin.9"11 However, the authors did 
not specify whether the studies were carried out in the distant uninvolved or 
paralesional skin. 
The discrepancy between the presence of proinflammatory events and 
absence of inflammation and proliferation in the clinically uninvolved skin 
suggests that anti-inflammatory and antiproliferative events occur in the nor­
mal looking skin of psoriatics. Indeed, a down modulation of protein kinase 
С in the epidermis and a reduced expression of PAL-Ε, ICAM 1 and PN-E2 
positive endothelial cells characterize the clinically uninvolved skin of psoria­
t ics . 1 2 1 3 
It can be concluded from the available data that epidermal growth and 
differentiation are essentially normal in the distant clinically uninvolved skin, 
however, proliferation enhancing stimuli (increased activity of phospholipa­
se A2, increased production of arachidonic acid) are balanced by antiprolif­
erative and anti-inflammatory processes (down modulation of protein kinase 
С and decreased availability of activated endothelial cells). It is attractive to 
hypothesise that the capacity of the antiproliferative and anti-inflammatory 
systems is already reduced in the clinically uninvolved skin of psoriatic 
patients which might explain for the occurance of psoriatic lesions in 25% of 
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the patients following injury and for the increased and prolonged epidermal 
proliferation following injuring the uninvolved skin 14 Psoriasis can be regar-
ded as a defect in the off-switch of skin regeneration. 
5.3.2 THE I N T E R P H A S E BETWEEN U N I N V O I V E D 
AND LLSIONAL SKIN 
As presented in chapter 2, the interphase between the clinically uninvolved 
skin and involved skin is a three phase transition. The first phase involves the 
stroma. This phase is characterized by an increased expression of the extra-
cellular matrix molecule tenascin and an increased expression of alkaline 
phosphatase activity, which is a marker for endothelial cell activiation.15 The 
second phase is the appearance of the inflammatory infiltrate together with 
the expression of keratin 16 and the third phase the simultaneous appearance 
of increased recruitment of cycling epidermal cells together with a decreased 
expression of filaggnn and an increased expression of involucrin. 
Phase 1 — The changes of the stroma could well be the result of mediators, 
diffusing from the psoriatic lesion into the clinically uninvolved skin. Possi-
ble candidates include: TGFß, a mediator which is capable of inducing tenas-
cin;16 and arachidomc acid dérivâtes which have a potent effect on endothe-
lial cells. A remarkable feature, however, is the relatively large interval 
between phase I and phase II (the infiltrate formation and keratin 16 expres-
sion). A reduced responsiveness of the clinically uninvolved psoriatic skin to 
epicutaneous application of the eicosanoid leukotnene B4 has been demon-
strated in previous experiments.17 18 Such a defense system against pro-
inflammatory events could be interpreted as an attempt of the skin to keep 
psoriatic plaques restricted to sharply demarkated plaques. It is attractive to 
speculate that this process prevents overt inflammatory events in the sympt-
omless skin and during phase I of the interphase. 
Phase 2 — Phase 2 represents the expression of keratin 16 in the suprabasal 
compartment and the appearance of the inflammatory infiltrate. In a previous 
experiment an association between keratin 16 expression and cutaneous 
inflammation was shown.2 Following tape stripping of the normal human 
skin, keratin 16 expression appeared already after 24 hours, well before overt 
epidermal hyperprohferation, whilst the inflammatory infiltrate was present 
24 hr post stripping. Several other observations further strenghten the SUP-
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position that the expression of keratin 16 is not the result of epidermal prolif­
eration but rather might be independent from proliferation of the epidermis 
In lupus erythematodes, a skin disorder characterized by atrophy of the skin, 
the expression of keratin 16 is prominent above the inflamed skin ι ς In 
monogenic disorders of keratimzation, the expression of keratin 16 appeared 
to be associated with the inflammatory conditions, but to our surprise did not 
always occur in hyperproliferative diseases 2 0 Therefore, not only in psoriasis 
but in manv skin conditions keratin 16 expression should be regarded as part 
of an inflammatory response Controversy has existed and so far remains 
with respect to the question which inflammatory cell can be identified as "le 
premier" According to some authors the PMN is the first invader, according 
to others the mast cell, the monocyte, or the Τ lvmphocyte 2 2 1 2 3 So far, the 
communis opinio is that there is no single cell type involved as the "on-
switcher" of psoriatic inflammation 
Phase 3 — Phase 3 comprises a process of recruitment of cycling epidermal 
cells and a change in the cell lavers containing involucnn and filaggrin Al­
though the molecular regulation of these changes is by no means totally 
understood, the observation of a simultaneous transition of these processes 
is most likely caused by a common regulating process It has been shown, in 
vitro, that activation of the bGF receptor and an enhanced transcription of 
TGFa can be induced byTNFa, IL8 and γ-interferone 2 4 Activation of the EGF 
receptor and increased transcription of TGFa is associated with activation of 
phosphohpase C, yielding into increased intracellular Ca2+ concentration, 
and activation of protein kinase С An increased intracellular concentration 
of calcium leads to activation of transglutaminase Phosphorylation of the 
sodium hydrogen antiport by protein kinases will elicit the recruitment pro­
cess of cycling epidermal cells It has been shown that activation of protein 
kinase С will induce keratimzation 2 5 Therefore the induction of epidermal 
growth and altered keratimzation following the infiltrate formation can be 
controlled by joint molecular pathways However, the identification of the 
exact mechanisms involved, requires further investigations 
5 3 3 P E R P E T U A T I O N A N D I N V O L U T I O N 
OF T H E PSORIATIC LESION 
The psoriatic lesion is not homogeneously involved It consists of "hot spots" 
and "cold spots" 2b The "cold spots" represent an aspecific dermatitis The 
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hot spots are the active sites with infiltration of PMN and parakeratosis sur-
rounding the micro-abscesses of Munro. In the studies described in this the-
sis a patchy distribution pattern of these classical histological features was 
shown. However, the distribution of Ki-67 positive nuclei, involucrin and 
filaggrin showed a more uniform distribution pattern. It is attractive to spe-
culate that the perpetuation of the psoriatic lesion is caused by a focally arran-
ged propulsive factor. The distribution pattern of pits in the nail plats is also 
compatible with focal distribution of propulsive psoriatic actors. 
Transpassing from the rim of the psoriatic lesion to the central areas, in 
general, the preponderance of propulsive actors changes to an equilibrium 
between propulsive and antipsoriatic factors: 
1. Accumulation of polymorphonuclear leukocytes is more abundant in the 
peripheral areas and less in the central zones.27"28 
2. Skin associated antileukoprotease (SKALP), a protein which neutralysis 
elastase and is supposed to represent an anti-inflammatory mechanism, 
increases further in the central areas of the lesion. Interestingly SKALP has 
a domain which is substrate for transglutaminase and SKALP is predomi-
nantly present in the suprabasal compartment.29"31 
3. The presence of transglutaminase becomes more marked in the central 
areas of the lesion, in line with the distribution pattern of SKALP (chapter 
2). 
4. Ki-67 positive nuclei, involucrin- and filaggrin-positive cells are represen-
ted to the same extent in the peripheral and central zones of the lesion 
(chapter 2). 
Comparing the margin of the spreading psoriatic plaque with the central area 
of the lesion the question arises to what extent prepsoriasis or acute psoriasis 
is the same as chronic plaque psoriasis. From the studies presented in this 
thesis it can be concluded that assessment of epidermal proliferation with 
antibodies against proliferation-associated antigens and expression of in-
volucrin, filaggrin and transglutaminase will not inform us on the acute sta-
ges of the psoriatic lesion. It is possible that therapeutic manipulation of 
these epidermal aspects will not interfere with the initial stages of the psoria-
tic process. 
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5-4 The epidermis as target for antipsoriatic treatments 
5.4.1 T H E RFSULT OF REMOVAL OF T H E E P I D E R M I S 
186 It has been reported by Eyre and Krueger that following removal of an epider-
mal slice of the uninvolved skin with a keratotome, in 75% of the psoriatic 
patients this side will not adopt a psoriatic lesionai appearance, but instead 
heal as normal looking skin.14 Interestingly, patients showing a koebner 
phenomenon of the symptomless skin, showed induction of a lesion at the 
biopsy site. Various groups have reported that removal of the epidermis and 
stratum papillare of the dermis of longstanding psoriatic plaques using der-
mabrasion resulted in a prolonged resolution of the psoriatic lesion 32 " 
From these observations it is evident that the perpetuation of the psoriatic 
lesion is governed by processes located in the epidermis and dermoepidermal 
interphase. 
5.4.2 ARTIFICIAL RESTORATION OF T H E SKIN BARRIER 
W I T H H Y D R O C O L I O I D DRESSINGS 
In chapter 3 it was shown that restoration of the skin barrier with a hydrocol-
loid dressing during three weeks resulted in a considerable improvement of 
the psoriatic lesion. A pronounced reduction of the number of involucrin 
positive cells and an expansion of the number of filaggrin positive cells occu-
red during treatment. Interestingly, following 2 weeks treatment with a 
hydrocolloid dressing the composition of the inflammatory infiltrate (dermal 
Langerhans cells and 1 lymphocytes) and some immune markers such as 
HLA DR were not modulated.34 Restoration of the skin barrier in psoriatics 
leads to a recovery of the keratinizaton process resulting in a reduction of 
psoriatic hyperproliferation.3 
5.4.3 T H E IN VITRO BEHAVIOUR OF T H E E P I D E R M I S 
D U R I N G EXPOSURE TO ANTIPSORIATIC DRUGS 
All antipsoriatic treatments consistently have been shown to inhibit growth 
of keratinocytes in culture. Information on the interference with the process 
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of keratinization is only, fragmentary Retinole acid inhibits keratinization 
markers such as transglutaminase and cornified envelope formation, where­
as vitamin D3 enhances these markers."" 4 0 Treatments seem to interact 
differently with the process of differentiation. In addition to these effects, 
antipsoriatic treatments interfere in various ways with inflammation. 
In order to find out the clinical relevance of these effects, in vivo studies are 
needed. The bioavailability at the target structures might differ considerably 
in vivo. 
5.4.4 T H E E P I D E R M I S AS TARGET FOR ANTI PSORIATIC 
T R E A T M E N T S 
5.4.4.1 Pharmacological modulations of the psoriatic plaque 
Various aspects of epidermal growth and differentiation have been studied on 
biopsies before and during antipsoriatic treatments. Table 5.2 overviews 
these interferences. 
Table 5.2 In vivo effects of antipsoriatic treatments studied at the Nijmegen Institute 
Treatment 
Calcipotriol 
Calcitriol 
Tacalcitol 
HCD 
Cortico­
steroids 
Dithranol 
Epidermal 
growth 
444 
444 
444 
4 
444 
u 
Keratin 16 
41 
11 
14 
-
44 
44 
Involucrm 
? 
4 
4 
4 
? 
? 
Filagqnn 
? 
Τ 
τ 
TT 
? 
? 
Tramaluta-
taminase 
? 
4 
4 
? 
? 
? 
Reference 
41 
Chapter 3 
Chapter 3 
Chapter 3 
+3 
42 
43 
It can be seen that a rather consistent pattern occurs with a reduction of epi­
dermal proliferation and a tendency of normalization of the keratinization 
process. However the intensity of the various treatments differs considerably 
with respect to these effects. 
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5·4·4·2 Pharmacological modulation of the regeneration response to tape stripping 
Table 5.3 overviews the interferences of antipsoriatic drugs with the induc-
tion of epidermal proliferation using the tape stripping model. 
Table 5.3 Epidermal proliferation following tape stripping in patients treated with 
antipsoriatic drugs 
Vitamin D3 
Topical corticosteroids 
Cyclosporin 
Acitretin 
Epidermal 
I 
i 
= 
I 
1 proliferation Reference 
44 
45 
Chapter4 
Chapter4 
It has been demonstrated that the regeneration following one single course 
of tape stripping approaches the epidermal abnormalities in psoriasis (chap-
ter^. 
Most treatments proved to inhibit the induction of epidermal prolifera-
tion. Cyclosporin did, however, not inhibit epidermal proliferation directly, 
although this drug proved to inhibit epidermal proliferation in vitro. 
5.4.5 DISCREPANCIES BETWEEN IN VIVO A N D IN VITRO 
Various discrepancies exist comparing the data obtained in the in vitro and in 
the in vivo experiments. 
In the in vitro situation active vitamin D3 enhances normal differentiation 
such as transglutaminase activity and the cornified envelope formation.,5"37 
In contrast, in the in vivo situation during treatment of psoriatic plaques with 
vitamin D3 analogues, the number of transglutaminase positive cells de-
creased substantially (chapter 3). Such was interpreted in chapter 3 as a re-
duction of the suprabasal compartment during antipsoriatic treatment. 
Dithranol has been shown in vitro to inhibit the proliferation of keratino-
cytes.47 In vivo, however, dithranol enhanced the recruitment of cycling epi-
dermal cells in normal skin.48 Application of dithranol on psoriatic lesions 
proved to reduce the number of cycling cells after two weeks of treatment.48 
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This discrepancy may be explained by the irritant effect of dithranol. Indeed a 
considerable inflammatory infiltrate and expression of keratin 16 follows 
dithranol application onto the normal skin.48 The proliferation of the epider-
mis following dithranol application can be explained as part of the inflamma-
tory response 
Cyclosporin has been shown to inhibit proliferation of keratinocytes in 
culture.49 S5 Epidermal cells do contain cyclophilin, which is the intracellular 
receptor protein for cyclosporin. During treatment of psoriatics with cyclo-
sporin epidermal proliferation is not affected directly by cyclosporin (chapter 
4). The discrepancy with respect to cyclosporin between in vivo and in vitro 
could be explained by a different concentration of the drug in both situations. 
Concentrations of cyclosporin in vivo are well below the concentration which 
inhibit keratinocyte growth in vitro. 
It can be concluded that extrapolation of data from in vitro experiments to the 
in vivo situation are hazardous due to: 
1 recompartimentahzation; 
2. pluriform effects on various compartments of the skin, 
3. in vivo bioavailability at target structure. 
5.4.6 NFW ANTIPSORIATIC PRINCIPLES 
From our point of view on the pathogenesis of psoriasis it follows that anti-
psonatic drug targetting deserves further specification. Patients in a stage of 
remission can be treated by maintenance treatments. It is feasible that these 
treatments should be aimed at increasing the anti-inflammatory and antipro-
liferative capacity of uninvolved skin of psoriatics, which has been shown to 
be decreased in the uninvolved skin of psoriatics. 
In patients with active psoriasis with punctate papules, inhibition of the 
inflammatory events are essential. In chronic plaque psoriasis therapies 
intervening with epidermal growth and differentiation seem to be appropria-
te. As most of the existing antipsonatic therapies are interfering with 
different aspects of the psoriatic lesion, in the near future such diversification 
may not be possible (table 5.4 page 190). 
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Table 5.4 Estimated value of antipsoriatic treatments with respect to phases of the 
psoriatic process. A tentative summary. 
Acute psoriasis Chronic psoriasis 
++ + 
++ ++ 
++ ++ 
++ ++ 
++ ++ 
++ ++ 
- ++ 
+ + 
However, a mission statement for further drug development might be to find 
drugs for the specific aspects of psoriatic phases. In this respect it is of 
importance to broaden the assessment of efficacy in chronique plaques pso­
riasis to assessment of the efficacy in acute exacerbating psoriasis. 
From the observation in chapter 3 and 4 it is evident that the treatments for 
psoriasis do not have one single mode of action. Combined treatments might 
be a powerfull approach. 
The rather different effects of cyclosporin on one hand and acitretin and 
vitamin D3 on the other had suggest that a combination therapy of cyclo­
sporin with etretinate or cyclosporin with vitamin D3 analogues might be 
very effective. Indeed the combinations of acitretin with cyclosporin and 
cyclosporin with calcipotriol have been shown to be very effective.56"57 
Drug finding can be based on analogies of compounds. In this respect it is 
of interest that vitamin D3 analogues (chapter 3), corticosteroids, and acitre­
tin (chapter 4) are potent antipsoriatic drugs and are ligands of the steroid 
receptor superfamily. Other members of this family, not yet tested for anti­
psoriatic efficacy are estrogens, and thyroid hormone. It is of importance to 
evaluate the antipsoriatic efficacy of these compounds in the future. 
Drug finding can be based on insights in the pathogenesis of psoriasis. In 
this respect cellular signalling and in particular the regulation of transfor­
ming growth factor α and the regulation of protein kinase С activity are pro-
missing targets for the future. 
Further studies on the pathogenesis of psoriasis and a further insight in 
the mode of action of antipsoriatic therapies are important investments for 
the patient of tomorrow. 
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Summary 
In Chapter ι the most relevant aspects of psoriasis have been presented: epi­
demiology, genetics, aetiology, clinical aspects, histological aspects, patho­
genesis and therapy. Aspects of keratinization and proliferation (filaggrin, 195 
involucrin, transglutaminase and recruitment of cycling epidermal cells) and 
in uiuo models such as the margin zone model, the tape stripping model and 
the regression of the psoriatic lesion, were introduced. 
In Chapter 2, two in mvo models for psoriasis have been investigated: the mar­
gin zone of spreading plaques and the repeated tape stripping model of nor­
mal skin. Remarkable is the observation of a sharp transition point between 
uninvolved and involved psoriatic skin with respect to the differentiation pro­
cess (filaggrin and involucrin) and recruitment of cycling epidermal cells. 
The repeated tape stripping model appeared to be an adequate model for 
studies on epidermal proliferation, hypergranulosis and hyperkeratosis. In 
comparison to one single course of stripping of the normal skin, this ap­
proach caused a more prolonged induction of hyperproliferation and regene­
rative hyperkeratoses. The induction of filaggrin and hypergranulosis as seen 
in this model indicates that this model is not compatible with psoriasis or 
woundhealing. 
In Chapter 3 the effects of two new vitamin D3 analogues, 1,25 (ОН)г D Ì (cal-
citriol) and 1,24 (OH)2 D3 (tacalcitol), and the effect of a hydrocolloid dres-
sing on epidermal growth and keratinization have been studied. 1,25 (ОН)г 
D Ì as well as 1,24 (ОН)г D Ì showed antipsoriatic efficacy. Both therapies had 
substantial cell biological effects (antiproliferative, anti-inflammatory and 
differentiation normalizing effect). The very low irritancy potential of 1,24 
(ОН)г D3 makes this analogue promising for the treatment of psoriasis in the 
next future. 
The increase of the filaggrin expression after three weeks of treatment with 
a hydrocolloid dressing, accompanies the normalization of the hydration 
state of the stratum corneum, which might explain the antipsoriatic effect of 
occlusion. This phenomena might contribute to the pronounced antipsoria­
tic efficacy of application of a corticosteroid under hydrocolloid occlusion. 
In Chapter 4 the response of the clinically uninvolved skin of psoriatic 
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patients to tape stripping during systemic treatment with cyclosporin A and 
acitretin have been described 1 he results showed that epidermal hyperprohf-
eration and abnormal keratinization are modulated directly by Acitretin but 
not by Cyclosporin A 
In Chapter 5 the conclusions which have been reached in the various investi-
gations of this thesis are discussed 
The interphase between the clinically uninvolved skin and involved skin of 
psoriatic patients is a three phase transition The first phase involves the stro-
ma and is characterized by an increased expression of the extracellular matrix 
molecule tenascm and increased endothelial activation The second phase is 
the appearance of the inflammatory infiltrate together with the expression of 
keratin 16 and the third phase the simultaneous appearance of increased 
expression of the nuclear antigen K1-67, representing the recruitment of 
cycling epidermal cells, together with a decreased expression of filaggrm and 
an increased expression of involucrin Antipsonatic treatments show a rather 
consistent pattern with a reduction of epidermal proliferation and a tendency 
of normalization of the keratinization process The intensity of the cell biolo-
gical effects of the various treatments, however, differs considerably 
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Samenvatting 
In hoofdstuk ι worden de meest relevante aspecten van psoriasis besproken, 
zoals de epidemiologie, de genetica, de klinische aspecten, de histologische 
aspecten, de Pathogenese en de behandelingsvormen De onderzochte 197 
aspecten van het keratinisatieproces en epidermale groei (filaggnne, ïnvolu-
crme, transglutaminase en K1-67 positieve kernen) en de gebruikte in vivo 
modellen, de randzone van de actieve psoriatische plaque, het tapestnp 
model en de regressie van de psoriatische plaque, worden in dit hoofdstuk 
geïntroduceerd 
In hoofdstuk 2 worden twee in vivo modellen voor psoriasis, de randzone van 
de actieve psoriatische plaque en het chronische tapestnp model van de nor-
male huid onderzocht Opmerkelijk is de bevinding van een duidelijk 
omslagpunt van aspecten van het keratinisatieproces (filaggnne, involucrine, 
transglutaminase) en van de K1-67 positieve kernen, van de niet aangedane 
naar de aangedane psoriatische huid 
Het chronische stnpmodel is een adequaat model voor de bestudering van 
epidermale proliferatie, hypergranulosis en hyperkeratosis Vergeleken met 
het eenmalige stnpmodel, zoals in 1951 geïntroduceerd door Pinkus, veroor-
zaakt het chronische stnpmodel een langdurige inductie van de onderzochte 
verschijnselen De inductie van de filaggnne expressie en de hypergranulosis 
maken het chronische model ongeschikt om psoriasis of wondgenezing te 
bestuderen 
In hoofdstuk 3 worden de effecten van twee nieuwe vitamine Di analogen 
1,25 (OH)2 D3 (calcitnol) en 1,24 (ОН)г DB (tacalcitol), en het effect van een 
hydrocolloid op epidermale groei en keratinisatie besproken Zowel 1,25 
(OH)2 Di (calcitnol) als 1,24 (ОН)г Da (tacalcitol) hebben een antipsoriatisch 
effect Beide therapieën heten een substantieel celbiologisch effect (antipro-
hferatief, anti-inflammatoir en differentiatie modulerend) zien De zeer 
geringe irritatieve bijwerking van 1,24 (OH)2 D3 maakt dit analoog veelbelo-
vend voor de behandeling van psoriasis in de nabije toekomst 
De observatie van een normalisering van de filaggnne expressie na een drie 
weken durende behandeling met hydrocolloiden, resulterend in een normali-
satie van de hydratietoestand van het stratum corneum, zou de zeer sterke 
antipsoriatische werking van corticosteroiden onder occlusie, zoals eerder is 
beschreven, kunnen verklaren 
SAMENVATTING 
In hoofdstuk 4 is de klinische niet aangedane huid van psoriasis patiënten na 
tapestrippen, gedurende de systemische behandeling met cyclosporine A en 
acitretin onderzocht. De resultaten tonen dat epidermale hyperproliferatie en 
abnormale keratinisatie direct worden gemoduleerd door acitretin, maar niet 
door cyclosporine A. 
In hoofdstuk 5 worden de conclusies van de verschillende onderzoeken 
besproken. 
De interfase tussen de klinische niet aangedane en de aangedane huid van 
een psoriasis patient is een drie fase proces. De eerste fase heeft betrekking 
op het stroma en wordt gekarakteriseerd door een verhoogde expressie van 
het extracellulaire matrix molecuul tenascin en de versterkte endotheliale 
activatie. De tweede fase is de verschijning van het inflammatoire infiltraat 
met de expressie van kératine 16 en de derde fase is de gelijktijdige verschij-
ning van een toegenomen expressie van Ki-67, samen met een afgenomen 
filaggrine en een toegenomen involucrine expressie. 
De antipsoriatische behandeling laten een redelijk consistent celbiolo-
gisch patroon van effecten zien, zoals de reductie van de versnelde epiderma-
le groei en een normalisatie van het keratinisatieproces. De intensiteit van 
deze celbiologische effecten van de verschillende behandelingen echter ver-
schilt aanzienlijk. 
SAMENVATTING 
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Het chronisch stripmodel is een adequate methode om epidermale groei, 
hypergranulosis en hyperkeratosis te bestuderen. Dit proefschrift. 
Het chronisch stripmodel is ongeschikt voor de bestudering van psoriasis 
of wondgenezing. Dit proefschrift. 
De verschillende aangrijpingspunten van behandelingen voor psoriasis 
maken het aanbevelingswaardig meerdere therapieën tegelijkertijd te 
combineren. Dit proefschrift. 
De normalisering van de filaggrine-expressic in de epidermis na behande-
ling met hydrocolloiden, resulterend in een verbetering van de hydratatie-
toestand en permeabiliteit van het stratum comeum, zou de sterke anti-
psoriatische werking van de corticosteroiden onder occlusie kunnen 
verklaren. Dit proefschrift. 
Een psoriasispatiënt ervaart aanraking vaak als een gewenste intimiteit. 
Laagdrempeligheid in de gezondheidszorg werkt niet per definitie gezond-
heidsbevorderend. 
Het vak van een dermatoloog wordt helaas nogal eens verward met dat van 
een schoonheidsspecialist. 
Het verdient aanbeveling krachtsport op te nemen als onderdeel van de 
opleiding tot dermatoloog. 
Door de grens voor de studiefinanciering bij 27 jaar te leggen, wordt een 
groep van vaak uiterst gemotiveerde mensen uitgesloten van universitair 
onderwijs. 
Er lijkt een rechdijnig verband te bestaan tussen de wetenschappelijke out-
put van een afdeling en de output van haar koffie-automaat. 
Een proefschrift komt nooit alleen. 
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